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Throughout its 36-year history, Touro’s Lander College of Arts and Sciences in Flatbush 
(with separate men’s and women’s schools) has provided cohorts of aspiring high school 
graduates from well-regarded yeshivas and seminaries with a foundation of academic excel-
lence for professional career growth, in an environment that is supportive of the religious 
values of its students. Graduates have assumed leadership roles and continue to strengthen 
Jewish communities throughout the world.
Lander College of Arts and Sciences–Flatbush offers more than 25 majors and preprofes-
sional options, and three joint undergraduate/graduate degree programs in occupational 
therapy, physical therapy and physician assistant studies with the School of Health Sci-
ences. Honors tracks in biology, the health sciences, political science and psychology are 
currently offered.
Students are also required to complete a carefully designed core curriculum that empha-
sizes the development of communications skills, critical thinking and analytical competen-
cies, computer literacy and quantitative reasoning. Enrollment in science courses, notably 
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Faculty members continue to earn recognition for outstanding achievements, including 
Joshua November, Assistant Professor of Languages and Literature, who was selected as 
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CAN MARIJUANA BE HARMFUL WHEN USED PRENATALLY OR DURING 
ADOLESCENCE? 
 
Penninah Dean 
 
Abstract 
 Marijuana is a popular recreational drug with a  strong following campaigning to legalize it for 
both medicinal and recreational use. This paper serves to illustrate the harmful effects of marijuana use 
as it pertains to prenatal, adolescent and adult use. By understanding the methods of absorption and 
mechanism of interaction in the body, we can see a correlation between the effects of marijuana and its 
toxicity. Through extensive research of case studies on marijuana use we were able to determine 
marijuana’s harmful effects physically, developmentally and cognitively. Through these methods of 
research, it can be concluded that marijuana has detrimental effects on the developing body in utero ,as 
well as, during adolescence. Furthermore, marijuana has consistently been found to cause long term 
damage such as short stature, attention span, and verbal retention (Solowij, et. al. 2011). In adults, 
smoke inhalation of the substance has been found to be more detrimental than the smoke inhalation of 
tobacco.  While marijuana touts a variety of medicinal benefits in its application as a form of palliative 
care, its toxicity and the prolonged adverse effects of the substance are too strong to ignore. 
 
Introduction: 
 Cannabis is one of the first plants to have been used medically, recreationally, and spiritually 
dating back 5000 years, with the first documented medical use in Central Asia and later in China and 
India (Pertwee, 2006). Cannabis is the most widely used illicit recreational drug after the three most 
popular substances, tobacco, alcohol, and caffeine (Green, 1998). Since its discovery, cannabis has been 
used by millions to both induce pleasure and alleviate pain. Physicians have prescribed it for a plethora 
of ailments until the government classified it as a Schedule I substance, rendering it illegal, and without 
medical value. 
 There is a lot of effort being done by the public to try to legalize marijuana with claims that there 
is no basis for the fear and anxiety the public is placing on the drug, and it is in fact a benign substance. 
(NORML, 2013). There are surprisingly limited resources for research done on marijuana, largely due to 
the fact that it is difficult to find subjects willing to cooperate with a study concerning their illegal 
behavior. With over 300 million users worldwide, 28 million of which live in the United States, it is 
important to educate the public about the substance, how to use it safely, and if it exhibits adverse 
effects (Diaz, 1997). 
 The purpose of the research done in this paper is to ascertain the safety or dangers of marijuana, 
focusing on a few aspects to determine if it is in fact harmless. It concentrates on the repercussions of 
prenatal use and its effect on the fetus,its effect on adolescents and determining if there is any 
observable long term damage.  
Method Used: 
The author’s research was done using Touro College’s search engines such as ProQuest, 
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MEDLINE, and EBSCO, as well as research articles found through PubMed and Google Scholar. The 
method of research included reviewing studies and published articles that have been peer reviewed. In 
certain cases the author questioned the validity and accuracy of the methods used to attain the data 
presented and documented their uncertainty of the method of research. In other cases the author 
presented conflicting arguments to refute some peer reviewed studies to present that not all studies can 
be accepted at face value. 
 
Marijuana Intake and Potency: 
Cannabis, colloquially known as marijuana, is a recreational drug whose leaves, flowers, and 
stems are all utilized in its use. The chemical compounds found within the Marijuana plant identify it as 
a member of the cannabinoid class. The cannabinoid plant, whose scientific name is Cannabis sativa, 
has a distinctive smell that is similar to that of skunk musk. The described effects of marijuana are 
relaxing, calming, mellowing, and sometimes anxiety and paranoia provoking. Collectively, these 
effects are referred to as a ‘high.’ (Sharman, et. al. 2013). 
 The predominant psychoactive component in marijuana that determines its potency is 
delta-9-tetrahydrocannabinol, or THC, and was only isolated in 1964. This molecule is the chemical 
stimulant in the Cannabis plant that produces the altered states of consciousness in the user. 
 THC actually exists as Tetrahydrocannabinolic acid, THCA, in the Cannabis plant and is the 
biosynthetic precursor of THC. Conversion of THCA to THC occurs through burning of the plant. 
Combustion causes decarboxylation to occur on the THCA converting it to the more psychoactive THC 
molecule (Hazekamp, et. al. 2005). The depth or strength of the psychoactive component of the cannabis 
is highly dependent upon the growing conditions and the genetic strain of the plants (Copeland, et. al. 
2006). 
 There are a variety of common methods for marijuana intake. These include but are not limited to 
smoking the dried leaf of the plant in a the form of a rolled cigarette or “joint”, using a water pipe or 
“bong” to inhale the fumes, consumption in food, inhalation of vapors through a vaporizer, and ingestion 
of the plants oils. Smoking is the most common and preferred route of intake but it is dulled by the fact 
that only 5-14% of the smoke is actually THC, and 30-80% of the smoke in the “joint” is lost to escaped 
smoke (Copeland, et. al. 2006). 
 Smoking in itself is a dangerous method of intake as it is harmful to the lungs and respiratory 
system. Marijuana smokers are subject to the same dangers and health risks as tobacco smokers with 
similar negative results such as respiratory distress, asthma, cardiovascular disease, lung and esophageal 
cancers (Ellenhorn, Barceloux, 1988).  
 The second method of choice involves using a water pipe commonly known as a “bong”. The 
bong minimizes the THC lost in the smoke because it is all contained within the bowl and then 
effectively inhaled. This method can be dangerous due to the larger amounts of carbon monoxide and tar 
inhaled. Smoking hashish, which is the resin from the plant smoked in a pipe, is less common but is 
done by adding a few drops of oil to tobacco or cannabis leaves and smoking it in a joint. Another 
alternative is heating the oils and inhaling the vapors. The oil can also be incorporated in food and 
consumed, but produces less of an intense high and causes a delayed onset of effects (Copeland, et. al. 
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2006). 
 Newer methods, such as the use of vaporizers, have been utilized and have less harmful effects. 
These machines heat the cannabis and trap the tar and toxins in a special chamber allowing only the 
THC to be inhaled without the added harmful smoke. This is a useful method for patients who are using 
marijuana to aid in palliative care and treat illnesses. Through this method they are able to maximize the 
benefits of marijuana use without risking further damage to their health. Inhalers are also available for 
oral doses of THC, once again created for the purpose of medical palliative care (Martin, Wiley, 2004). 
 
Chemical Pathways of THC: 
 THC is an extremely potent chemical and takes only a matter of seconds to enter your bloodstream 
and reach your brain. When smoked, it takes effect almost immediately and can last anywhere from 1-3 
hours. When consumed in food there is a delayed onset of the desired effect, but the THC stays in your 
system for a longer period of time. Though the full mechanisms of THC still remain unknown, 
neuroscientists have some information about its effects on the brain  (Diaz, 1997). 
 To understand how THC is interacts with the brain’s cells, we must first understand the 
mechanisms that the brain uses to communicate. Neurons are the cells of the brain that transmit 
information. Neurons interact with each other through a chemical messenger system known as 
neurotransmitters. Neurotransmitters attach to protein structures imbedded in the membrane of the 
receiving neuron known as receptors. The attachment of neurotransmitters to these receptors facilitates 
the transmission of important information from one cell to the other. Each neuron has thousands of 
receptors and each receptor is specific to a certain neurotransmitter (Diaz, 1997). 
  THC is a cannabinoid and is therefore able to mimic endogenous cannabinoid neurotransmitters, 
such as N-arachidonoylethanolamine (anandamide) or 2-arachidonoyl glycerol. The discovery of these 
endocannabinoids in 1992 by Israeli scientist Raphael Mechoulam emerged from a study in which he 
was trying to determine the purpose of cannabinoid receptors in the body (Devane, et. al. 1992).  It was 
discovered that these endocannabinoid neurotransmitters are released by the body into the brain when 
the body senses an elevation in intracellular calcium. The THC binds to the cannabinoid receptors in 
place of the anandamide and therefore activates the appropriate neurons that would alternately be 
activated by anandamide (Sharman, et. al. 2013). THC exerts a majority of its influence through the 
midbrain reward center, triggering dopamine release in the prefrontal cortex which causes marijuana to 
have an addictive quality (Kogan, Mechoulam, 2007). 
 The presence of THC in the brain interferes with the neurons’ normal function by artificially 
stimulating the cannabinoid receptors. Certain portions of the brain have concentrated cannabinoid 
receptors while others contain only a small number. These receptors can be found in areas of the brain 
including; the cerebellum, hippocampus and basal ganglia, areas that influence pleasure, 
memory,  concentration, sensory and time perception, as well as coordinated movement. Therefore, 
THC can affect the sensations associated with thefunctions of these regions of the brain in which the 
cannabinoid receptors are found, resulting in the sensation of being ‘high’ (Devane, et. al. 1992). 
 The largest portion of the cannabinoid receptors are found in the hippocampus which is located in 
the medial temporal lobe, beneath the cortical surface of the brain and is associated with short term 
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memory. THC therefore, has the greatest effect on that portion of the brain, explaining why users 
typically report having trouble with short term memory. The cerebellum and basal ganglia have many 
cannabinoid receptors as well and therefore those under the influence of THC also report problems with 
coordination and muscle movements (Sharman, et. al. 2013). 
 There are two types of cannabinoid receptors identified as CB1 and CB2, in order of their 
discovery. These receptors act through inhibiting adenylate cyclase. The CB1 receptors are primarily 
found in the central nervous system, brain and nerve tissue, specifically the basal ganglia, hippocampus, 
cerebellum, and cerebral cortex, as well as, on the peripheral neurons. Their main function is to mediate 
inhibition of on-going release of certain excitatory and inhibitory neurotransmitters. CB2 is found in non 
neuronal cells in immune system tissues such as leukocytes, the spleen, and bone marrow, and was first 
discovered in human leukemia (Green, 1998). 
 
Marijuana Toxicity: 
 An important factor to consider is the toxicity level of marijuana. In comparison with regular 
tobacco smokers, marijuana smoke creates a greater cardiovascular burden due to the high levels of 
carbon monoxide and tar found in cannabis resulting in a heavy respiratory burden on the smoker. 
 Marijuana smokers are also known to take larger, deeper puffs and hold the smoke in their lungs 
for a longer period of time. Because of this practice, the retention of  tar in the respiratory tract is one 
third greater than the amount of tar built up from tobacco smoke. Additionally, smoking marijuana 
results in much higher level of carboxyhemoglobin than its counterpart, tobacco. Regardless of the THC 
content, the smoking of cannabis in itself yields a higher carbon monoxide and tar weight on the 
respiratory tract (Wu, et. al. 1988). 
 Marijuana has also been found to exacerbate psychotic illnesses in susceptible users, particularly 
schizophrenia. After testing the correlation between THC and psychosis, marijuana was found to cause 
consequent anxiety and neuropsychological impairment in users. THC can induce a transient, acute 
psychotic reactions in psychiatrically well individuals (Rais, et. al. 2008; Barch, Smith, 2008). 
Minutes after a dose of THC is delivered in an individual there are notable deficits in working 
memory and executive functions with a trend towards an impaired episodic memory. This is significant 
as it is well established that schizophrenia is associated with deficits in those functions (Rais, et. al. 
2008; Barch, Smith, 2008). Although the data is telling, the properties of THC are highly dose 
dependent with a possibility for bidirectional effects. There is also not much explanation of why some 
individuals are more susceptible to psychotic symptoms than others. 
 Marijuana is absorbed in the bloodstream from the lungs within minutes of inhalation generating 
an extremely immediate reaction in the body with the swift onset of a ‘high.’ The degree of intensity of 
the high depends on the quality of the cannabis, the method of use, and the experience of the user. 
Familiarity is a factor because a more experienced user will know how to maximize the inhalation, but 
also may be immune and therefore unaffected by some of the THC absorbed (Copeland, et. al. 2006). 
Immunity occurs when the body is chemically altered and builds a certain level of tolerance to the 
presence of marijuana thus requiring a higher dose to attain identical results from the previous use. The 
effects of tolerance can be dangerous when the subjects gradually increase their dose to achieve a certain 
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degree of high, while compromising his body and health. While the THC carries out it psychoactive 
effects, it is simultaneously harming the body’s cardiovascular system by lowering blood pressure and 
increasing heart rate: a potential danger for chronic marijuana users (Gorelick, et. al. 2013). 
 
Marijuana and Fetal Development:  
 To further understand the toxicity level and dangers of the substance, we must observe its effects 
on a developing fetus. Studies have been conducted that test the neurodegenerative effect of cannabis 
exposure on a developing rodent’s brain. Tests like these help scientists build a parallel analysis on the 
effects of cannabis in human neonatal development.   
 Because of the differences in human and rodent development, analyses were done on a seven day 
old rodent which is most similar to a third trimester fetus. Perhaps the most obvious limitations to this 
study is that testing was done exclusively on rats rather than relying on information gathered from actual 
human case studies and assessing the available neurodegenerative data. Furthermore, the fact that the 
rodent was not in utero during testing raises questions as to the environmental differences in the 
conditions of the third trimester of a human fetus. One might argue that there is a level of neonatal 
protection when a child is in the womb, and that could protect it from foreign toxins as opposed to a 
rodent pup that has to fend for itself. There can also be claims that a child in utero may be exposed to 
more toxins due to the direct stream of oxygen and nutrition passed from the mother, therefore exposing 
the fetus to greater risk when its body is still vulnerable and reliant on maternal nutrients rather than 
depending on its own immune response. 
 There is evidence, however, supporting the research done on rodents by studying the effects of 
marijuana on a fetus during the second trimester. Smoking of marijuana was found to have a significant 
effect on the stature of the unborn child. There is an additional increased risk of premature birth, stunted 
growth, and morbidity if the offspring is that of an adolescent even if their levels of drug use are lower 
than those of adult pregnant women (Cornelius, et. al. 2002).  
 Further evidence can be found in preschool children who were assessed for sustained attention 
after fetal exposure to marijuana. In these studies, children were found to have various levels of 
decreased sustained attention. Although this implies that marijuana can have an adverse direct effect on 
the fetus, the fact that these mothers were users of other drugs including alcohol and tobacco, 
complicates analysis. Therefore, although there is conclusive data linking marijuana to these results, it is 
difficult to isolate which substance was the precise cause of the inattentiveness (Fried, et. al. 1992).  
 With an increase of admitted dose of marijuana use, however, there was a correlated increase in 
the failure of the exposed children to maintain vigilance and sustain information appropriate to their 
grade level. There is also a greater likelihood of omission errors, indicating a lack of attention and a 
described impulsivity and hyperactivity that grew with increasing prenatal dose exposure (Noland, et. al. 
2005). These effects were predominantly exhibited in preschool aged children as altered inattentive 
behavior and if exposed to these drugs at a young age, they also exhibit greater trouble with behavior 
and focusing, 
 Double blinded studies such as these are well assessed and dependable due to the fact that the 
testers are not aware of the substance exposure status of the children and therefore minimizing biased 
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answers or observations. There are limitations as noted previously as many of the mothers of the 
children tested were exposed to various drugs as well. This limits the scope of observation and obscures 
our view as to which of the substances were the cause of the inattentiveness. (Richardson, et. al. 2002). 
 Experiments on pregnant mammals have shown adverse effects and though the results have been 
quite supportive of the data, it remains difficult to predict how similar levels of THC would affect 
pregnant humans. One aspect that has been neglected by these studies is the adverse effect that smoke 
inhalation may have on the child. Although THC in itself is proven to be detrimental to the fetus, there is 
an added risk when marijuana is smoked, which is usually the case since that is the most common form 
of intake. Although there are some human studies revealing the effects on a fetus, there is limited data 
available due to the shortage of people willing to be included in a study (Jutras-Aswad, et. al. 2009). 
 Clearly, marijuana use and exposure during pregnancy is extremely harmful to the unborn 
child. THC is especially dangerous due to the ease in which it is able to cross the placental barrier, 
therefore entering the fetus’s blood supply where it could cause adverse effects. The THC builds up in 
the fat and liver tissue of the mother and is then passed through the placental barrier. The levels of THC 
present can be easily measured in the amniotic fluid, with stronger concentrations yielding more harmful 
results. The speed of transfer is essential because it enables the drug to achieve its pharmacological 
effects once it comes in contact with the fetus. Consequently, injection of THC during early pregnancy 
in rodents produced a seventy percent feticide (Harbison, Mantilla-Plata, 1972).  
Additionally, negative effects of the marijuana are also observed if the fetus survives. Once 
the child develops, they can exhibit; an altered response to visual stimuli, increased tremulousness, 
problems with sustained attention and memory, and poor problem-solving skills (Diaz, 1997).  
 
Adolescent Use: 
  The number of teenagers informed of the harmful effects of marijuana is decreasing, and 
consequently there is an increase in adolescent daily marijuana smokers. Marijuana can have an effect 
on the brain for users who began to smoke during adolescence, as opposed to adulthood. This creates a 
noticeable decline in IQ from the point of adolescence to adulthood. Through standardized IQ testing it 
was determined that there was an average of an eight point decline of IQ by mid age. There is a 
significant impairment of cognitive function, specifically related to attention and memory, and there is 
an increasing vulnerability to psychosis. There is no proof that stopping use of marijuana will improve 
cognitive function, and the effects of persistent cannabis remain, causing a neuropsychological decline. 
Many teenagers and even clinicians are not aware of the high probability of intellectual or 
psychopathological impairment due to the neurotoxic effects of THC (Meier, et. al. 2012). 
 Long term cannabis use is specifically detrimental to the white matter of the brain in adolescence 
and early adulthood. Magnetic Resonance Imaging devices make it easy to determine the portion of an 
individual’s white matter that has been affected. Heavy cannabis use affects axonal connectivity and 
impairs fimbria of the hippocampus. This is due to the many cannabinoid receptors present in the 
developing white matter of the brain in fibre pathways (Zalesky, et. al. 2012). The age of 
commencement of use of cannabis is crucial in determining its effect on white matter, the earlier the 
onset of use, the more detrimental its effects. This is also in line with extensive research that establishes 
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a link between long term marijuana use and the onset of schizophrenia as discussed previously (Rais, et. 
al. 2008). 
 Overall, cannabis use is more detrimental to the cognitive effects of a growing adolescent than in 
adults. Unfortunately, marijuana has always been linked to younger users, where it has the greater effect 
on the subject’s cognitive function. Even more so, smaller doses of marijuana pose a greater risk to the 
developing brain than larger doses will have on a fully developed adult brain. (Solowij, et. al. 2011) 
 Tested at differing intervals of exposure; before use, during, and after, cannabis users are found to 
be more anxious, more susceptible to depression, and have lower cognitive abilities than their 
counterparts. Those that used marijuana consistently have lower verbal learning and memory scores than 
even alcohol users and control groups alike. There is also impaired retention, storage, and retrieval in 
cannabis users. Cannabis at low doses in adolescents is still proven to be destructive. The earlier the use 
of cannabis, and the more frequent, the greater the damage associated with the brain even once cannabis 
use has ceased (Solowij, et. al. 2011). A convincing amount of data builds a strong correlation between 
the use of marijuana and impaired cognition.  This demonstrates that even in low doses, cannabis can 
impair the memory of young adults (Reynolds, Parfit, 1993). 
Debate: 
 In a 1992 study, information was published concerning marijuana safety. The scientists, Nahas and 
Latour, (1992) concluded that extended marijuana use caused prolonged impairment of psychomotor 
performance; impairment of memory in adolescents; cancer of mouth and jaw; fetotoxicity; an increase 
in the incidence of schizophrenia; and leukemia in children of marijuana smoking mothers.  
 Soon after reviewing the information presented, further research was conducted to determine its 
accuracy. Regrettably, the additional investigation into the study confirmed that eighty percent of the 
citations were inaccurate and numerous others were misrepresented or biasedly reported. Hence, it is 
certainly necessary to inquire further whenever new research material is presented, and to be aware of 
possible discrepancies in any form of research (Macdonald, Gregory, 1994). This of course does not 
discredit all the research presented, but advises the reader to always verify sources and inquire further. 
 Another instance of contradictory studies is a 2003 analysis stating that cannabis use was found to 
cause impairment in both cognitive function and mood (Klugman, Gruzelier, 2003). A later review in 
2006, however, noted that workers reported that they performed equally well in controls, working 
memory, and selective attention tasks as their counterparts (Wadsworth, et. al. 2006).  
 In addition to possible discrepancies with research studies, there are other possible perspectives on 
marijuana. While the effects of smoking marijuana itself can be harmful to the health of an individual, 
and by all accounts it is extremely toxic in young adults as well as fetuses, it is not considered a highly 
toxic substance. Marijuana is unique in that it has an extremely high lethal dose. Meaning, an individual 
would have to consume 40,000 times the usual dose to trigger a lethal response. Equal amounts of 
caffeine would lead to death quicker than marijuana. As of yet there are no documented cases 
implicating marijuana as the cause of death (Annas, 1997).  
Recent interest has fueled progress in development of medicinal drugs. One such drug can be 
used topically to introduce the lipophilic substance into the body by using micro-emulsions and 
cyclodextrins to create greater solubility in aqueous solutions. This new form of application could result 
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in a less harmful method to utilize the beneficial medicinal properties of marijuana. (Green, 1998). 
 In addition, new forms of use can enable patients suffering from life threatening illnesses with 
symptoms that compromise their health and quality of life a way to control the pain. The discovery of 
the endocannabinoid system has led to an interest in the production of cannabinoid medications for 
treatment of symptoms such as nausea, vomiting, weight loss, and pain relief. Some of these 
synthetically produced cannabinoid medications have already been FDA approved which could prove to 
significantly enhance the quality of life for a patient suffering from an illness (Martin, Wiley, 2004).  
 While marijuana may have therapeutic benefits, a majority of the research conducted is on real 
users of the substance. This is a drawback because the dosage of THC in their systems are too high to 
properly assess what the outcome would be if the doses were administered and regulated. Even though 
there is promise in the study for the drug to be used medically, not enough case studies have been 
performed as of yet to examine all the parameters of the drug (Zuurman, et. al. 2009).  
 
Conclusion: 
 Educated by the media and influenced by current social cultures, the author initially began this 
research project with the impression that marijuana was a benign and harmless substance. After doing 
extensive research on the subject, and reading a wealth of information, the author’s views have been 
dramatically transformed. 
The data concerning prenatal use as well as adolescent abuse of marijuana have proved to be 
quite conclusive with evidence demonstrating the harmful effects of the substance. There is a 
considerable amount of information available detailing a plethora of study methods and techniques 
which all yield similar adverse results. Although there seems to be promising research regarding 
marijuana as a medicinal therapeutic drug, as of now it is a very new and undeveloped method of 
treatment with lack of adequate information to ensure its long term safety. 
 While there is still a lot more research to be done, the information gathered concerning 
marijuana’s adverse effects are too strong to ignore.  
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THE CARCINOGENIC EFFECTS OF ASPARTAME 
Devora Sara Gelbfish 
 
Abstract 
 Aspartame, one of the most common artificial sweeteners, is used as a food additive worldwide. 
Because of early experimentation with rats linking aspartame to higher risk of cancer, there is much 
concern regarding the safety of aspartame. However, analytical review and numerous subsequent studies 
have disproven previous experimentation and reaffirmed that aspartame consumption in humans does 
not increase the risk of cancers. At the current time there is no credible evidence to support the idea that 
aspartame is carcinogenic. The evidence confirms that at current levels of consumption aspartame is a 
safe alternative to sucrose. 
 
Introduction 
In recent years artificial sweeteners have become more and more popular as consumers continue 
to seek alternatives to regular table sugar that offer sweetness without calories. Because artificial 
sweeteners contain virtually no calories, they can be very effective in aiding weight control. 
Additionally, artificial sweeteners like aspartame are useful to diabetics because they are not 
carbohydrates, and therefore, do not raise blood sugar.  Instead, aspartame is broken down into its 
constituent amino acids and incorporated into normal metabolism without impacting blood sugar levels 
(Renwick 1986).  
However, the safety of artificial sweetener consumption has been debated for years due to early 
studies linking them to incidents of cancer. Despite the fact that these studies were later overturned, 
concern about the long-term deleterious effects of artificial sweeteners remains strong. 
On the one hand, excess sugar consumption is unhealthy. The prevalence of obesity and diabetes 
is rising at alarming rates, leading to numerous health problems. On the other, with the increase in 
consumption of artificial sweeteners, are we putting ourselves at risk for cancer? Unfortunately, so many 
studies have been conducted only later to be overturned, leading to much confusion in the area of 
artificial sweeteners. Many consumers avoid artificial sweeteners because they believe that the 
“chemicals” are hazardous to their health or because they have read headlines linking aspartame to 
cancer. However, are those claims backed by scientific data? Is it all just publicity and hysteria, or is 
aspartame truly carcinogenic? 
 
History of Aspartame 
Aspartame is formally known as L-α-aspartyl-L-phenylalanine methyl ester. (Figure 1) 
Commonly known by the brand names Equal and NutraSweet, aspartame was accidentally discovered in 
1965 by a scientist who was working on the synthesis of a gastrointestinal secretory hormone inhibitor. 
While working in the lab, some solution was accidentally spilled and splashed on his hand. Soon 
afterwards, against all good safety practices, he licked his finger to pick up a piece of paper and was 
shocked by the intense sweetness of the aspartame that had been splattered there (Magnuson et al. 2007).  
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 Aspartame was originally proposed for approval in the United States in 1974, but it was not 
until 1981 that it was approved for dry products. Finally, in 1983 it was further approved for use in 
drinks and subsequently all foods (European Food Safety Authority 2006). Then, in 1996, the safety of 
aspartame was questioned, once again, due to a report suggesting that aspartame consumption was 
responsible for an increase in brain tumors between 1975 and 1992. However, later studies and further 
analysis showed that the data did not establish a definite link between cancer development and 
aspartame consumption (National Cancer Institute 2009). 
Trailing only saccharin, aspartame is the second most used artificial sweetener in the world. It is 
found in over 6000 kinds of products worldwide, among them soft drinks, chewing gum and candies. It 
has been used as a popular food additive for more than thirty years due to its intense sweetness which is 
about two hundred times the sweetness of sucrose.  In the United States alone aspartame consumption 
is estimated at about 8000 tons per year. But, in the words of Soffritti et al. (2006), “[Aspartame’s] 
ever-growing use…has been accompanied by rising consumer concerns regarding its safety, in particular 
its potential long-term carcinogenic effects.” 
The acceptable daily intake of aspartame is 40 mg/kg of body weight in Europe and 50 mg/kg 
body weight in the United States. Pharmacokinetic data in humans indicates that even when the full 
acceptable daily intake is taken at once, the aspartame is digested fast enough so that systemic exposure 
to aspartame never occurs. Moreover, it is important to note that current use levels, even by high users, 
remain well below the established acceptable daily intake levels. If all sucrose in the typical American 
diet was replaced with aspartame, the proposed estimated consumption would fall between twenty-two 
and thirty-four mg/kg of body weight per day. In more commonly relatable measurements, these 
amounts are equivalent to about fifty-seven packets of sweetener, or ten cans of diet soda, per day. In 
actuality, the most current data available shows that, on average, aspartame intake is 4.9mg/kg body 
weight per person per day (Stegink et al. 1981).  
 In rodents, pigs, nonhuman primates, and humans alike, aspartame is metabolized into aspartic 
acid, phenylalanine, and methanol in the gastrointestinal tract. Post-ingestion, the aspartame is 
hydrolyzed, resulting in the breakdown products listed above. After being absorbed into systemic 
circulation, the broken down compounds follow the metabolic pathways as they would if ingested 
through other foods. Aspartate and phenylalanine are used as amino acidic building blocks or 
transformed into alanine plus oxaloacetate and tyrosine, respectively, and partially into 
phenylethylamine and phenylpyruvate. The methanol is oxidized to become formaldehyde and then 
formic acid (Soffritti et al. 2006). 
 According to the European Food Safety Authority, “At doses relevant to human consumption 
hydrolysis is very efficient.” All available evidence indicates that aspartame does not enter the 
bloodstream until after it is hydrolyzed. Consequently, it is important to bear in mind that studies in 
which aspartame was administered through injection, (thereby avoiding digestion,) “are not 
representative of oral administration, which is how aspartame is always consumed by humans” (Stegink 
Figure 1. Structure of aspartame 
(L-α-aspartyl-L-phenylalanine methyl 
ester).  
(Magnuson et al. 2007) 
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1987). Any cancers that resulted from systemic exposure to aspartame are not relevant to humans, since 
when ingested orally, aspartame is always broken down before entering systemic circulation. 
 
Overview and Analysis of Original Studies Performed 
 From the time of its introduction by Searle Laboratories, aspartame has been surrounded by 
controversy. With the assistance of various scientists, Searle conducted hundreds of tests, summarized in 
Table 1 below, to ascertain the safety of aspartame as a food additive. Among the experimental works 
were studies conducted on rats, mice, hamsters, dogs, and monkeys. At the time, many felt that some 
important data was not reported to the Food and Drug Administration when Searle applied for the 
approval of aspartame. Ultimately, however, further analysis proved that none of the studies found 
evidence linking aspartame consumption to cancer.  
In a 1996 report by Olney et al., the authors suggested that aspartame might be a cause of the 
increase in brain cancer in humans. From a descriptive analysis of national cancer data, they noted that 
the introduction of aspartame in food in the early 1980’s corresponded to the rise in brain cancer in the 
United States. They recommended that the safety of aspartame as a sugar substitute be reevaluated. 
 Consequently, Gurney et al. performed a case-control study to assess the relationship of 
aspartame consumption and the risk of childhood brain tumors. They held in-person interviews with the 
biological mothers of their fifty-six case patients and ninety-four control subjects, collecting data on 
aspartame consumption prior to the date of diagnosis or reference date. The children were all born 
during or after 1981, corresponding to the Food and Drug Administration’s approval of aspartame. In 
addition, for forty-nine case patients and ninety control subjects, the authors evaluated the risk of brain 
tumor as a result of the mother’s aspartame consumption during pregnancy and breast feeding. 
  As a result of their studies the authors found that “case children were no more likely than 
control children to consume foods containing aspartame,” and that “there was no suggestion of a 
dose-response relation based on age at first consumption, number of years of consumption, or frequency 
of consumption.” Additionally, they found no correlation between maternal consumption of aspartame 
during pregnancy or breast feeding and increased risk of brain tumors (Gurney et al. 1997). 
 This study is informative; however, due to a number of weaknesses, it is not a strong enough 
proof to rule out the possibility that aspartame is linked to elevated risk of brain tumors. Firstly, much of 
the data was amassed through in-person interviews with the mothers of the case patients and control 
subjects, leaving lots of room for error as a result of biases. Aside from the 
fact that no one has perfect recall, people also tend to lie or exaggerate information. Also, it is very 
possible that the interviewers asked leading questions and that the interviewees skewed the information 
in an attempt to provide what they thought the interviewers wanted to hear. Furthermore, the study 
sample was very small and may not have been an accurate representation of the full population. Finally, 
studies of children are naturally limited because one cannot study the effect of the possibly carcinogenic 
agent over time. Therefore, even if one were to accept the results of the study, the possibility that the 
children who were exposed to aspartame consumption would have increased brain tumor risk as adults 
cannot be ruled out. 
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Table 1: Chronic Oral Toxicity Studies with aspartame and diketopiperazine (Magnuson et. al 2007) 
 
 
Aspartame Consumption in Relation to Childhood Brain Tumor Risk: Results from a 
Case-Control Study 
 
Nevertheless, there is one last important point that the authors did make. Given the fact that the peak rise 
in brain tumors and the introduction of aspartame occurred almost simultaneously, without the expected 
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period of latency, “it appears unlikely that any carcinogenic effect of aspartame ingestion could have 
accounted for the recent brain tumor trends as Olney et al. contend” (Gurney et al. 1997) 
 
Aspartame Induces Lymphomas and Leukemias in Rats 
 In 2005 and 2006 Soffritti et al. of the European Ramazzini Foundation published a set of 
alarming study results. In fact, much of the concern regarding the safety of aspartame was generated by 
the initial findings of their research. In their study, the authors administered aspartame to male and 
female Sprague-Dawley rats with their feed. The rats, which were eight weeks old at the start of the 
experiment, were treated with aspartame containing feed until spontaneous death. The groups of 
100-150/sex were given concentrations of 100,000; 50,000; 10,000; 2,000; 400; 80; and 0 ppm to 
simulate assumed daily intake by humans of 5,000; 2,500; 500; 100; 20; 4; and 0 mg/kg of body weight. 
 The study continued for 151 weeks until the death of the last rat at 159 weeks. Upon their deaths, 
the animals underwent complete necropsy and examination. The authors reported the following 
differences observed between the treated groups and the untreated control.  
1. “An increase in malignant tumor-bearing animals with a significant positive trend in males…and 
in female…and a statistically significant difference in females treated at 50,000 
ppm…,compared to controls; 
2. An increased incidence of hyperplasia of the olfactory epithelium with a significant positive 
trend in males and females…; 
3. An increase in the incidence of…carcinomas of the renal pelvis and ureter were observed in 
females…; 
4. A dose-related increased incidence in malignant schwannomas of peripheral nerves was 
observed, with a significant positive trend in males…, while in females, nine malignancies were 
observed among treated animals of the different dosage groups and none among controls…; 
5. A dose-related increased incidence in lymphomas-leukemias was observed, with a significant 
positive trend in males…and females. When compared to controls, a statistically significant 
difference was observed in females treated at doses of [400 ppm and above]…” 
Finally, they also reported sparse brain malignancies observed in the treated groups, (among males 
and females,) whereas none were found in the control groups. 
 They concluded that, for the first time, they had demonstrated a dose-related, statistically 
significant increase in lymphomas and leukemias in females as a result of aspartame intake. 
Furthermore, they felt that these results were noted at levels close to those to which humans can be 
exposed. “Since the results of carcinogenicity bioassays in rodents, mainly rats and mice, have been 
shown to be a consistent predictor of human cancer risk,” they closed their work by calling for an 
“urgent re-examination of permissible exposure levels of aspartame in both food and beverages” 
(Soffritti et al. 2006). 
 
 
Evaluation of the European Ramazzini Foundation Study 
Immediately following the publication of the disquieting carcinogenicity study carried out by the 
European Ramazzini Foundation, many scientists and researchers began to assess their reported results. 
As stated previously, the European Ramazzini Foundation “considered that the results of their study 
indicate that aspartame is a ‘multipotential carcinogenic agent,’” leading to much concern. As a result, 
many specialists set out to attempt to either verify or discount their findings.  
For example, after extensive evaluation, the European Food Safety Authority Panel concluded 
that the studies by the European Ramazzini Foundation contained “too many methodological flaws to be 
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taken into consideration when determining the carcinogenic potential of aspartame” and that the Panel 
had “no reason to revise the previously established acceptable daily intake for aspartame (European 
Food Safety Authority 2006). Below are a number of flaws which invalidate the findings of the 
European Ramazzini Foundation study. 
Firstly, there was a high background incidence of chronic inflammatory disease among the 
colony of rats used (European Food Safety Authority 2006). This condition was not mentioned in the 
study. However, the fact that the colony was already suffering from chronic respiratory disease is a very 
plausible explanation of the lymphomas and leukemias that developed. This information, along with the 
lack of a positive dose-response relationship, makes it unlikely that the increased lymphomas and 
leukemias were related to aspartame. 
Additionally, concerning the lesions of the renal pelvis, ureter, and bladder, although they were 
likely treatment related, the same results cannot be expected in humans due to differences between rat 
and human metabolism. Due to differences in urinary protein levels, rats are much more susceptible to 
these tumors than humans are when exposed to high doses of chemical irritants (Cohen 1995). 
According to the European Food Safety Authority panel, “It is widely accepted that the effect is a high 
dose effect of irritant chemicals or chemicals producing renal pelvic calcification as a result of 
imbalances in calcium metabolism, specific to the rat.” The Panel did not consider these effects to be 
relevant to humans in any way.  
Furthermore, the authors reported statistics for “total malignant tumors.” However, aggregating 
all of the incidences of malignant tumors for statistical purposes was not justified given that the 
lymphomas, leukemias, and renal tumors should have been excluded, as explained above. 
With regard to the malignant schwannomas, the number of tumors were low. Also, despite the 
fact that the dose-response relationship showed a positive trend in males, it was very flat over a wide 
range. The European Food Safety Authority panel felt that there was also general uncertainty as to the 
diagnoses of these tumors and that further histopathological peer-review of the relevant nervous system 
slides was necessary for complete evaluation. 
Finally, actual human consumption of aspartame is far less than the concentrations at which the 
treated rats exhibited differences from the control group. Some might be tempted to say that 
carcinogenicity at high doses shows that there is carcinogenicity at low doses as well, but that it is at a 
lower rate, referred to as dose extrapolation. However, it is incorrect to automatically assume that this is 
so (Cohen 1995). 
As a result of the numerous flaws present in multiple areas of the study findings, the results of 
the European Ramazzini Foundation study are considered invalid. Further studies were necessary to 
ascertain the safety of aspartame. 
 
Consumption of Aspartame-Containing Beverages and Incidence of Hematopoietic and Brain 
Malignancies 
In 2006, following multiple animal experiments which attempted to link aspartame to 
hematopoietic (pertaining to blood cell formation) and brain cancers, most importantly the seemingly 
positive linkage found in the European Ramazzini Foundation studies, a group of scientists set out to 
investigate the risks in humans. They “investigated the association between self-reported consumption 
of aspartame-containing beverages and incident hematopoietic and brain cancers.” 
 The authors mailed out 3.5 million questionnaires to AARP members who were between the 
ages of fifty and seventy-one years old. Information about daily aspartame intake was obtained from 
these self-administered food frequency questionnaires. Of the 617,119 that were returned, 567,169 were 
satisfactorily completed. Excluded from the study were 52,887 persons with history of cancer, one 
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withdrawal, a number of duplicates, and people who had died. As a result, 473,984 questionnaires were 
considered, (285,079 men and 188,905 women).  
 During a follow up of more than five years, 1,888 hematopoietic cancers and 315 malignant 
gliomas (brain cancer) were discovered. These findings were largely comparable to overall rates of 
hematopoietic cancers and gliomas within the age range, for both the male and female subgroups. 
Moreover, the findings were not in any way linked to aspartame intake, nor was there any correlation 
between higher levels of aspartame intake and increased cancer risk. 
As a result of their study, the authors concluded that their findings do not support the hypothesis 
that aspartame increases the risk of hematopoietic or brain cancer, and that it was in direct contradiction 
with the study conducted by the European Ramazzini Foundation. Furthermore, the authors noted the 
fact that the European Food Safety Authority dismissed the findings of the European Ramazzini 
Foundation due to the high background of chronic inflammatory conditions in the rat colony used, the 
lack of a dose-response, and other issues, as mentioned previously (Lim et al. 2006). 
The study of Lim et al. has a number of strengths.  First and foremost, the large sample size 
provided for more accurate results. Additionally, the fact that the dietary and lifestyle data was collected 
before the patients were diagnosed with cancer minimized the biases normally found due to differential 
reporting between cases and controls. (This is unlike the study by Gurney et al., for example, in which 
the data was collected from the mothers after their children had been diagnosed.) Furthermore, the food 
frequency questionnaire used was developed by the National Institute of Health in conjunction with the 
AARP through extensive cognitive testing. 
(All the same, it is important to bear in mind that any information obtained through self-reporting 
by study members is bound to involve at least a small amount of bias.) 
 
Conclusion 
 After thorough review of all of the scientific data available with regard to aspartame, there is no 
evidence that aspartame, as consumed by humans, is carcinogenic. Nevertheless, despite the lack of 
scientific evidence, many people feel that aspartame is “dangerous” and “causes cancer.” Popular media 
often refers to aspartame with phrases like “deadly sweet” or “the sweet poison.” Headlines like 
“Aspartame linked to cancer” are quickly believed and difficult to overturn in the minds of the public.  
For example, following the European Ramazzini Foundation study in 2005, a branch of Harvard 
hospital promoted research which analyzed hospital records of tens of thousands of men and women. A 
report publicized by the hospital concluded that “those who drink a daily diet soda sweetened with 
aspartame could have an increased risk of leukemia, lymphoma, or non-Hodgkin’s lymphoma.” 
However, in actuality, the risk was prevalent among drinkers of mostly sugared soda, as well. The lead 
author of the study was asked whether the research proved that aspartame is dangerous, and she 
emphatically replied, “No, it does not” (Bazell 2012).  
Subsequently, the hospital apologized and admitted that the science it promoted was weak. 
However, the damage was already done. In the words of Dr. Steven Nissen, chair of the Cleveland 
Clinic’s cardiovascular medicine department, “Promoting a study that its own authors agree is not 
definite, not conclusive, and not useful for the public is not in the best interests of public health.” 
Unfortunately, much of the commonly believed information about aspartame is exactly that, 
inconclusive data that was only intended to lead to further studying (Bazell 2012). 
Despite the lack of evidence proving the carcinogenicity of aspartame, wouldn’t it be better to 
stick to sucrose, which is considered “natural,” and avoid the chemically produced aspartame? No. With 
the ever-growing obesity and obesity-related conditions, sucrose itself is like a toxin. Obesity related 
conditions are now the number one leading cause of preventable death in the United States. More than 
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one third of adults in the United States are obese, resulting in overwhelming numbers of conditions like 
heart disease, stroke, type 2 diabetes, and even obesity-related cancers (statistics based on review by the 
Centers for Disease Control and Prevention 2011). 
Whereas the carcinogenic effects of aspartame in humans are doubtful, the deleterious effects of 
obesity are unambiguous and very alarming. So, where it’s a question of the diet soda or a glass of 
water, no one would recommend the soda. However, when it’s between a cup of juice and an 
aspartame-sweetened beverage, it is not so clear-cut. In essence it comes down to the question of which 
“poison” is worse. 
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COMPLEX REGIONAL PAIN SYNDROME: A REVIEW OF CURRENT TREATMENTS 
Yosef Lewis 
 
Abstract 
  Complex Regional Pain Syndrome (CRPS) is a syndrome that develops infrequently in 
patients that experience a minor or severe trauma to a bodily extremity. CRPS has two subtypes; Type-I 
and II, both are clinically characterized by hyperalgesia. During its acute stage, CRPS hyperalgesia is 
clinically characterized by edema in the subcutaneous tissues of the epidermis, allodynia, and localized 
bone resorption. In the later chronic stage, hyperalgesia is aroused by the disregulation of blood flow to 
the extremity and permanent dystonic and trophic changes to the skin. Because the epidemiology and 
central causation of CRPS remains unknown until today, health professionals are challenged to diagnose 
and treat its unique and changing presentations as they appear. This approach, has led to a plethora of 
tests and treatments that address the syndrome as it presents its clinical features. This paper is an 
in-depth review of available treatment modalities and surmise the efficacy of the treatments based the 
quality of the available research. By reviewing the effectiveness of some of the currently available 
treatment modalities we may gain some understanding of this enigmatic syndrome. 
    
Introduction and History 
CRPS type-I has previously been known as Sudeck’s Atrophy and Reflex Sympathetic 
Dystrophy. Sundeck’s Atrophy was the syndrome’s original name. It was named after Paul Sudeck who 
proposed in 1902 that this syndrome was an exaggerated response to nerve damage, or soft tissue injury, 
(Janig, 2003).  In the 1950’s, John Bonica, the founder of the International Association for the Study of 
Pain, proposed the name Reflex Sympathetic Dystrophy; “sympathetic” dystrophy because it aptly 
described the pathology of the syndrome that was discovered to be maintained by the Sympathetic 
Nervous System. This SNS trend was discovered after patients treated with a temporary blockade of the 
sympathetic nervous system experienced relief from the syndrome’s symptoms, (Bonica, 1990).  
CRPS Type-II was previously known as Causalgia, a derivative of the Greek terms, “Caus”, and 
“Algia”, which mean, heat and pain, respectively. The name, Causalgia, was coined by Dr. Silas Weir 
Mitchell, a nerve pain pioneer during the American Civil War. He noted in his observations the 
exaggerated nature of the presentation of pain in relation to the injury, a problem that was frequently 
found in veterans of the Civil War who were exposed to low velocity, high mass missiles used by the 
confederates, which overtime caused an extreme inflammatory response, followed by trophic changes at 
the site of injury. He also recorded, that the ensuing level of pain following injury was dependent on the 
extent of peripheral nerve damage, (Lau and Chung, 2004).  
It became evident in the 1990’s that the dissonance created by the syndromes varying names was 
affecting the ability of doctors to accurately diagnose this syndrome. With this in mind a consensus 
workshop was held in Orlando, Florida in 1993 to develop singular terminology for the syndromes 
multiple etiologies and manifestations. The term Complex Regional Pain Syndrome Type-I and II was 
determined to be a more accurate and descriptive of the syndrome. At the same conference consensus 
diagnostic criteria were also laid out for two CRPS types, (Stanton-Hicks, et al., 1995). 
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The defined IASP diagnostic criterion for CRPS type-I is: The presence of an initiating noxious 
event or a cause of immobilization. Continuing pain, allodynia or hyperalgesia that is disproportionate to 
the inciting event. Evidence, at some time, of edema, changes in skin blood flow, or abnormal 
sudomotor activity in the area of pain. The diagnosis is excluded by the existence of any condition that 
would otherwise account for the degree of pain and dysfunction. 
The defined International Association for the Study of Pain diagnostic criterion for CRPS type-II 
is: The presence of continuing pain, allodynia, or hyperalgesia after a nerve injury, not necessarily 
limited to the distribution of the injured nerve. Evidence, at some time, of edema, changes in skin blood 
flow, or abnormal sudomotor activity in the region of pain. The diagnosis is excluded by the existence of 
any condition that would otherwise account for the degree of pain and dysfunction, (1995). 
 A majority of CRPS patients can identify an initial noxious event that preceded the clinical 
features of CRPS. In the case of CRPS type-I, which presents without a nerve lesion, the initial event is 
usually a minor trauma, such as an ankle sprain. In the case of CRPS type-II, which presents with a 
nerve lesion, a severe trauma is the usual culprit. Both CRPS Type-I and II usually present in a unilateral 
fashion with only one limb being affected. Both CRPS Type-I and II are marked by the dysfunction of 
the sympathetic nervous system (SNS), which leads to many forms of pain. About 81% of patients 
complain of spontaneous burning and stinging pain. Discoloration and  vasomotor changes occur in 
86.9% and 78.7% of patients, respectively. Allodynia, found in 69% of patients, is an abnormal 
sensitivity to normal mechanical or temprature stimuli. The sensitivity is so great with regards to 
mechanical and temperature stimuli, that clothing resting on a limb, or a breeze passing over the limb, 
instigates hyperalgesia. Additionally, CRPS type-II patients have symptoms that are common to 
neuropathy, i.e. electrical sensations, shooting pain, (Birklein, 2005).  
CRPS type-I and II are marked by three distinct stages. The “Acute Stage”, during which 
patients are found to be undergoing an extreme inflammatory response and which is characterized by 
reddening and edema at the distal end of the affected limb. During the second “Chronic Stage” the 
affected limb begins turning bluish and cold and is said to be undergoing sudomotor dysfunction. During 
the final “Trophic Stage”, permanent changes to the underlying tissues occur leading to extreme 
weakness and fixed dystonia in the affected limb, (Johan, et al,. 2011). 
Incidence rates of CRPS are unclear; two population-based studies arrived at very different data 
sets. A Netherlands based study found 26.2 cases per 100,000 person-years, and a USA based study 
found 5.5 cases per 100,000 person-years. Based on these varying data sets it can be surmised that there 
may be between 20,000-80,000 new cases per year in the USA. CRPS, once considered a rare syndrome, 
has lately become a more prevalent diagnosis, (Johan, et. al,. 2011). Some medical professionals believe 
its discovery by personal injury lawyers has greatly increased the reported incidents of CRPS, (Harden, 
2011).   
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1. CRPS Susceptibility via Genetic, Physiological, Psychological Predispositions and 
Onset Prevention 
 
A predisposition to Complex Regional Pain Syndrome (CRPS) would go far in helping to explain 
why only some patients with CRPS inducing injuries go on to develop the full-blown syndrome and why 
others do not. 
A. Genetic Predisposition 
Two studies have been done focusing on genetics being a predisposition variable in the onset of 
Complex Regional Pain Syndrome.  A study by Dutch researchers found evidence that CRPS, “runs in 
the family”. In this study, families with multiple familial CRPS occurrences were recruited through the 
Dutch Association of CRPS Patients and through referral by clinicians. The number of affected 
members per family and the phenotypic expression and inheritance were assessed. Demographic and 
clinical characteristics of Familial CRPS (fCRPS) patients were compared with those of sporadic CRPS 
(sCRPS) patients from a Dutch population-based study. Thirty-one CRPS families with two or more 
affected relatives were identified, including two families with five, four with four, eight with three and 
17 with two affected relatives. In comparison with sCRPS patients, fCRPS patients had a younger age at 
onset and more often had multiple affected extremities and dystonia. The study concluded that CRPS 
could occur in a familial form, but no with clear inheritance pattern, even in the absence of a trauma, for 
siblings of young on-set patients. The sibling recurrence risk ratio provides the ratio of risk of disease 
for a person given that a sibling is affected, compared with the risk to develop the disease in the general 
population. The study outcome found the sibling with a familial occurrence of CRPS under the age of 50 
had recurrence risk ratio of 3.4 to 5.6, values higher than 1 are indicative of familial aggregation, (de 
Rooij et al, 2008). 
Another CRPS genetic study, used gene technology to type the Class-1 and Class-2 Major 
histocompatibility complexes of CRPS patients. The study found that it’s fifty-two CRPS patients CRPS 
were found to have a higher frequency of the HLA-DQ1 antigen then the general population (M.A. 
Kemler et al, 1999). 
Taken as whole, these results indicate that there may be a genetic component to CRPS, and that 
young patients with a history of familial CRPS (fCRPS) should be aware that they carry a greater risk of 
developing this CRPS even in the absence of a severe trauma. 
 
B. Physiological Predisposition 
Early studies have found that the immobilization that follows an injury, especially in the case of 
fractures, due to casting, leads to physiological susceptibility and can cause the onset of CRPS (Johan et 
al, 2011). Supporting this theory, a recent study found that mechanosensitivity and thermosensitivity, 
characteristic features of CRPS, can be artificially induced, in healthy individuals, by immobilizing an 
extremity for four weeks, (Terkelsen et al, 2008).  
 
C. Psychological Predisposition 
In the past, there was a school of thought that promoted the concept of a “Sudeck personality” 
that predisposes one to CRPS. This “personality” construct was premised on the idea that individuals 
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with a speciﬁc psychiatric pathology are prone to develop CRPS. This psychiatric perspective of CRPS 
has persisted even in the absence of evidence to support such a conclusion (Feliu and Edwards, 2009). In 
fact, a recent multi-center cohort study of 600 bone fracture patients, clearly disputes the psychiatric 
perspective (Johan et al, 2011). In the study, 600 patients were made to undergo the “Symptom 
Checklist-90”, which is an instrument that helps evaluate a broad range of psychological problems and 
symptoms of psychopathology. The checklist results found that none of the psychological factors 
included in the list predicted the onset of CRPS (Beerthuzin et al, 2011). This isn’t to say that 
physio-phsyco co-morbidity does not exist in patients with CRPS. It has been definitively proven that 
CRPS patients have higher incidences of depression and anxiety then the general populace, (Bruhel, 
1992). Whether patients with CRPS have a higher rate of depression and anxiety then patients with other 
chronic pain syndromes is as of yet undetermined, (ibid).   
Regardless of if depression is a factor in the onset of CRPS, treatment for depression with 
tricyclic anti-depressants has tri-fold benefits for CRPS patients. A majority of CRPS patients are 
depressed because of the pain and immobility that CRPS causes. Tricyclic anti-depressants relieve the 
depression.  Pain is reduced due to the inhibitory affects that anti-depressant agents have on the 
re-uptake of  norepinephrine and sertonin, known analgesics. Patients with CRPS are known to suffer 
from insomnia due the incessant pain they experience. Some anti-depressant medications have sedation 
type affects that bring a welcome respite from the incessant pain, (Rho et al, 2002)  
 
D. CRPS Onset Prevention - Vitamin C 
An interesting, randomized, double blind trial, studied 123 patients with casted wrist fractures to see 
if vitamin C could help prevent the onset of CRPS. The experimental group was treated with 500 mg of 
Vitamin-C per day for 50 days; the control group was treated with a placebo. Seven percent of patients 
in the group taking vitamin C developed CRPS-I, against 22% of patients in the control group, (Paul 
Zollinger et al, 1999).  
There are many pharmacotherapy and interventional therapeutic techniques that are available in the 
treatment of CRPS. A line can be drawn between those with a discernible mechanism and those without. 
In addition, some treatments are directed at a specific presentation of the syndrome, while others are 
non-specific to the chronology and treat the general pain that is present in CRPS.   
 
I.  Pharmacotherapy & Interventional Therapeutic Techniques that are Stage Specific with 
Known Mechanisms.  
 
Acute Stage – Inflammation, Testing, Pain, and Treatment 
The origin of the inflammation during the acute stage of CRPS has pharmacotherapy 
implications, but its presence alone plays an important role in the diagnosis of CRPS, (Getson, 2006). 
Infrared Thermography is used to test for inflammation. The test is conducted on several symmetrical 
points on the affected and contra-lateral extremity, a temperature difference of 0.1 Celsius between 
contra-lateral limbs is considered telling and unusual,  (Rho et al, 2002). Magnetic Resonance Imaging 
(MRI) machines are also used in diagnosing the inflammatory component of CRPS because of their 
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ability to show activity deep in the muscle and connective tissue. The unusual MRI abnormalities found 
in the acute phase of CRPS are consistent with muscular edema, interstitial edema, and vascular 
hyper-permeability. Such MRI findings usually suggest the presence of hemodynamic abnormalities 
caused by sympathetic changes which may lead to ischemia of affected muscles. Chronic phase 
abnormalities indicated the presence of muscle atrophy and fibrosis or fatty infiltration of the affected 
muscle (Nishida, et al,. 2009).   
 
Three types of inflammation are possibly at play during the acute stage of CRPS, each with its own 
mechanism and treatment options:  
A. The Classic Inflammatory Response 
B. Neurogenic Inflammation 
C. Autoimmune Inflammation 
 
A1) Classic Inflammatory Response - Mechanism 
  Cornelius Celsus, a Roman encyclopediast, was the first to observe and transcribe the “Classic 
Inflammatory Response” as the presence of calor, dolor, tumor and rubor, which translate to warmth, 
pain, swelling, redness  (Celsus, 47 BC). In the case of CRPS patients, an acute Classic Inflammatory 
Response is undoubtedly present. Today, the cause of Celsus’s observations are known to be the result 
of localized macromolecule extravasation, tissue acidosis, and reduced oxygen extraction, which leads 
to severe pain via the formation of free oxygen radicals that damage and thicken the basement 
membrane, (Goris, 1991).  
 
A2) Classic Inflammatory Response - Treatment 
The theorized role that free oxygen radicals play in the pain and inflammation associated with 
CRPS has been shown to be efficacious by the successful use of treatment modalities that scavenge and 
remove free oxygen radicals. In a comprehensive randomized double blind study two free radical 
scavenger medications were used. Topical 50% Dimethylsulfoxide (DMSO) was applied five times a 
day, or N-Acetylcysteine (NAC) tablets were ingested three times a day. Both treatments were found to 
be equally effective in providing temporary relief from CRPS’s inflammatory response, (Perez et al, 
2002).  
 
B1) Neurogenic Inflammation - Mechanism 
A second possible culprit in CRPS’s inflammatory response may be caused by abnormal 
cytokine activity at the trauma site, which leads to “Neurogenic Inflammation”. Cytokines are heavily 
involved in the cascading reaction that activates the natural nociceptor response by the retrograde 
depolarization of small-diameter primary afferent nerves. This leads to the release of numerous 
neuropeptides, including, Substance P, Calcitonin Gene Related Peptide (CGRP), and Somatostatin, 
(Birklein F. , 2001). These neuropeptides in turn evoke a vasodilation and a protein extravasation 
response in the epidermis, leading to the signature reddening, warming, and edema, of CRPS, (Weber et 
al, 2000). 
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B2) Neurogenic Inflammation - Treatment 
Some neuropathic pain treatments that are used in 
treating other neuropathic pain conditions can be used in 
treating CRPS “Neurogenic Inflammation”. Capsaicin, a 
topical  
analgesic provides some inflammation relief for CRPS patients. Capsaicin is a unique alkaloid 
found primarily in the fruit of the Capsicum genus, is the primary capsaicinoid in the chili pepper fruit 
and is the cause of its pungent and spicy flavor. Structurally (Figure 1), Capsaicin or 
8-methyl-N-vanillyl-6-noneamidemide is almost always found in the trans isomer form. Cis form, would 
place the CH(CH3)2 and the longer chain on the other side of the double bond causing them to repel 
each other slightly; leading to severe steric hindrance which does not exist in the trans isomer, 
(Reyes-Escogido et al, 2011). 
Capsaicin works by binding to Transient Receptor Potential Vanilloid 1 (TRPV1), a 
non-selective, ligand-operated cationic channel, located primarily in the small fibers of nociceptive 
neurons. Bonding of Capsaicin to the TRPV1 receptor increases intra-cellular calcium and triggers the 
release of the neuropeptides: Substance P and calcium gene-related peptide (CGRP), which produces 
inflammation and a localized heat sensation by activating TRPV1’s heat-sensitive subunit. The initial 
release of Substance-P and CGRP is quickly followed by the inhibition of the re-uptake of Substance P 
from the terminals afferent nerves, which produces an analgesic affect due to the desensitization of the 
sensory neurons caused by Substance P depletion. CRPS patients with Allodynia, are hypersensitive to 
touch, and may not be able tolerate this topically applied treatment, (Reyes-Escogito et al, 2011).  
A CRPS double-blind study that investigated the use of Capsaicin in treating CRPS found it to be 
an effective pain reliever; all of the study’s 10 patients reported an average 4 point drop on the Verbal 
Analog Scale (VAS) which measures pain, (Wendye, Robbins et al, 1998). A mitigating variable may 
have been the use of commercially unavailable concentrations of capsaicin, average Capsaicin 
concentrations in over the counter creams are 2%, this study used much higher concentrations of 5%, 
7.5% and 10 percent. Because such high concentrations were administered the study’s patients were 
treated with epidural anesthesia prior to its application to avoid the intense burning sensation that it 
provoked.  It is very possible that the administration of the epidural anesthesia may have invalidated 
the study’s outcome by playing a role in modulating the neurologic and sensory response to the 
treatment.  
 
C1) Autoimmune Response - Mechanism 
A third, recently researched possibility, posits that CRPS inflammation is an “Autoimmune 
Response”. A study published in the journal of Clinical and Experimental Immunology found that an 
elevated monocyte count was not present in CRPS patients, a raised monocyte count being the usual 
marker of an autoimmune response. Still present, was an elevated count of the pro-inflammatory 
monocyte subgroup, CD14+CD16+. This result, coupled with research showing that patients with high 
CD14+CD16+ have low plasma concentrations of interleukin-10, a dominant player in the suppression 
of pro-inflammatory cytokines, lends credence to an autoimmune theory of CRPS inflammation (Ritz et 
Figure	  1	  (Google	  images)	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al, 2011). A small trial at University College London gave further support to an autoimmune 
inflammation theory. Participants in the trial were prescribed Intravenous Immunoglobulin (IVIG) 
antibodies, an autoimmune treatment modality, to treat CRPS inflammation. The study found that 
patients experienced 50% more pain relief with Intravenous Immunoglobulin over placebo, (Andreas 
Goebel et al, 2010). Limitations of the trial were its small size and that the effective dosage was not 
ascertained. 
 
C2) Autoimmune Response - Treatment 
 
  Ketamine, a veterinary and human anesthetic has been found to be efficacious in treating the 
CRPS “Autoimmune Response” inflammation.  Recent research found that ketamine suppresses 
lipopolysaccharide-induced tumor necrosis factor-A, interleukin (IL)-6, and IL-8 production, and 
recombinant human tumor necrosis factor-induced IL-6 and IL-8 production in human whole blood, all 
of which play a role in the proliferation of pro-inflammatory cytokines, (Kawasaki et al, 1999). In a 
recent case study in Germany, a single CRPS patient was treated with Ketamine after other CRPS 
treatment modalities failed to relieve the symptoms. Under standard ICU conditions the patient was 
given bolus injections of Ketamine while sedated with Midazolam. Upon waking the patient was 
relieved of all CRPS pain. After discharge from the hospital, the patient’s chief complaint was regarding 
the psycomimetic side effects of Ketamine. Steady treatment with Midazolam helped negate this side 
effect, which abated after a month. In a subsequent German study, a larger grouping of patients was 
used. The study concluded that Ketamine is only effective during the acute stage of CRPS, when pain 
and swelling is localized to the distal end of a limb. It was ineffective in treating chronic CRPS patients 
whose symptoms were refractory and spreading, (Kiefer et al, 2007). A recent double-blind study 
arrived at similar findings with Ketamine delivering significant pain relief when administered on an 
outpatient basis and in low doses, (Schwartzman et al, 2009). The aforementioned study did not find any 
evidence that Ketamine was ineffective based on the duration of the syndrome; the case study outcome 
can therefore be called into question.  
 
Corticosteroids – A non-mechanism specific inflammation treatment 
Corticosteroids, known commonly as steroids are part of a number of options that health 
professionals have when treating inflammation. Steroids are one of the most oft prescribed 
anti-inflammatory drugs and are an accepted treatment for the acute inflammatory stage of CRPS. The 
predominant effect of corticosteroids is to switch off multiple inflammatory genes that encode for, 
cytokines, chemokines, adhesion molecules, inflammatory enzymes, receptors and proteins that are 
activated during a chronic inflammatory process, (Fischera et al, 2010). 
A recent study evaluated the use Prednisolone, a steroidal anti-inflammatory, versus Piroxicam, a 
non-steroidal anti-inflammatory. The study found Piroxicam to be an effective inhibitor of arachidonic 
acid metabolism, an inflammation enhancing intermediate. It was also found to inhibit the production of 
the pain neurotransmitters, substance P and Calcitonin Gene Related Peptide, which play a part in the 
production of inflammation enhancing leukotrienes. The study concluded that Piroxicam seems to have 
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definitive chemical benefits, but little if any benefit in actually reducing sensory and motor pain, which 
continued unabated, (Kalita et al, 2005).  
These findings suggest a dominant neural mechanism in the pathophysiology in CRPS. 
Confounding this possibility was the study’s discovery that Prednisolone, the steroidal 
anti-inflammatory, was very effective in relieving actual pain in 83% of patients, (ibid). A drawback to 
this study was the failure to address this discrepancy. Some of the recorded side effects of long-term 
steroid use are hematologic, hepatic, musculoskeletal, neurologic and psychiatric damage and in some 
cases a severe weakening of the heart, (Parker and Thompson, 2010). 
 
IV. Acute Stage - CRPS Bone Resorption, Testing, Pain and Treatment 
Bone Resorption Testing 
Bone resorption in CRPS can be diagnosed by simple radiography and Three Phase Bone 
Scintigraphy tests. Both tests register the presence of bone resorption and osteoporosis. A normal bone 
scan finding, without radiographic osteoporosis, precludes a diagnosis of adult CRPS.  Some 
disagreement has been registered as to how early-on radiography can be used. A study by  P.H.J.M 
Veldman (1993) I in the Netherlands, found spotty osteoporotic changes 4-8 weeks after a CRPS 
diagnosis. Other research has pointed to there being spotty changes earlier at the two-week marker, (Rho 
and Brewer, 2002).  
Three Phase Bone Scintigraphy coupled with the tracer, Technetium Tc-99 Bisphosphonates, is 
highly sensitive test that can detect osseous changes earlier then radiography. A positive result will 
register a marked increase in tracer uptake during bone scintigraphy’s, blood pool, blood, and 
mineralization phases. Increased tracer uptake is an indication of increased bone metabolism and 
breakdown. Some variability in the results of Bone Scintigraphy has been found based on the duration of 
CRPS , (Rho and Brewer, 2002).  
 
Bone Resorption Pain 
Immunohistochemical studies of the bone have shown there to be an extensive network of 
peptidergic and sympathetic sensory fibers that are present throughout the bone marrow and periosteum, 
Included in this network are two acid sensors, Acid-Sensing Ion Channels (ASICs) and Transient 
Receptor Potential Vanilloid Subtype 1 (TRPV1). In CRPS patients these pain-inducing receptors are 
activated by the presence of an acidic microenvironment in the bone. CRPS’s acidic bone environment 
is generated by osteoclasts, a membrane bound proton pump that releases protons (acid) through 
Vacuolar H+-ATPase. Osteoclasts are the primary culprit in bone resorption, (Yanow et al, 2008).  
Also active and present during CRPS bone inflammation are: mast cells, macrophages, 
endothelial cells, osteocytes, osteoblasts, and bone marrow stromal cells, which are involved in the 
production and storage of Nerve Growth Factor (NGF) protein. When present, NGF initiates the 
transcription for genes that encode the TRPV1 pain receptor, causing a further increase in the already 
painful CRPS nociceptive response. Cytokines and Prostaglandins are also found in the CRPS bone 
micro-environment and act synergistically to activate the network of nociceptors innervating the bone 
and bone marrow (Leon and Buriani, 1994). 
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Bone Resorption Treatment  
An accepted treatment for CRPS bone related pain are, nitrogen and non-nitrogen 
bisphosphonates, which have anti-nociceptive properties that ameliorate bone pain; bisphosphonates 
work on osteoclasts and inhibit their activity leading to a decrease in the proton concentration and Nerve 
Growth Factor expression in the bone micro-environment. The non-nitrogen bisphosphonates, 
Clodronate ® and Etidronate ®, work by causing the buildup of metabolites in the cell which inhibit 
osteoclasts from functioning, causing cell death. Nitrogen-containing bisphosphonates, such as 
Alendronate®, Risedronate® and Zoledronate® interfere with the mevalonate biosynthetic pathway and 
protein lipidation, and in the signaling functions of key regulatory proteins, also leading to cell death. 
Bisphosphonates are a well-vetted and efficacious treatment, which has been well documented in four 
studies, (Manicourt et al, 2004; Robinson and Sandom, 2004; Varenna and Zucchi, 2000; Admai and 
Fossaluzza, 1997).  
 
The randomized, double-blind study done by Varenna and Zucchi on the use of Clodronate®, 
found that 72% of patients showed significant pain relief 40 days into the trial. The numbers continued 
to improve with the passage of time, 75% at 90 days and 93.2% at 180 days, all experienced significant 
pain relief.  Taken as a whole, these studies point to bisphosphonates being very useful in the treatment 
of CRPS bone related pain. The aforementioned studies did not find that bisphosphonates relieved any 
of CRPS other symptoms and the pain associated with them. Since their use is limited to bone pain, 
bisphosphonates need to be incorporated into a complete pharmacotherapy solution in order for CRPS 
patients to gain effective relief from the syndrome. 
 
V. Non-Stage Specific Pharmacotherapy & Interventional Therapeutic, with known 
mechanisms.  
 
Neurogenic Pain relief via Regional Sympathetic Blockade 
Intravenous regional anesthesia was first proposed by Dr. August Bier in 1908 and till today is 
known  as the “Bier Block”. Technically the treatment is simple. A tourniquet is applied to the ailing 
extremity creating a complete venous blockade followed by the injection of an analgesic. This treatment 
modality has since been used in the treatment of many localized pain diseases. In 1974 John 
Hannington-Kiff proposed a CRPS treatment with a derivative of the Bier Block, called Intravenous 
Regional Sympathetic Blockade (IRSB), (Hanington-kiff, 1974). The favored analgesic for this 
procedure was Guanethidine, because it is sympatholytic that selectively prevents peripheral 
sympathetic nerve transmission with the following mechanism: at first, when injected, Guanethidine 
causes the release of norepinephrine from the synaptic cleft, followed by the movement of Guanethidine 
into the synaptic cleft via uptake 1; it is then transferred into the presynaptic norepinephrine vesicle via 
norepinephrine transporter, also known as NET. Because norepinephrine is prevented from returning to 
the vesicle there is an initial spike in the sympathetic tone of the limb. Once the released norepinephrine 
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is metabolized, the Guanethidine populating the norepinephrine vesicle prevents the further production 
and release of norepinephrine, leading to a state of analgesia, , (Tollison and Satterthwaite, 2002).   
The few double-blind studies that have reviewed the use of Guanethidine have shown it to be 
ineffective against a saline placebo in both short and long-term observations, (Kingery, 1997). A number 
of other sympatholytics such as Reserpine®, and Clonidine® have been found to be ineffective in 
relieving CRPS pain, aside from Bretylium®, which showed positive effects when used in the IRSB 
treatment, (ibid).  
Local Anesthetic Sympathetic Blockade (LASB) is another Bier Block type treatment modality 
that is precluded from needing a tourniquet because the anesthetic solution is injected directly into the 
spine’s sympathetic structures. In this procedure, one of two spinal structures are targeted, either the 
stellate ganglion, or the lumber sympathetic chain. The injection takes place under fluoroscopic or 
computed tomographic guidance to avoid damaging the spinal column. Once injected, the anesthetic 
solution induces a complete signal blockade. All sympathetic signals to and from the affected limb are 
effectively muted by the anesthetized spinal structure.  
In the past, the “gold standard” for the treatment of CRPS was the local anesthetic sympathetic 
blockade (LASB). The LASB treatment played a unique role in diagnosing and treating CRPS. It was 
unique in this dual application. The 1993 Orlando Conference changed this role when CRPS’s 
diagnostic criterion was modified to exclude an analgesic response to a sympathetic nerve block. 
Thereafter, LASB was no longer considered an essential piece of confirmatory diagnostic information 
because the syndrome’s classification was broadened to include patients without Sympathetically 
Maintained Pain (SMP). Accordingly, a response to a sympathetic block is not required to diagnose 
CRPS because the syndrome’s criterion now includes patients without sympathetic dysfunction. 
Identifying patients who have Sympathetically Maintained Pain is still very important because of the 
short term relief gained from a sympathetic blockade; this effective short term relief has made the LASB 
the go to adjunctive therapy for patients undergoing physiotherapy, (Sharma and Williams, 2006).  
But this positive view of LASB has been tempered by a comprehensive review on behalf of the 
Chocrane Collaboration where little evidence was found to support the positive view of LASB  . The 
Chocrane Collaborations criteria for inclusion were that the trials be randomized and double blind. 
Excluded from the review were studies evaluating somatic nerve blocks and studies evaluating the 
effects of orally, intravenously and epidurally administered anesthetic or sympatholytic drugs.  Two 
unpublished studies cited in this review, fit this criterion.  One, a double-blind study by Dr. Donald D. 
Price, found that six out of seven patients experienced at least 50% short-term pain relief when treated 
with the anesthetic Lidocaine® over normal saline. The duration of relief was 3 days for local 
Lidocaine® versus 19.9 hours for the saline placebo. A second study by R.J. Verdugo found that 12 of 
16 patients had at least 50% short-term pain relief while receiving Bupivacaine® versus the saline 
placebo. The combined Relative Risk Ratio of these two trials was 1.17. A Relative Risk Ratio of 1.17 is 
slightly greater then a Risk Ratio of 1, which implies little significant difference was found between 
experimental and control groups in the study. These findings clearly show that LASB treatment needs 
further research to reclaim its status as a “gold standard” in treating CRPS. The studies long-term 
outcomes were precluded from being combined in a Risk Ratio because the both studies gauged 
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different outcomes. Dr. Price recorded the duration of pain relief, while Dr. Verdugo evaluated number 
of subjects who had at least 50% of pain relief (Cepeda et al, 2010).   
  
Neurogenic Pain Treatment: Surgical and Chemical Sympathetic Denervation  
  CRPS patients with Sympathetically Maintained Pain (SMP) suffer from a dysfunctioning 
Sympathetic Nervous System. Permanently denervating the system inhibits signaling and can be 
achieved via a surgical or chemical sympathectomy.  
 
Surgical denervation 
Surgical denervation is accomplished via Open Lumbar or endosopic sympathectomy surgery, 
(Bandyk et al, 2002). In these procedures the sympathetic ganglion are destroyed via its open removal or 
by electro-coagulation. A well recognized side effect to a surgical sympathectomy is hyperhidrosis, this 
side effect was recognized as early as 1933, when a Dr. J. Paterson Ross lectured at the Royal College of 
Surgeons in London and recounted that, “some of our patients have stated emphatically that the 
secretion of sweat has been considerably more profuse in areas not affected by the operation . . . the 
remark has been so frequently made that the possibility of compensatory hypersecretion cannot be 
excluded”, (Ross, 1933). Current research wholly concurs with his observation. In one study, patients 
experiencing palmer hyperhidrosis that underwent a sympathectomy almost all experienced some form 
of compensatory sweating, usually in the trunk area, (Gossot et al, 2003; Ojimba & Cameron, 2004). 
Another study of 73 patients found that 8 out of the 83 surgical sympothectamy procedures done in the 
study, 10 of the studies 73 patients needed the procedure to be repeated, resulted in Hyperhidrosis, 
(Bandyk et al, 2002).  
 
Chemical Sympathectomy 
  Chemical Sympathectomy is achieved by injecting 50% to 100% ethanol or 7% to 10% Phenol 
into sympathetic ganglia, (Dunn, 2000). Phenol, a strong anti-septic solution causes protein coagulation 
and necrosis when directly applied to nerves (Copping et al, 1969). Ethanolcauses alcohol neurolysis, 
which involves the extraction of phospholipids and cerebrosides from the neural membranes and by 
precipitation of mucoproteins. Both are effective in causing nerve / ganglion death which delivers 
anesthesia by the inhibition of nociceptive signaling.  The only available double blind of chemical 
sympathectomy contrasted the use of chemical sympathectomy to radio frequency sympathectomy. Both 
treatments were found to equally effective in delivering 50% pain relief in a grouping of 20 patients, 
(Straube et al, 2010).   
 
VI. Pharamcotherapy & Interventional Therapeutic Techniques with Unknown 
Mechanisms  
 
Bone Resorption Treatment - Calcitonin  
In 1961, Dr. D.H. Copp discovered a calcium-regulating neuropeptide hormone. At the time of 
his discovery he was studying the control of calcium secretion by parathyroid hormone (PTH) when he 
found that a neuropeptide was released in the presence of hypercalcemia that lowered plasma calcium by 
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inhibiting osteolysis. The newly discovered neuropeptide was named calcitonin (Copp, 1994). 
Subsequently, experiments were performed to see if in vivo use of calcitonin would be useful in the 
treatment of osteoporosis / bone resorption, (Özoran and Seçkin, 2005),  studies have concluded that 
Calcitonin is an effective in the treatment of osteoporosis, (Karsdal et al, 2010).The use of intramuscular 
or subcutaneously injected calcitonin is not without side effects. Its most common side effects being 
gastrointestinal: anorexia, nausea, vomiting, a metallic taste and diarrhea are the prevalent presentations 
of its gastrointestinal effects. Vascular phenomena, such as flushing or shivering, are also observed in 
some patients. Generally these side effects are dose related and inconvenient rather than serious, but 
they can occur in up to 80% of patients on high doses, (Siminoski et al, 1996).  
In addition to inhibiting osteoporotic type bone resorption, calcitonin was found have analgesic 
effects on bone related pain, making it a perfect candidate for the treatment of CRPS patients suffering 
from bone resorption and bone pain, (Blau, 2003). A study of CRPS patients by Fushun Sahin and Figen 
Yilmaz assessed the efficacy of salmon calcitonin in a randomized, single-blind study. The control 
group received Paracetamol®, an over the counter analgesic 1500 m/day, while the other experimental 
group received salmon calcitonin 200 IU/day, for 2 months. Both the control and experimental groups 
showed remarkable recovery on either paracetamol or calcitonin when given the treatment in 
conjunction with physical therapy, but little marked difference was found between the two groups. The 
study concluded that physical therapy combined with a simple analgesic is an efficient means of therapy 
and that calcitonin makes little or no contribution in the treatment of patients with acute CRPS, (Sahin et 
al, 2006).   
Another study utilized nasal calcitonin given the disadvantage in the administration of regular 
calcitonin, i.e. it must be administered parenterally. This prospective randomized double-blind study; 
using sensitive methods of measuring the response to treatment, did not demonstrable any effect on the 
clinical or skeletal progression of CRPS bone resorption,. The authors hypothesized, “not finding a 
difference between the treated and placebo wing is that the bioavailability of the nasal formulation was 
too low. Although there was a small decrease in serum calcium during the treatment period, the response 
was not associated with changes in the indices of bone turnover. In particular, the fasting urine excretion 
of calcium did not change. This suggests that the decrease in serum calcium was due to a decrease in 
renal tubular reabsorption of calcium, a known action of calcitonin”, (Bickerstaff and Kanis, 1992)  
A blinded meta-analysis of 21 CRPS treatment clinical trials concluded that using Calcitonin in 
the treatment of CRPS has a positive effect on pain on average and encouraged its use, (Perez et al, 
2001). Perez based his assertion on a study that found calcitonin to have the conclusively beneficial 
effect of significantly less pain, (Gobelet et al, 1992). Calcitonin’s mechanism and effectiveness as a 
treatment option, remains as of yet undetermined. The antinociceptive properties of calcitonin have been 
attributed to serotoninergic and cathecholaminergic mechanisms, Ca 2 fluxes, protein phosphorylation, 
endorphin production, cyclooxygenase inhibition and histamine inference. None of these mechanisms 
have been conclusively proven.   
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Gabapentin   
Gabapentin was marketed for the first time in Febuary 1994 as an anti-convulsant drug. Today it 
is widely viewed as an affective adjunctive therapy for seizures. Structurally, it is an analogue of 
y-aminobutyric acid (GABA). It’s synthesis as a GABA mimetic drug was so that it could cross the 
blood-brain barrier. Pharmacologicaly it is different from other substances that interact with GABA 
synapses for the reason that it binds only in the outer layers of the neocortex and hippocampus and does 
not bind with GABA receptors at all.  
The first gabapentin study on RSD patients had a remarkably successful outcome with all six 
patients, with one fully recovering from RSD.  The authors hypothesized that a gabapentin induced an 
increase in 5HT, (which are serotonin receptors) and serotonergic-like activity at a novel receptor site in 
the CNS, and also via serotoninergic fibers in the raphe magnus which descend into the posterior portion 
of the lateral funiculus of the spinal cord.  
These descending fibers they posited blocked the transmission of nociceptive information 
through the dorsal horn and root ganglion by reciprocally blocking pain-inducing catecholamines, 
resulting in a gradual reduction of the nor-adrenergic induced hyperalgesia, , (Mellick and Mellick, 
1995). A problem with their hypothesis is that it was vicariously deduced from the increased presence of 
serotonin in patients treated with gabapentin. Therefore few definitive conclusions can be drawn from it. 
Even so, the efficacy of the use gabapentin to treat CRPS “pain” is well founded. A double-blind and 
randomized placebo-controlled 8-week study of 304 CRPS patients found that measured pain scores 
decreased by 21% in patients receiving gabapentin and by 14% in placebo treated patients, (Serpell, 
2002). 
 
Spinal Cord Stimulation 
Spinal cord stimulation is a relatively new therapeutic modality to gain acceptance in the 
treatment of CRPS. In 1965, Melzack and Wall published a revolutionary paper that theorized that a 
“gate” existed in the dorsal horn of the spinal cord which controlled the transmission of neural activity 
that signaled pain. This “gate” was said to be open when there was an excess of small over large afferent 
fiber activity in the peripheral nervous system, and the gate was closed when there was an excess of 
large-diameter afferent fiber activity. On the basis of this theory, scientists have tried to selectively 
activate large diameter afferent fibers through electrical stimulation, thereby closing the “gate” and 
reducing or eliminating painful inputs to the spinal cord and brain, (Melzack and Wall, 1965). Utilizing 
this theory, medical professionals have been able to induce this effect using a spinal cord stimulator 
which is surgically placed along the spine. It is theorized that its analgesic effect may come from 
neuromodulation that restores normal gamma-aminobutyric acid (GABA) levels in the dorsal horn and 
affects the release of adenosine, which is an anti-inflammatory, thereby reducing neuropathic pain 
(Oakley and Prager, 2002).  
A systematic review of the literature on spinal cord stimulation reported a meaningful 2-point 
mean reduction in the Visual Analogue Pain Scale ratings in patients with CRPS type-I, (Taylor et al, 
2006). This was based on results derived from a randomized controlled study (Kemler et al, 2000), and 
25 other case series. The controlled study wasn’t blinded for the obvious reason that it is not advisable to 
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try to mimic parasthesia-type effects on the spinal cord of patients in the placebo group. The controlled 
study showed -2.7 drop on the Visual Analogue Pain Scale  scale in the spinal cord stimulated group at 
12 months, while the control group had a +0.4 increase on the Visual Analogue Pain Scale pain scale. 
The systematic review data showed that almost two-thirds of CRPS type-I and type-II patients, reported 
at least 50% improvement in their pain scores over a median follow-up period of 33 months. It can be 
concluded that spinal cord stimulation is an efficacious treatment for CRPS patients with 
sympathetically maintained pain.  
 
In addition to the study’s pain analysis, Taylor also reviewed treatment cost to ascertain long 
term cost of spinal cord stimulation vis-à-vis physical therapy.  He found that the control group which 
received physical therapy cost $6000 over 12 months. The spinal cord stimulation treatment group had a 
significantly higher balance of $10,200. But in an interesting turn around, the cost numbers reversed 
over time and the spinal cord stimulation treatment produced a lifetime cost saving of approximately 
$60,000.  
 
 
Opioids 
Opioids are one of the oldest classes of pain relievers, (Ballantyne and Mao, 2003).   Victorian 
women were said to use a morphine containing tincture called, laudanum, which is a 40% ethanol 
solution of dissolved opium and herbs. This was done to treat the travails and boredom of  Victorian 
life, accomplishing what is known in the vernacular as getting high, (Berridge and Edwards, 1987). 
Opioids are still used in the treatment of chronic nociceptive and neuropathic pain, (Harke et al, 2001). 
Research has shown that opioids are ineffective in delivering analgesia in low dosage; concurrent 
research has found that the use of opioids in large dosage can itself cause hyperalgesia, a key symptom 
of CRPS. Other known opioid side effects are hypogonadism, long-term cognitive impairment, 
personality changes, tolerance, long-term toxicity and drug dependence (Harden, 2007). The use of 
opioids in treating neuropathic pain has been frowned upon for some time, not because of its cornucopia 
of side effects, but also because research found it be an ineffective treatment modality.   A study found 
infusions of morphine to be completely ineffective in relieving neuropathic pain, (Arnér and Meyerson, 
1989).  
Current research is slowly shifting this negative opioid perspective. A randomized control study  
used Methadone to treat 20 patients and found statistically significant pain relief P 0.013-0.020 on the 
Visual Analogue Pain Scale  scale, (Morley et al, 2003). Dose titration must be done cautiously, since 
large differences in Methadone dose tolerance have been found, (Cruciani, 2007). In too large dosage 
Methadone causes drug toxicity and affects the heart by causing an elongated QTc interval, (Kornick et 
al, 2003). Still, its prolonged half-life, potency, and low cost make it a preferable candidate amongst 
other opioids.  Tramadol, another opioid, has also been vindicated as an effective reliever of allodynia 
and other pain in recent randomized double-blind study, (Sindrup et al , 1999). Intrathecal analgesia can 
be achieved with an injection of Baclofen for patients that cannot tolerate orally administered opioids 
because of their side effects, (Cohen 2007). 
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Physical Therapy   
 Physical Therapy is broadly mentioned in the literature as an important aspect in recovering from 
CRPS, (Harden R.  2011; Kemler et al, 2000; Rho et al, 2002). Unfortunately there is little hard 
evidence to support this treatment modality. An oft mentioned proof of Physical Therapy’s 
effectiveness, is randomized double-blind study of patients with CRPS Type-I of less than one year of 
duration, which indicated that physical therapy was superior to occupational therapy, and that both 
physical therapy and occupational therapy were more effective then social work therapy, (Oerlemans et 
al, 2000). Unfortunately, the study’s outcome was tempered by the fact no signiﬁcant differences were 
found in the long-term for active range of motion of the shoulder, elbow, and forearm utilizing the three 
treatment modalities.  The immediate improvement seen in patients that were treated with physical 
therapy weren’t any different then the control group a year after inclusion in the study.  
 
Conclusion 
If left untreated, CRPS can result in permanent deformities and chronic pain requiring a range of 
long-term pharmacologic and non-pharmacologic treatments. If CRPS is caught early, sympathetic 
nerve blocks may be used to stop or cure the progression of the disease. Other therapies used to treat 
patients with CRPS such as, spinal cord stimulation, opioids, anti-inflammatory medications can all play 
a role in modulating and sometimes curing CRPS pain. The absence of well-defined criteria for the 
diagnosis of this syndrome has resulted in a lack of Randomized Controlled Trials for the treatment of 
CRPS. Some of the medications that have been tested to treat the CRPS population include certain 
antidepressants, anticonvulsants, anesthetics, anti-inflammatories, opioids, calcitonin, bisphosphonates, 
and neuropathic coanalgesics. There are no medications that are FDA approved for the treatment of 
CRPS.  
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Abstract 
  This review seeks to find the most efficient treatment for alopecia areata. Alopecia is not very well 
understood as demonstrated by the unsatisfactory treatment options. The author reviewed many studies 
with different treatment options and concluded that treatment with Diphenylcyclopropenone (DPCP), a 
topical sensitizer, has the best results and that extensive research into the pathogenesis of alopecia areata 
is still necessary and may result in better treatment options for those afflicted with the disease. 
Alopecia Areata: an Overview 
Hair is an important part of the human presence; it is the crowning glory that sits upon one’s 
temples. Therefore, hair loss of any sort is extremely painful and embarrassing.  Most people 
automatically correlate hair loss with cancer treatments or old age. However, there is another less known 
mechanism of hair loss; alopecia areata, an autoimmune disease, causes partial or complete hair loss to 
occur. Alopecia areata affects approximately four and a half million people in the United States (Etzioni 
et.al. 2012).  The prevalence of this disease raises many questions, namely: Why does this spontaneous 
hair loss occur? Does alopecia areata occur in response to stress, or is it due to genetic factors? How can 
it be treated? 
  The Hair Cycle 
 In order to understand the nuances of the pathogenesis of alopecia areata, it is necessary to be 
familiar with the normal hair cycle. Normal hair follicles go through several stages; the anagen or 
growth phase, the catagen or regression phase, and the telogen or rest phase. Then the follicle goes 
through a fourth, shedding phase, called the exogen phase. 
 The dermal papilla of the hair follicle consists of an oval cluster of mesenchymal cells. A 
substance that is full of acid mucopolysaccharides surrounds the mesenchymal cells. The whole 
structure is at the very bottom of the follicle, and is surrounded by the matrix cells. The dermal papilla is 
responsible for initiating and directing hair growth (Alaiti, 2011). Figure 1 depicts the location of the 
dermal papilla on a healthy hair follicle. 
 
 
Figure 1- structure of hair follicle (Promocell). 
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  During the anagen phase, the dermal papilla grows (Botchkarev, Cotsarelis 2012). The hair 
matrix, of the follicle, consists of many epidermal cells that then proliferate rapidly into six different 
types of cells. These daughter cells move upward and become part of the Inner Root Sheath (IRS) and 
the Hair Shaft (HS). The HS cells shed their organelles and become stratified with bundles of 
cysteine-rich hair keratin filaments. The IRS also keratinizes by forming trichohyalin granules.  Soon 
the matrix cells cannot proliferate any further, and the follicle enters the catagen stage (Alonso, Fuchs 
2006). 
 In Catagen, the epithelial cells in the outermost epithelial layer undergo apoptosis (Botchkarev 
et.al. 1997).  The Hair bulb becomes keratinized forming a club hair. This cuts the follicle off from its 
blood supply. The club hair then travels upwards, pushed forward by a column of epithelial cells. At first 
the column of cells is thick but soon begins to shrink upward becoming secondary follicular germ cells 
(Alonso, Fuchs 2006) (Alaiti, Samer 2011).  
 After the club hair is formed, the telogen phase begins. The follicle prepares to shed the hair 
from the scalp (Botchkarev, Cotsarelis 2012). The dermal papilla and secondary germ cells form the 
telogen germinal unit.  
 Exogen is the shedding phase.  In this phase, the old hair is shed after the new anagen phase 
begins.  
 Figure 2 illustrates the four stages of the normal hair cycle. 
 
Figure 2 - The Stages of the Normal Hair Cycle (Australian Skin Clinics). 
In alopecia areata, the general hair cycle is disrupted and disfigured.  The follicles show signs 
of dystrophy in the anagen phase. This is caused by an inflammatory infiltrate that surrounds the hair 
bulb, the base of the hair follicle. The infiltrate is mainly composed of T-cells, but it also includes 
eosinophils, mast cells, plasma cells and Langerhans cells. There is also some penetration of 
lymphocytes to intrafollicular areas (McElwee, Wang 2011). Most cells enter and attack the dermal 
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papilla and hair matrix, causing apoptosis and necrosis of the follicle’s epithelium. The inflammation 
cripples the hair shaft, eventually forming the exclamation-point hairs that are associated with alopecia 
areata (Dy, Whiting 2011).   
 Although old hair is only shed after the new growth begins in healthy hair follicles, in follicles 
with alopecia areata, exogen commonly occurs before anagen begins. This results in a state where no 
visible hair fiber is left in the follicle. This state is called kenogen (McElwee, Wang 2011).  
In the most severe form of alopecia areata, all body hair is lost. This condition is referred to as 
alopecia universalis. This condition is rare. 
Diagnosis Of Alopecia Areata 
 The first step in treating any disease is to diagnose it. Alopecia areata is identified through a 
physical examination.  In its general form, alopecia areata is recognized by its typical hair loss pattern- 
causing round or oval, smooth patches of hair loss that are most noticeable on the scalp and eyebrows 
(Etzioni et.al. 2012). Figures 3a and 3b depict the pattern of hair loss triggered by alopecia areata. 
                   
Figure 3a- alopecia areata symptoms http://www.curespotbaldness.com 
Figure 3b- alopecia areata symptoms http://www.curespotbaldness.com 
First, the dermatologist will perform the “hair pull” test. The doctor will use his/her thumb and 
index fingers to gently tug at hairs in various areas of the scalp. On a healthy scalp, between 2 and 6 
hairs will detach. If more hairs fall out, that indicates excessive shedding.  The dermatologist will then 
proceed to study the hairs underneath a microscope. This is done to determine the growth phase of the 
hair. Normally, the hairs that fall out easily are in the telogen phase. Anagen roots are stronger, younger 
and still growing. If the pulled roots are in the anagen phase, this is indicative that there is a serious 
health problem (Tosti, Gray 2007) 
A newer diagnostic tool is known as videodermoscopy; it involves a high-definition video 
camera allowing for a direct, magnified examination of the scalp (Ross et.al. 2006). Videodermoscopy is 
a helpful diagnostic tool when trying to differentiate between similar diseases. In the case of alopecia, 
videodermoscopy can be used to differentiate alopecia areata from other causes of patchy alopecia. Use 
of the technology shows that in cases of alopecia areata, numerous yellow dots, known as degenerate 
follicular keratinocytes, are found on the scalp surface (Tosti, Gray 2007).  Figure 4 shows the 
exclamation mark hairs and yellow dots found on patients with alopecia areata. 
a	  
	  
b	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Figure 4- Alopecia areata- standard exclamation mark hairs (Tosti, Gray .2007) 
The dermatologist will also examine the patient’s nails, as alopecia areata is thought to be 
associated with nail dystrophy (Bergfeld, 2009). At times, nail distortion is one of the first signs of 
alopecia areata. Symptoms include; tiny dents on nails, white spots, lines, roughness, loss of natural 
shine, and splitting.  
Causes 
The etiology of alopecia areata is complex: determinants of the disease include genetic factors, 
psychological factors, autoimmune processes, and infectious factors. Despite active research on alopecia 
areata, investigators still have a limited understanding of its pathogenesis and etiology. 
Genetics 
 A genetic basis for alopecia areata was indicated by statistical studies which showed that 
relatives of a patient diagnosed were more likely to have the condition themselves. For example, in one 
study of 206 patients with alopecia areata, 5.5% of their immediate family members (parents, siblings, 
children) were also stricken with alopecia. Of the 206 patients, forty-five had at least one immediate 
family member with the disease (Blaumeiser et.al. 2006). 
After early statistical studies of alopecia areata showed high family-linked prevalence for the 
disease, researchers began searching for genes linked to its outbreak.  In 2011, researchers performed 
the first genome-wide association study of alopecia areata. This identified 139 significant single 
nucleotide polymorphisms (SNPs) in eight sections throughout the genome, which implicated genes of 
the immune system and the hair follicle. For example, one important find was the involvement of 
chromosome 2q33.2 (CTLA4). CTLA4 becomes displayed following T cell activation (Petukhova et.al 
2011). It is assumed that CTLA4 plays a critical role in the onset and maintenance of alopecia areata. 
CTLA4 binds CD80 and CD86 on antigen-presenting cells. One study injected monoclonal antibodies 
(mAb’s) against antigen presenting cell (APC) surface markers CD80 and CD86 as well as a 
monoclonal anti-CTLA4 antibody into mice that were predisposed to develop alopecia areata in an 
attempt to interfere with the interactions between T cells and antigen presenting cells that involve 
CTLA4. The treatment prevented the onset of the disease, proving that CTLA4 plays a big role in the 
pathogenesis of the disease  (Sundberg et al. 2011). 
Psychological Factors 
In a group of 45 patients with alopecia areata, 31 identified stressful events, including death of a 
parent, family disputes, and exams. Most events occurred less than three months before the onset of the 
disease (Manolache, Benea 2007). Another study investigated the effects of a heat treatment, a stressful 
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event, on mice that were predisposed to develop alopecia areata. Petroleum jelly was applied to the 
mural skin to improve conductance. Then, heat was applied with a copper cylinder connected to a 
precision water bath (119.3°F) for twenty minutes daily for 12 consecutive days. Researchers then used 
an icepack to cool the area (Wikramanayake et.al. 2012). While the mice generally begin to show signs 
of alopecia at 18 months, mice that underwent the treatment developed signs of the disease at least ten 
months earlier than normal. This study suggests that stress does not cause alopecia areata to occur, but it 
may help promote onset of the disease (Wikramanayake et.al. 2010). 
One question arises from this study: Perhaps the heat itself destroys the hair follicle, and that’s 
what caused the hair loss. The study used a control; forty mice were treated with room temperature 
water. Of these mice, only 7% developed the disease. Was the higher hair loss rate in heat-treated mice 
due to the stress or to the heat itself? While it is possible that some of the hair loss was due to the heat 
itself, the presence of alopecia areata was confirmed when histological studies showed that there were 
leukocyte infiltrates in anagen hair follicles (Wikramanayake et.al. 2010). 
Autoimmunity 
 Research results overwhelmingly point to the conclusion that alopecia areata is an autoimmune 
disease. There are many indications supporting this belief:  
Firstly, as mentioned previously, a thick cluster of lymphocytic cells surrounds alopecia areata- 
affected hair follicles. These include antigen presenting cells (APCs) such as macrophages and 
Langerhans cells, which are sometimes even found within the hair follicle. 
Another reason is that alopecia areata is associated with other autoimmune diseases such as 
thyroid disorders and vitiligo (Thomas et.al. 2008). Alopecia areata also responds to immunomodulatory 
treatments such as corticosteroids, light phototherapy, and non-specific irritants such as anthralin and 
inducers of contact dermatitis (Lu et.al. 2006).  
One proposed hypothesis is that the follicles’ immune-privileged state is compromised in 
alopecia areata. Thus, normally innocuous hair-follicle-specific proteins are exposed to activated 
antigen-presenting cells. The antigen-presenting cells capture and process these proteins, which are then 
expressed on major histocompatibility complexes class II and I as antigens (Lu et.al. 2006). These 
antigens originate in the body and are known as autoantigens (Hordinsky, Ericson 2004). The exposed 
antigens activate T cells; they proliferate and travel to the skin forming the infiltrate around 
anagen-stage hair follicles, disrupting hair growth and the hair follicle dystrophy. As a result, the anagen 
phase is cut short and the follicles enter an early telogen phase. This cycle continues and hair loss occurs 
(Lu et.al. 2006).  
A few questions arise from the previous paragraph. The first question is: what stimulates the 
breakdown of immune privilege in the hair follicle? The second question is: What causes the 
dysfunction of immunoregulation that is supposed to delete autoreactive T cells? A third question is: 
which proteins function as the autoantigens in alopecia areata?  
These questions are important because their answers can give insight on how to treat the disease. 
For example, if the disease initiation were caused by loss of immune privilege in the follicle, a possible 
therapeutic mechanism would be to replace or reinforce immune privilege. This can be done through 
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promoting immune-protective cytokines and cell ligands, which reduce the exposure of follicular 
antigens (Lu et.al. 2006). 
The first two questions can be explained by genetic studies, as discussed previously. The third 
question is the subject of a lot of current research on alopecia areata. If the autoantigens involved in 
alopecia areata were identified, new treatment strategies can be developed. It could be possible to 
modify or inhibit autoantigen presentation. Another method mentioned by Lu and his co-authors would 
be to expose the immune system to such large amounts of antigen polypeptides that would then overload 
the receptors of pathogenic, autoreactive lymphocytes and could theoretically cause anergy or death of 
these cells (Lu et.al. 2006).  
However, Hordinsky and Ericson (2004), mention that an autoantibody has yet to be implicated 
in alopecia areata. Gilhar and Kalish (2006), came to the logical conclusion that the autoantigen 
involved should be melanocyte derived. This is because generally alopecia areata affects only pigmented 
hair.  
In a separate experiment, researchers used immunoperoxidase stains to test scalp samples for 
melanocyte density. They found that scalp samples from alopecia areata patients had a decreased 
number of follicular melanocytes. The researchers did not know if the decrease in melanocyte density is 
caused by the immune attack or by the rapid hair cycles that characterize the disease (Trautman et.al. 
2009). Although these results are not conclusive, they do back the theory that autoantigens in alopecia 
areata may be derived from melanocytes. 
 Another recent study isolated a structural protein, trichohyalin, as a potential autoantigen 
involved in alopecia areata, as well as Keratin 16. Researchers used mass spectrometry on ten samples; 
these showed strong reactivity to the protein trichohyalin in all alopecia areata sera (Leung et.al. 2010). 
Trichohyalin is a 200-kDa protein of the IRS. It is a doublet in some animals but is a single polypeptide 
in humans (O’Keefe et.al. 1993). Moreover, immunofluorescense studies with alopecia areata sera and a 
monoclonal antibody to trichohyalin supported the theory as the immunoreactivity in the alopecia areata 
sera was in the same location as the trichohyalin in the inner root sheath of the hair follicle (Leung et.al. 
2010). IgG tightly binds the inner root sheath and reacts with a 200/220kDa doublet by immunoblotting 
in all species studied, including canines affected by alopecia areata (Tobin et.al. 2003).  
With further research, one of the above possibilities may be implicated as the definitive 
autoantigen in alopecia areata. This would promote new treatments directed toward the autoantigen itself 
or toward the lymphocytic cells that respond to it. 
Hair-follicle-specific autoantibodies are found in the peripheral blood of individuals with the 
disease. Although some are found in normal individuals, autoantibodies such as hair-follicle specific 
IgGs are found in higher concentrations in alopecia areata patients than in non-affected individuals (Lu 
et.al. 2006). These appear to be targeting intracellular antigens. Abnormal deposits of complement and 
immunoglobulin IgG and IgM were also found in 92% of 12 patients with alopecia areata (Bystryn et.al. 
1979). These findings indicate that autoimmune processes are responsible for the hair loss associated 
with alopecia areata. 
 One study questions this theory.  In this study forty nude mice were grafted with scalp skin 
transplants from patients with alopecia areata. One group of mice was given intravenous injections of 
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serum from patients, and the other group was given normal serum. Although deposition of 
immunoreactants such as immunoglobulins and complement was noted in hair follicles of mice who 
received patients’ serum, hair growth was observed in most cases.  The researchers concluded that 
immunoreactants do not inhibit hair growth in alopecia areata (Gilhar, Pillar 1992).  
Although hair follicle-specific antibodies may not be responsible for the initiation of alopecia 
areata, their production and presence in the hair follicle may stimulate extra damage or even maintain 
the disease.  Tobin and his colleagues performed a study to further understand the pathogenic potential 
of these antibodies. They conducted the passive transfer of serum from horses affected by alopecia 
areata into the anagen skin of C57BL/ 10 mice. Although normal hair regrowth was observed in mice 
injected with the normal serum, hair did not regrow in the area around the injection site of the alopecia 
areata serum even 13 weeks after the injection (Tobin et.al. 1998). The evidence shown here supports 
the idea that anti-hair follicle autoantibodies promote the pathogenesis of alopecia areata. 
Infectious Factors 
 The theory that alopecia areata was caused by an infectious disease was the leading theory until 
recently. In 1899, sixty-three out of sixty-nine teenage girls in a homeless shelter found bald patches on 
their heads (Bowen 1899).  In 1971, there were reports of a widespread breakout of alopecia areata 
(Messenger, McDonagh 1997).  Scientists of the time believed that alopecia areata was a contagious 
disease. 
After one study where scientists tested ten scalp biopsies for the presence of cytomegalovirus 
DNA, alopecia areata was thought to be associated with the viral infection. Out of ten samples, nine 
tested positively- leading to the belief that CMV infection leads to alopecia areata. However, in 1996, 
when the above study could not be replicated, it was determined that the first samples were 
contaminated, and that CMV has no connection to alopecia areata (Tosti et.al. 1996). The results of a 
study in year 2000 support the idea that CMV is neither a triggering factor for the immune response in 
alopecia areata nor an activator of the autoimmunity (Offidani et.al. 2000). Perhaps the teenage girls and 
other hair loss patients had another non-related disease whose side effects include hair loss. 
The etiology of alopecia areata is complex and involves many factors. It appears to have both a 
genetic and autoimmune basis. While scientists once believed that alopecia areata was itself, or was 
associated with, an infectious disease, that belief is insignificant today.  Evidence of strong family 
history trends indicates that alopecia areata is, indeed, genetically based.  Additionally, there are many 
studies that support the hypothesis that alopecia areata is an autoimmune disease and lead to the 
conclusion is that alopecia areata is mediated by autoimmune processes caused by chromosomal 
mutations in the genome. 
 Current Treatment Methods 
 Available treatments for alopecia areata include: corticosteroids, topical anthralin, topical 
minoxidil solution and contact sensitizers. Most of these therapies “bandage” the disease, stimulating 
hair growth instead of solving the immune problem. 
Corticosteroids 
 Corticosteroids have an anti-inflammatory and immunomodulatory effect. Immunomodulators 
lessen the immune system’s ability to produce antibodies that recognize and react with the antigen that 
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stimulated their production. Corticosteroids weaken the T-cell mediated immune attack on the hair 
follicle (Kumaresan M. 2010). Based on the theory that alopecia areata is carried out through attack of 
follicular autoantigens, treatment with corticosteroids should be successful at lessening the severity of 
the disease. 
Corticosteroids are heavily used in the treatment of alopecia areata.  However, their efficacy 
remains uncertain.  
In one case study, eighteen patients with severe alopecia areata were given an oral dose of 
prednisone daily. Terminal hair growth (satisfactory growth- over 50% of the scalp) occurred in seven 
patients. Upon discontinuation of the drug, all the patients had a relapse.  The researchers concluded 
that although initial growth was observed, this therapy does not produce lasting effects. Moreover, it was 
determined that the only way growth is retained after tapering the dosage or discontinuing the treatment 
is if spontaneous remission occurs (Alabdulkareem et.al. 1998). Oral corticosteroid therapy is also not 
recommended because of the adverse side effects (Nakajima et.al. 2007).  Based on these results, one 
can state that corticosteroid treatment mitigates disease symptoms while undergoing treatment but does 
not cure the disease in one case.  
The use of topical corticosteroid treatments yield slightly better results.  In one study, five out 
of twenty-eight patients (17.8%) had almost complete hair renewal after being treated with 0.05% 
Clobetasol ointment. Eleven participants experienced painful folliculitis on the treated scalp (Tosti et.al. 
2003).  Although these results aren’t excellent, the researchers noted that all participants had already 
undergone and failed to respond to topical immunotherapy. Therefore, they conclude that clobetasol 
propionate under occlusion should be listed as an effective treatment (Tosti et.al. 2003). Patients apply 
the ointment and then cover the area with plastic wrap, securing it to the skin with tape. Occlusion holds 
perspiration close to the skin, hydrating the top layer of the epidermis. Topical medications are absorbed 
into moist skin much more efficiently than with dry skin (Brannon, 2010).  
Intralesional corticosteroids have an advantage over the oral and topical treatment options; this 
treatment maximizes the effect of the corticosteroids by penetrating the skin and injecting its contents 
straight into the affected tissue (Gregoriou et.al. 2011).   
Doctors prescribe steroids with low solubility, this allows maximum action at the injection site 
for they absorb very slowly (Kumaresan, M. 2010). The most common drugs used are triamcinolone 
acetonide and betamethasone (Gregoriou et.al. 2011).  
This method of treatment works best in groups of patients who have experienced less than 75% 
scalp hair loss, who have had a shorter duration of hair loss, and in children (Kumaresan M. 2010). 
However, a study using ten participants with over 50% loss showed that the treatment does work well 
for patients with extensive loss. Six of the ten participants responded to treatment of intralesional 
triamcinolone acetonide. The researchers concluded that the reason intralesional corticosteroids are not 
generally used on patients with extensive loss is because it is painful and time consuming for the patient 
This study also mentions that the average length of the episode of alopecia areata was the same in 
responders and non-responders (Chang et.al. 2009). From this it can be determined that the treatment is 
not curative, but can interfere with the pathogenesis of the disease while in use. 
Another faster, less painful option is now being used to treat extensive alopecia areata. Instead of 
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using conventional needles to apply the steroids, doctors use a multi-injection plate. There are several 
advantages to this method. Firstly, it allows for the simultaneous injection in five to seven different 
points at a fixed distance. This leads to uniformity in application, which may prevent skin atrophy.  
Treatments are followed by a gentle massage, also to help spread the steroids evenly. Another advantage 
is that the needle is long and the tip can reach the desired depth of the hair bulb where the drug is 
delivered. The disadvantage to this treatment is that the needles are large, and if not handled gently, can 
cause pain (Ferrando, Moreno-Arias 2000).  
 Although the aforementioned studies indicate that the intralesional treatment of alopecia areata is 
beneficial to those with excessive hair loss, this method is still considered the best option for patients 
with less than 50% loss (Kumaresan, M. 2010).  
Minoxidil 
 Minoxidil is an antihypertensive vasodilator known to slow the onslaught of alopecia areata and 
promote hair regrowth. Minoxidil’s exact mechanism is not known. However, tissue studies showed that 
treatment with minoxidil causes an increase of follicles in anagen and a reduction of follicles in telogen. 
This is indicated by the fact that after treatment, increased hair length is found on the forehead and other 
areas of the body that do not usually grow long hairs. The abnormal growth, referred to as 
hypertrichosis, suggests that the anagen phase of these follicles is of a longer duration (Messenger, 
Rundegren 2003). 
 Cellular uptake studies in murine follicles showed that minoxidil and minoxidil sulphate 
converged in the melanocytes and pigmented epithelial cells of the hair follicle.  This is interesting 
because previously mentioned studies implicate melanocytes as a possible source of autoantigens in 
alopecia areata. If minoxidil binds to melanocytes, and then is observed to cause an increase in hair 
growth, this observation can then serve as proof as to the role of melanocytes in the pathogenesis of 
alopecia areata.  
However, in this case, the researchers believed the reaction of minoxidil and melanin had no 
bearing on the growth that resulted, as there was no evidence of minoxidil binding to non-pigmented 
follicles although there was noted growth in both pigmented and non-pigmented follicles (Messenger, 
Rundegren 2003). This was a significant realization, as alopecia areata does not affect non-pigmented 
hair follicles. 
 Perhaps the mechanism that minoxidil uses does not include or affect the melanocytes but causes 
growth in a way that both interferes with the pathogenesis of the disease and enhances growth of healthy 
follicles as well.  Or, maybe the minoxidil and melanin connection does exist and does reverse the 
pathogenesis of the disease, as well as it enhances healthy, non-pigmented follicular growth by other 
mechanisms. This would explain why there was excessive growth noted in non-pigmented hair follicles 
as well. 
 The concentration of the active ingredient in minoxidil treatment can be varied. However, study 
results imply that the treatment is more effective when higher concentrations of minoxidil are used. In 
one experiment, forty-seven patients were treated with topical 1% minoxidil and forty-six patients were 
treated with topical 5% minoxidil. Patients with extensive hair loss showed a response rate of 38% with 
1% minoxidil, while those who received 5% minoxidil showed an 81% response rate (Fiedler-Weiss, 
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1987).   
In one double blind, placebo controlled study, researchers divided patients into two groups; eleven 
patients received 3% topical minoxidil while fourteen other patients received a placebo. Hair growth 
was observed in seven of the eleven patients (63.6%) in the minoxidil group and in five of the placebo 
group (35%). Furthermore, 27% of the minoxidil group showed cosmetically acceptable hair growth 
compared with 7.1% in the placebo group (Price, 1987). This study showed that treatment with 3% 
minoxidil results in hair growth, even though the dosage is not as strong as 5% minoxidil drugs.  
Although the topical 5% minoxidil treatment plan yields better results than the versions with lower 
concentrations, it is also known to cause hypertrichosis on the face and neck, especially in children 
(Wang et.al. 2012). Several patients also reported contact dermatitis as another adverse side effect. This 
may be the reason that most treatment plans for alopecia areata include a low concentration of topical 
minoxidil along with other drugs such as corticosteroids. 
Studies also suggest that patients with minimal hair loss have a better chance of hair renewal with this 
treatment than those patients with more hair loss. An early double-blind study observed that patients 
with severe hair loss responded more weakly to treatment of topical 1% minoxidil than those with 
moderate hair loss. Those with localized alopecia areata gained cosmetically acceptable hair regrowth 
(Gregoriou et.al. 2011).  
Anthralin 
 Treatment with anthralin is another possible option for achieving hair regrowth. In one study, 
patients with extensive alopecia areata were treated with 0.5%- 1.0% anthralin cream. As a result of the 
treatment, 25% had cosmetically acceptable hair renewal. All patients suffered from the same side 
effects: intense itchiness, scaling, and erythema on the treated area (Fiedler-Weiss, Buys 1987).  
 However, in another study, only five of fifty-one patients treated with a mixture of 5% minoxidil 
and 0.5% anthralin had cosmetically acceptable hair growth (Alsantali, 2011). While it is possible that 
the co-treatment of minoxidil and anthralin has undesirable effects, it is more likely that there are other 
factors involved. More research must be done on treatment of alopecia areata with anthralin in order to 
render this treatment worthy. 
Topical Immunotherapy 
Diphenylcyclopropenone (DPCP) is a topical sensitizer used in the treatment of alopecia areata. 
DPCP is a novel therapy because of its high success rate. It has a response rate of 60% in severe 
alopecia areata and about 88 to 100% in patients with patchy alopecia areata (Singh, Lavanya 2010).  
Perhaps its success rate is due to the fact that contact sensitization agents may modify antigen 
presenting cells. The antigen presenting cells then have trouble recognizing autoantigens. This stops the 
alopecia areata cycle (Hordinsky, Ericson 2004). 
Generally, treatment is performed on the scalp. A cotton-tipped applicator soaked with 2% 
acetone solution of DPCP is applied to an area on the scalp.  Two weeks later, a 0.001% solution of 
DPCP is applied. The solution should be retained on the scalp for forty-eight hours. The application is 
repeated weekly, increasing the concentration each time until a mild dermatitis is observed (Singh, 
Lavanya 2010). If the patient does not respond after six months, the patient should terminate DPCP 
treatment.  
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 Out of fifty-four Greek alopecia areata patients that underwent immunotherapy, 83% responded.  
All research participants had extensive alopecia, or long lasting alopecia. Twenty patients experienced 
re-growth of terminal hair on the whole scalp; fifteen achieved re-growth of most terminal hair with 
some remaining patches of alopecia; nine had sparse regrowth of pigmented, terminal hair; and one 
patient observed regrowth of vellus hair. Terminal hair is dark, thick and long, while vellus hair is 
described as short, fine and barely noticeable hair. Overall, the treatment was very successful. 
Thirty-one patients had a relapse after conclusion of the treatment and underwent immunotherapy again 
(Avgerinou et.al. 2007). The relapse rate is high, but according to the researchers, this may be due to the 
failure of patients to undergo maintenance therapy once they experience cosmetically adequate regrowth 
(Gregoriou et.al. 2011).  
Topical immunotherapy can cause side effects such as persistent dermatitis, swollen lymph 
nodes and contact leukoderma (Singh, Lavanya 2010). 
Conclusions 
  Although some patients with alopecia areata have positive hair growth as a result of treatment, 
most are disappointed. Many patients who respond to treatment initially experience a relapse as soon as 
they taper the dosage or stop treatment. This is because most of the treatments that are currently 
available to patients do not rectify the problems that cause alopecia areata. Rather, they are general hair 
growth treatments that are nonspecific to alopecia areata. The best treatment option on the market today 
is immunotherapy with DPCP. This is because the mechanism that DPCP uses actually alters the cells 
that promote pathogenesis of alopecia areata. If more research is done into the etiology of alopecia 
areata, newer treatments can be developed that target the disease’s pathogenic development. 
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THE SCIENTIFIC EVIDENCE VALIDATING THE USE OF HONEY 
 AS A MEDICINAL AGENT 
Raitzel Chemda Bernstein 
 
Abstract: 
 Honey has been used to treat wounds, infections, and other diseases since ancient times. Due to 
the widespread bacterial resistance to antibiotics, scientists have investigated the healing power of 
honey. Numerous studies have documented the broad-spectrum antibacterial effect of honey and its 
success in inhibiting MRSA. The use of honey as a wound dressing has proven to successfully heal 
chronic wounds in short amounts of time by inhibiting pathogens, reducing inflammation, rebuilding 
damaged tissue, and minimizing scarring. The mechanisms of action are directly related to the high 
hydrogen peroxide and rich polyphenol content present in honey. These two components account for 
much of the antibacterial, anti-inflammatory, and antioxidant activity of honey. Other significant 
components include acidic molecules and water and sugar content. Current research is exploring the 
antiproliferative effect of honey on cancer cells, and the results are positive. Many companies have 
patented medical-grade honey, and the scientific proof regarding the medicinal properties of honey 
demonstrates that honey should be considered as a treatment option for various diseases.  
Introduction 
Humans have known the medicinal properties of honey since the origin of mankind. The use of 
honey to treat wounds, bacterial infections, and other ailments has been popular in the field of 
alternative medicine. Recently, honey has been experiencing a revival in modern medicine. The 
development of antimicrobial agents has always been a priority in reducing the casualties of infectious 
diseases. As a result of the overuse of antibiotics, pathogens are becoming resistant and no longer 
respond to traditional treatment. This emerging threat has led scientists to reevaluate the effectiveness of 
ancient remedies, including honey, and much research has been done proving the medicinal and 
antimicrobial properties of honey. (Mandal M, Mandal S, 2011) 
Honey is composed of numerous unique qualities that allow it to ideally improve wound healing. 
Honey provides a moist healing environment due to its low water content. The high viscosity of honey 
serves as a protective barrier that prevents infection and cross contamination. Honey has a pH of 3.6-3.7, 
and most bacteria are unable to grow in that acidic environment. In addition, honey stimulates the 
production of lymphocytes, which aid in the body’s immune response. One of the key antibacterial 
components present in honey is hydrogen peroxide; however, some types of honey are effectively inhibit 
bacteria despite their low levels of hydrogen peroxide. (Lotfi, 2008) 
Although many of the mechanisms behind the success of honey are a mystery and are currently 
being delved into, scientists have proven that using honey as a wound dressing has multiple benefits. 
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Rapid healing, especially in burns, was noted, and ulcers that were present for long periods of time were 
healed due to the ability of honey to stimulate the healing process. Unlike antibiotics, honey has no side 
effects, yet it is an effective antimicrobial agent for even resistant bacteria such as, methicillin-resistant 
Staphylococcus aureus (MRSA). Honey has powerful cleansing properties and is unique in the manner 
in which it rebuilds damaged tissue while minimizing scarring. In addition, honey has anti-inflammatory 
and antioxidant properties. (Molan, 1999) 
Recently, the theory of using honey as a medicine has resurfaced and gained popularity. Multiple 
studies have proven that the once ancient remedy has  considerable scientific evidence supporting the 
miraculous role of honey in the treatment of wounds and other diseases.  
The Origin and Composition of Honey 
Honeybees create honey to serve as a food source during the winter. A bee will fly 55,000 miles 
and collect nectar from 2 million flowers in order to produce one pound of honey. The worker bees will 
regurgitate the nectar so that it is partly digested before storing it in the honeycomb. There, the bees 
will fan the honeycomb with their wings in order to evaporate the nectar and to avoid the fermentation 
of the honey (Jaganathan, Mandal, 2009). Bees incorporate the antibacterial characteristics of honey 
during the gathering of pollen and the ripening process (Garcia, et al. 2001). Hundreds of variations of 
honey are documented, and the differences lie in their botanical origin.  
In order to study the medicinal benefits of honey and its mechanisms of action, it is imperative to 
examine the composition of the substance. Although the nutrition found in honey is small compared to 
the recommended daily intake, its significance lies in its diverse physiological effects (Bogdanov, et al. 
2008). Honey is primarily composed of carbohydrates that take up 95% of the dry weight. In addition, 
honey contains other compounds such as organic acids, proteins, amino acids, minerals, polyphenols, 
vitamins, and aroma compounds.  
Figure 1 indicates the breakdown of the components present in honey. The primary sugars include the 
monosaccharides fructose and glucose. In addition, 25 oligosaccharides have been identified, 
significantly among them are the disaccharides sucrose, maltose, trehalose, turanose  
and other nutritionally essential ones. During digestion, the carbohydrates fructose and glucose are 
absorbed into the blood and can be used as an energy source by the human body. Honey is comprised of 
0.5% proteins that are primarily enzymes and free amino acids. Three important enzymes are diastase 
that breaks down starch or glycogen; invertase that decomposes sucrose into fructose and glucose; and 
glucose oxidase that produces hydrogen peroxide and gluconic acid from glucose. Another functional 
ingredient present in honey is polyphenols. The main polyphenols in honey are flavonoids and phenolic 
acids, which are responsible for the antioxidant properties of honey. (Bogdanov, et al. 2008) 
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The Antimicrobial Activity of Honey 
 Honey has been used to treat microbial infections and wounds since ancient times. In 1882, a 
Dutch scientist by the name of Van Ketel first documented the antibacterial properties of honey. Sacket 
followed in 1919 with the observation that the antibacterial potency of honey was increased by limited 
dilution. In 1937, Dold coined the term inhibine to describe the antibiotic feature present in honey 
(Molan, 1992). As explained by Bogdanov (1997), scientists debate the definition of inhibine. Some 
believe that the hydrogen peroxide produced by honey glucose oxidase is the main antibacterial agent. 
Others argue that the amount of peroxide present is not enough to inhibit bacteria, and that the 
non-peroxide activity plays a greater role. Honey is primarily composed of sugars, which kill bacteria by 
their osmotic effect. Research has also proven that the acids, pH levels, and flavonoids present in honey 
contribute to the antibiotic effect. Therefore, it can be concluded that a combination of these factors 
contributes to the antimicrobial effect of honey.  
 
 
Figure 1. Honey Composition (Data in g/100 g (Bogdanov, et al. 2008) 
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There are two basic microbiological techniques, outlined by Molan (1992), that are used to 
measure the antibacterial activity of honey. This first is the agar diffusion assay technique. A small 
amount of honey or solution of honey is placed on a nutrient agar plate inoculated with a microbial 
culture. During incubation, the honey spreads out into the agar from its point of application. A clear 
zone is observed where the concentration of honey is high enough to inhibit growth. The size of the 
clear zone indicates the measure of potency of the honey. Because the honey gets diluted as it diffuses 
across the agar, the actual effective concentration is lower than the concentration of honey applied. The 
second type of assay involves incorporating the honey into the nutrient agar or nutrient broth in which 
the culture is grown. Using different concentrations will help identify the minimum inhibitory 
concentration (MIC) for each kind of honey. A honey that can retain its antibacterial activity while 
undergoing dilutions will be most effective.  
The frequency of bacterial resistance to antibiotics and even last resort drugs is increasing at an 
alarming rate to the extent that drug companies have slowed research in the field of antibiotic drug 
discovery. Honey is emerging as a popular topical antimicrobial agent due to its effectiveness, and 
especially because bacteria resistance to honey has not yet been recognized (Kwakman, et al. 2008).  
Laboratory studies demonstrate that manuka honey is effective against several human pathogens, 
including Escherichia coli, Enterobacter aerogenes, Salmonella typhimurium, and S. aureus. Other 
experiments show that honey kills methicillin-resistant S. aureus (MRSA), β-haemolytic streptococci 
and vancomycin-resistant Enterococci (VRE). Figure 2 illustrates some bacteria that cause 
life-threatening diseases that are susceptible to honey(Mandal M, Mandal S, 2011). Willix, et al. (1992) 
studied seven major wound-infecting species of bacteria and compared their sensitivity to manuka honey 
and another type of honey. The two honeys differed in their known mechanism of action. In general, the 
high sugar content of honey controls infection by the osmotic effect; however, honey also inhibits 
bacteria by its hydrogen peroxide activity (standard honey) or by an unidentified floral source (manuka 
honey). At a concentration of 1.8% (v/v), the non-peroxide activity of manuka honey completely 
inhibited Staphylococcus aureus after an incubation of only 8 hours. All seven species of bacteria were 
completely inhibited by both manuka and standard honey at a concentration below 11% (v/v) (Willix, et 
al. 1992). In conclusion, the overall antibacterial activity of both peroxide and non-peroxide honeys 
successfully inhibit bacteria in only 8 hours. These studies bring undeniable proof that honey should be 
seriously considered as an antimicrobial agent.    
In order to document the efficacy of therapeutic honeys, scientists from all around the world 
compare the effectiveness of commercial, medical-grade honey to honey that is locally produced. One 
study analyzed the pollen source and antibacterial activity of Spanish honeys. Twenty-five samples of 
honey from various botanical origins were tested using Staphylococcus aureus as the resistant 
microorganism. Honey originating from the labiate and rosemary families exhibited the greatest zone of 
inhibition against S. aureus, while heather honey proved to be ineffective (Garcia, 2001). Another study, 
conducted in Australia, compared the effectiveness of Medihoney® (medical grade manuka honey), 
manuka honey, and honey obtained from local beekeepers (Lusby, et al. 2005). Results indicated that  
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Figure 2. Antibacterial activity of honey against bacteria causing life-threatening infection to humans. 
(Mandal M, Mandal S, 2011) 
 
twelve out of thirteen bacteria were inhibited by all honeys, with the exception of Serratia marcescens 
and the yeast Candida albicans. Evidently, local, unprocessed honey and medical-grade honey display 
antibacterial properties. However, three species of bacteria were more sensitive to Medihoney® proving 
that medical-grade honey possesses stronger antibacterial agents. In contrast to this, a study done in 
India comparing the antibacterial activity of manuka honey (Australia), heather honey (UK), and 
khadikraft honey (India) against 152 strains of resistant Pseudomonas aeruginosa isolated from chronic 
wound infections, proved that local khadikraft honey displayed the highest antibiotic power (Mullai, 
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Menon, 2007). Despite the fact that some local honeys seemed more powerful than some medical grade 
honeys, it would be wise to use medical grade honey due to the consistency of its components.  
The large variations in honey found in the natural environment can lead to inconsistent 
experimental results. An experiment conducted in Amsterdam used Revamil medical grade honey, 
which is produced by bees in closed greenhouses. The bactericidal spectrum of the honey was tested in 
vitro, and its usefulness in eliminating microbial skin colonization in healthy humans was measured by 
topical application. The activity of 11 batches of Revamil medical-grade honey was compared in a 
microdilution assay with B. subtilis as the target organism. At a concentration of 40% (v/v), the honey 
completely killed the inocula of resistant strains of S. aureus, S. epidermis, and E. faecium 
(gram-positive bacteria). At a lower concentration of 20% and 10% (v/v), most of the bacteria were 
killed as well. The honey was equally effective against gram-negative bacteria, including 
ESBL-producing strains that were killed after 24 hours of incubation in 20% (v/v) honey. The 
effectiveness of honey was tested in vivo by applying it to the forearm skin of healthy volunteers. After 
only 48 hours, the median level of skin colonization was reduced 100 fold (Kwakman, et al. 2008). It 
can be concluded that Revamil, which is produced under controlled conditions, is a reliable 
broad-spectrum antibacterial agent.  
The Antibacterial Activity of Honey against MRSA 
 One of the most acclaimed benefits of using honey as an antimicrobial agent is its success in 
inhibiting methicillin-resistant Staphylococcus aureus (MRSA). Cooper, et al. (2002) tested 18 strains of 
MRSA isolated from infected wounds against manuka honey, pasture honey and artificial honey. The 
minimum inhibitory concentration (MIC) values for all the strains were between 2.7-4% (v/v) for the 
manuka and pasture honey, yet none of the bacteria were inhibited by the artificial honey even at 
concentrations of >30% (v/v) (Cooper, et al. 2002).  
 A study investigated the effect of manuka honey on the cell cycle of MRSA (Jenkins, et al. 
2011). In staphylococci, cell division is preceded by the formation of a septum at the cell equator, 
followed by cleavage, which separates the two daughter cells. Murein hydrolases, also called autolysins, 
are the enzymes responsible for hydrolyzing structural components in the cell wall, such as 
peptidoglycan. A decrease in murein hydrolases will prevent cell cleavage from occurring. These 
enzymes are encoded by the atl gene, and sensitivity to manuka honey in S. aureus atl mutants cause an 
accumulation of cells containing septa. After treating MRSA cultures with various concentrations of 
manuka honey, results showed significantly higher proportions of cells with partial and complete septa 
(64-67%). Furthermore, murein hydrolase activity was not detected in MRSA treated with manuka 
honey (Jenkins, et al. 2011). Figure 3 indicates that enlarged cells containing septa were observed in 
MRSA that was treated with honey. In addition, treating MRSA with manuka honey reversed oxacillin 
resistance and down-regulated the mecR1 pathway responsible for oxacillin resistance (Jenkins, Cooper, 
2012). Evidently, treating MRSA with honey and antibiotic combinations may restore the bacteria’s 
susceptibility to a particular drug.  
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Honey in Wound Care  
In order to convince skeptical clinicians that honey is more than a therapeutic healing agent, 
Molan (2006a) collected all the experimental evidence proving the effectiveness of using honey as a 
wound dressing. In total, positive findings on honey in wound care have been documented from 17 
randomized controlled trials involving 1965 participants, and 5 clinical trials involving 97 participants 
treated with honey. Similar results were also seen in over 533 wounds on experimental animals. Wounds 
included burns of all degrees, chronic ulcers, surgical wounds, incisions plus others (Molan, 2006a). In a 
study surveying these patients, most reported complete healing of 99% within 2-9 weeks. However, in 
controlled clinical trials, the healing effect of honey was only 56% in 4-12 weeks (Medhi, et al. 2008). 
Figure 3. Effect of honey on the structure of MRSA cells. Transmission electron 
micrographs show MRSA at x32000 magnification following incubation for 120 min in 
(a) nutrient broth (NB), (b) NB+10% (w/v) artificial honey, (c) NB+2.5% (w/v) manuka 
honey (MH), (d) NB+5% (w/v) MH, (e) NB+10% (w/v) MH, and (f) NB+20% (w/v). The 
percentage of cells with septa was significantly increased following treatment with 
concentrations of MH >2.5% (w/v), and cells were also significantly larger than control 
cells. (Jenkins, et al. 2011) 
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The role of honey in pediatric wound management was evaluated by Bittmann, et al. (2010). Despite the 
fact that there is little research in this area, 15 pediatric oncology patients with infected wounds were 
successfully treated with Medihoney (Bittmann, et al. 2010). Therefore, it is clear that using honey as a 
wound dressing shows positive results; however, further research is needed to establish its true efficacy.  
Part of the success in using honey as a wound dressing lies in its antibacterial properties. A 
wound will not heal if it is heavily saturated with bacteria. Bacteria produce toxins that inhibit growth of 
repair tissue; proteases produced by bacteria will digest connective tissue; and bacterial endotoxins are 
known to stimulate inflammatory responses that restrict blood flow to the wound site (Molan, 2006b). 
The low water content component draws water away from the wound by osmosis, thereby inhibiting 
bacterial growth. Yet the watery layer present in honey will not adhere to the newly formed skin and 
will provide for painless dressing changes (Molan, 2006b). The glucose oxidase present in honey 
produces gluconic acid and hydrogen peroxide, which kills bacteria without harmful side effects 
(Bittmann, et al. 2010). These qualities depict honey as an ideal wound dressing. The antibacterial 
activity of honey has been widely established, and further research has been done concerning wounds 
that are specifically caused by resistant bacteria.  
The effectiveness of honey against antibiotic-resistant strains of coagulase-negative 
staphylococci was determined in a study by done Cooper, et al. (1999). Fifty-eight strains of 
coagulase-negative staphylococci, isolated from wounds, were inhibited by manuka and pasture honeys 
at concentrations of 2-4% (v/v), with manuka honey being more powerful. A similar study was done by 
French, et al. (2005), testing honey against coagulase-negative staphylococci present in biofilms on the 
surface of medical equipment. These pathogens are included in the top five causative agents of 
hospital-acquired infection caused by the insertion of temporary and permanent invasive medical 
devices. Despite the fact that these devices are initially sterilized, skin organisms contribute to 
contamination during implantation and following use. Both manuka and pasteurized honeys inhibited 18 
isolates of coagulase-negative staphylococcus at a concentration of 2.7-5% (v/v) (French, et al. 2005), 
proving that honey has great potential as an antimicrobial agent to prevent infection. Additionally, there 
are great advantages in applying honey to the damaged tissue around medical devices. Honey’s 
anti-inflammatory properties prevent serous exudates, which often supplies a medium for bacteria to 
grow; honey provides a moist environment to stimulate the growth of tissues; and honey has no harmful 
side effects on the tissue (Molan, 1999). 
Numerous studies conducted on animals prove the healing power of honey (Lotfi, 2008).  Of 
ten dogs suffering burns to part of their skin, those that received honey dressings showed 98% recovery 
in 21 days.  Their wounds displayed less bacterial growth in comparison with the group that received 
saline solution as a wound dressing (Jalali, et al. 2007). In an experiment done on 24 mice with skin 
excisions, the ones that received honey as a wound dressing showed more extensive epithelization and a 
greater thickness of granulation tissue in the center of the wounds compared to the control group 
(Bergman, et al. 1983). Gupta, et al. (1992) studied the effect of topical honey on the healing of 90 
infected skin wounds in buffalo calves. Surprisingly, the authors claim that honey was more effective 
than ampicillin in speeding up the healing process. This statement is hard to believe, but it does illustrate 
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that honey is a powerful healing agent. The honey treated wounds displayed less neutrophilic infiltration 
and greater formation of angioblasts and fibroblasts (Gupta, et al. 1992). Studies that compared the use 
of honey and silver sulfadiazine as a burn dressing for pigs and dogs reported more rapid results when 
using honey (Lotfi, 2008). These studies provide evidence for the success of using honey as a wound 
dressing over other conventional medications. 
The efficacy of using honey in wound dressings has also been documented in humans. One 
hospital in the UK has adopted the use of honey-impregnated dressings for over a year (Visavadia, et al. 
2008). An 80-year-old man with a split skin graft from his upper arm suffered from a MRSA infected 
wounds for 6 months. Figure 4 illustrates that the wound healed after only 2 weeks of applying a 
manuka honey dressing.  A woman with a 3-year-old recalcitrant wound had tried conventional 
medicine and four surgeries to treat her wound with no success. After using a manuka honey dressing 
for one week, the wound became smaller and less 
inflamed, the scarred area became more pliable, and bacteria ceased to grow. The infection stopped, and 
the wound completely healed within 4 months (Cooper, et al. 2001).  
 
 
 
 
 
 
 
Another study was done on 8 patients with leg ulcerations. Over a 4-week period, the wounds 
decreased by an average of 50% with the use of manuka honey dressings. Malodor, which is common in 
chronic wounds, was absent after one week. However, the 2 patients with arterial wounds did not report 
as successful results, leading to the conclusion that manuka honey may not be the best course of 
treatment for arterial wounds (Gethin, Cowman, 2005). Another study involves a 47 year old woman 
with a MRSA colonized, hydroxyurea-induced leg ulcer (Natarajan, et al. 2001). After 3 months of 
using topical medications with no results, gamma-irradiated manuka honey was applied to the wound. 
The wound completely healed within 3 weeks, and the MRSA was not present, despite the patient 
Figure 4. (A) Infected split skin donor site in the upper arm. (B) Upper arm healed 
after 2 weeks. (Visavadia, et al. 2008) 
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continuing hydroxyurea therapy, the direct cause of the ulcer. Figure 5 illustrates the progress over a 
3-week period. In addition to wound healing, using honey as a wound dressing promotes patient 
comfort, safety and quality of life as reported by 3 individuals undergoing treatment using Medihoney 
along with other antibiotics (Sare, 2008). Although a physician should always treat serious wounds, 
these studies all indicate that the use of honey as a wound dressing should be seriously considered 
among the treatment options for chronic wound infections.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Honey in Oral Health 
effects of honey is thought to counteract its cariogenic effects. In an experiment 
Several studies have explored the efficacy of using honey to limit oral pathogens. Streptococcus 
mutans, the main bacteria contributing to dental caries, along with other bacteria, forms a microbial 
community on the tooth surface called dental biofilm (plaque). The bacteria present produce lactic acid, 
which demineralizes the tooth (Nassar, et al. 2011).  Despite the fact that honey contains 70% sugar 
Figure 5. (a) Hydroxyurea-induced ulcer 
over the right lateral malleolus, (b) Ulcer 
1 week following commencement of 
honey treatment, (c) Healed ulcer 3 
weeks following commencement of honey 
treatment. (Natarajan, et. al. 2001) 
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and that high sugar consumption leads to tooth decay, the antibacterial testing two kinds of manuka 
honey against oral bacteria in their planktonic and biofilm states, the honey inhibited the bacteria at a 
high concentration (Badet, Quero, 2011). Another study measured the antimicrobial activity of natural 
honey (NH) versus artificial honey (AH) against the growth and biofilm formation of S. mutans. The NH 
wells indicated less growth and a greater zone of inhibition than the AH wells (Nassar, et al. 2011). 
Scientists have also evaluated the effectiveness of honey as a root canal medication against endodontic 
bacteria in comparison to standard drugs (Mittal, et al. 2012). At a concentration of 100%, honey 
displayed impressive results against S. aureus, P. aeriginosa, and other bacteria present in an infected 
root canal. Despite the fact that the antibiotics Ampicillin and Gentamycin revealed the maximum mean 
bacterial inhibition, honey did inhibit common endodontic microflora at a level deserving consideration 
for use as an intracanal medication. Further studies need to determine whether oral bacteria can be 
inhibited at levels lower than 100%, since such a high concentration of honey may potentially erode the 
tooth.  
Mechanisms of Action 
 The efficacy of honey has much to do with its medicinal properties such as its antibacterial 
activity, anti-inflammatory action, and antioxidant activity. In addition, honey boosts the immune 
system and stimulates cell growth (Molan, 2001). Some of the mechanisms contributing to the healing 
power of honey have been briefly mentioned, and in this section they will be explored in greater depth.  
Scientists have argued over the component present in honey that contributes to its antibacterial 
effect. The main theories are the osmotic effect, low acidity, and hydrogen peroxide activity. Honey is a 
saturated or supersaturated solution mainly comprised of sugar and partially made up of water. The 
sugar and water molecules interact strongly leaving very few water molecules available for other 
microorganisms. The free water is measured as the water activity (aw), and its values are as low as 
0.562-0.62 in honey. This environment inhibits bacteria; however, results of studies comparing the 
effectiveness of natural honey with artificial honey containing identical sugar and water concentrations, 
prove that honey contains additional factors responsible for inhibiting bacteria (Molan, 1992). The low 
acidity of honey (pH3.2-4.5) is caused by the presence of gluconolactone/gluconic acid, which is 
produced as a result of the enzymatic action in the ripening nectar. The low pH of honey would inhibit 
most organisms that grow under an optimum pH of 7.2-7.4; however, under experimental conditions, the 
growth medium can create a neutralizing effect on the honey, preventing inhibition. This is less likely to 
occur in a wound dressing where acidity plays a more significant role in inhibiting bacteria (Bogdanov, 
1997, Molan, 1992).   
White, et al. (1963) first identified hydrogen peroxide as the primary antibacterial agent present 
in honey. Hydrogen peroxide is produced by the enzyme glucose oxidase (found in the hypopharyngeal 
glands in honey bees), and upon dilution, its activity increases by a factor of 2,500-50,000 (Bang, et al. 
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2003, Molan, 1992). Catalase, an enzyme present in honey that originates from pollen, effectively 
destroys hydrogen peroxide. Therefore, the levels of hydrogen peroxide present in honey will be 
determined by the amount of glucose oxidase and catalase (Weston, 2000). At a very high concentration, 
hydrogen peroxide can cause cellular and protein damage in tissues by producing oxygen radicals 
(Bang, et al. 2003). Experiments done by Taormina, et al. (2001) and Bang, et al. (2003) have validated 
that upon dilution, hydrogen peroxide levels in honey are high enough to inhibit foodborne and wound 
pathogens without causing damage. However, certain dark honeys successfully inhibited bacteria despite 
the addition of catalase proving that other non-peroxide factors were in effect (Taormina, et al. 2001).  
Manuka honey exhibits non-peroxide antibacterial activity, and the primary factor that destroys 
the bacteria is yet to be determined. However, this component is believed to derive from the unique 
floral sources that the honey originated from. In an experiment done by Westen, et al. (1999), active 
phenolic compounds such as methyl syringate, phenyllactic acid, and flavonoid components were 
extracted. These products were determined to have antibiotic properties, but are only partly responsible 
for the non-peroxide antibacterial effects of manuka honey. Honeys are labeled ‘non-peroxide’ when 
they exhibit antibacterial activity despite being exposed to catalase, which destroys hydrogen peroxide. 
Weston (2000) hypothesized that the catalase added was insufficient to effectively destroy the hydrogen 
peroxide present in manuka honey, and that the honey contained abnormally high amounts of hydrogen 
peroxide. An experiment done by Snow and Manley-Harris (2004) compared the effect of a 10-fold 
excess of catalase and the normal amount of catalase used to destroy the hydrogen peroxide. No 
statistical difference was observed between the two, indicating that the non-peroxide antibacterial 
activity was not due to residual hydrogen peroxide present in manuka honey. Therefore, the healing 
mechanisms of manuka honey are still unknown, but are most probably derived from the honey’s large 
range of phytochemicals.   
It has been recently discovered that the activity of hydrogen peroxide alone does not cause DNA 
strand breaks, but rather, it is the coupling chemistry between the hydrogen peroxide and phenolic 
components present in honey. Hydroxyl radicals (OH ) are created as a result of the coupling chemistry 
between hydrogen peroxide and metal ions (Fe(II) or Cu(II)) via the Fenton reaction. When adding 
metal ions to honey, the hydroxyl radical content increases by 30-fold, and the resistant bacteria is 
inhibited by only 0.78% v/v, a much lower concentration than normally required (Brudzynski, Lanigan, 
2012a). Further experimentation determined that the removal of hydrogen peroxide by catalase 
prevented DNA degradation in bacteria, but the polyphenols extracted from honey degraded plasmid 
DNA in the presence of hydrogen peroxide and Cu(II) via the Fenton reaction. At low content, honey 
polyphenols exhibited pro-oxidant activity damaging to DNA (Brudzynski, et al. 2012b). Therefore, 
phenolic/hydrogen peroxide-induced-oxidative stress explains the mechanism of honey antibacterial and 
DNA damaging activities. This recent study proves that many unknown mechanisms regarding the 
activity of honey will be unraveled with systematic and advanced levels of experimentation.  
Honey inflammation is the immunological and pathological response of tissues, and it is 
triggered by infectious organisms, cancer, autoimmune diseases, toxic chemical substances, or physical 
injury (Kassim, et al. 2010). Typical wound healing is a complex process in which damaged tissue is 
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removed and slowly replaced by restorative tissue. Inflammation is an important step in wound healing, 
and honey has been shown to stimulate monocytes in cells to release cytokines TNF-a, 1, and IL-6, 
which are the cell messengers that mediate the immune response (Tonks, et al. 2003). In addition, honey 
stimulates the production of B-lymphocytes, T-lymphocytes, and neutrophils, which aid in immunity 
(Abuharfeil, 1999). In the case of a chronic wound, prolonged inflammation can prevent healing and 
cause damage. During excessive inflammation, leukocytes release prostaglandins which cause pain; 
other chemical messengers stimulate swelling, which restricts the flow of blood through the capillaries 
and starves the wounded tissues of much needed oxygen and nutrients; reactive oxygen species are 
produced, which can potentially erode body tissues; and excessive fibroblast activity leads to fibrosis 
and scarring (Molan, 2001). Honey demonstrates strong anti-inflammatory action, and when honey is 
applied to wounds, leukocyte action is reduced, minimizing pain, wound exudate, and scarring. The 
anti-inflammatory activity of honey is attributed to its phenolic content, and the results of an experiment 
done on the inflammation of rats’ paws showed that the methanol and ethyl acetate extracts of honey 
reduced inflammatory signs and markers, observed through the inhibition of swelling, decrease in pain, 
and reduction of the mediators of inflammation tested (NO and PGE2) (Kassim, 2012). Extensive 
research is yet to be done regarding the anti-inflammatory effects of honey on a cellular level, however, 
the present evidence provides proof that the honey does work as an anti-inflammatory agent.  
The presence of flavonoids and polyphenols in honey contribute to its antioxidant activity, which 
is defined as the ability of honey to scavenge free radicals. Free radicals are dangerous to the human 
body, because they attack DNA and proteins, leading to cell injury (Fujita, 2002). The antioxidant effect 
of honey is not only due to its ability to scavenge free radicals, but is also due to its initial inhibition of 
the formation of free radicals. Inflammation, the body’s natural response to infection or injury, creates 
superoxide that is then converted to hydrogen peroxide, which generates the extremely reactive peroxide 
radical. The peroxide radical is generated by the Fenton reaction and is catalyzed by metal ions such as 
iron and copper. The flavonoids and polyphenols present in honey sequester these metal ions in 
complexes with organic molecules, and through this mechanism, honey is a powerful antioxidant. 
(Molan, 2001)  
Apitherapy is the use of honey to treat wounds, burns, skin ulcers, dyspepsia, and peptic ulcers, 
specifically utilizing honey’s antioxidant activity, caused by its phenolic compounds. Polyphenols 
prevent serious chronic disease such as cancer, cardiovascular diseases, and diabetes, which are caused 
by oxidative stress. Oxidative stress is defined as the imbalance between free radical production and the 
antioxidant defense system. Specifically, the polyphenols in honey have proven to suppress oxidative 
degradative reactions. In a study done by Inoue, et al. (2005), the antioxidant activities of various honeys 
were evaluated with 1,1-diphenyl-2-picrylhydroazyl (DPPH) radical and free radical (methyl (CH3 ), 
hydroxyl (OH ), and superoxide anions (O2 -)) scavenging systems. Buckwheat honey displayed the 
highest scavenging activity for DPPH and hydroxyl radicals, and manuka honey specifically scavenged 
superoxide anion radicals due to its high content of methyl syringate (Inoue, et al. 2005). Evidently, the 
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polyphenols present in honey have much to do with the antibacterial, anti-inflammatory, and antioxidant 
activity of honey.  
Conclusion 
 Historically, honey has been utilized as a vital medicinal agent since ancient times. With the 
discovery of antibiotics, drug companies have shifted their focus to the development of expensive and 
potentially harmful antibiotics. Recent antibacterial resistance has led scientists to seriously consider the 
validity of ancient remedies. Upon experimentation, honey has proven itself to be a powerful 
broad-spectrum antimicrobial agent, even against resistant bacteria that is no longer responding to 
conventional medicine (Mandal M, Mandal S, 2011). Honey has revolutionized wound care, and upon 
using honey dressings, chronic wounds have been cured in relatively short periods of time without 
adverse side effects (Molan, 2006a). Some hospitals have incorporated honey wound dressings in their 
treatment plans (Visavadia, et al. 2008), and many companies have patented medical grade honey 
(Kwakman, et al. 2008, Lusby, et al. 2005). Scientists are currently delving into the mechanisms of 
action of honey, and many have successfully verified the biochemical explanation of these effects. The 
hydrogen peroxide content coupled with the phenolic content of honey successfully degrades bacterial 
DNA (Brudzynski, et al. 2012b). Other components present in honey contribute to its antibacterial, 
anti-inflammatory, and antioxidant activity. Scientists have begun to prove that the rich phenolic content 
present in honey inhibits cancer cell proliferation and provides anti-tumor activity (Jaganathan, et al. 
2010). The effectiveness of honey as a medicinal agent has been unequivocally demonstrated, and the 
once ancient remedy has gained widespread acceptance as a proven cure.  
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CAN HEALTHY TRANSPLANTED TISSUE BE USED TO RESTORE MOTOR 
FUNCTION IN PATIENTS WITH PARKINSON’S DISEASE? 
Aliza Erlbaum 
 
Abstract: 
 Parkinson’s Disease is a condition that disrupts the lives the many people. The disease is 
characterized by a loss of dopamine producing neurons in the pars compacta of the substantia nigra of 
the ventral midbrain, and symptoms include a lack of motor control and rigidity in motion. Currently, 
there are many treatments available to treat patients with Parkinson’s disease. However, each treatment 
involves many adverse side effects that most wish to avoid. Science is discovering possible innovative, 
alternative options to treat Parkinson’s disease such as the transplantation of healthy dopaminergic 
neurons directly into the striatum of the patient. Methods include using stem cells from original fetal 
sources, embryonic stem cells, induced pluripotent cells, or directly converting somatic cells into 
dopaminergic neurons. This study explores each possible treatment method along with the risks and 
advantages associated with each one, citing original experimental data and significant review articles. 
The results of this study do suggest potential in this new area of treatment for Parkinson’s disease, yet 
much perfection of techniques and additional research must be completed before this idea can be used as 
a standardized treatment plan.  
Introduction: 
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a loss of dopamine 
producing neurons, primarily in the pars compacta of the substantia nigra in the ventral midbrain (Aguila 
et.al 2012). The substantia nigra  is a part of a cohesive group of nuclei in the brain commonly referred 
to as the basal ganglia. Other nuclei of the basal ganglia include the caudate, putamen, globus pallidus, 
and the nucleus accumbens (Knierim 2012). In addition to the death of neurons in the substantia nigra, 
resulting in a loss of dopamine and melanin, this damage caused by PD can spread to other parts of the 
brain as well and affect other neurotransmitters and instigate other symptoms. Parkinson’s disease can 
also be characterized by a collection of protein consisting bodies found in the brainstem of the patient 
commonly referred to as Lewy bodies. Although the presence of Lewy bodies is now considered an 
acceptable neurological disorder of PD, there is still no identifiable direct relationship between their 
existence and the physical symptoms of Parkinson’s disease (Aguila et. al 2012).  The nigostriatal 
pathway, the pathway which transports dopamine from the substantia nigra to the striatum, is largely 
associated with motor control. Therefore, some primary features of PD are rigidness, trouble with simple 
motor movement such as standing, and tremor. Over the years various treatments have been used to treat 
Parkinson’s disease. Most of these treatments and medications involve either replacement of dopamine 
in the substantia nigra, or a chemical that can imitate the action of dopamine in the ventral midbrain. 
However, although most of these methods do temporarily relieve some symptoms of PD, the side effects 
of the medication, and the inability of the therapy to last permanently and alleviate all symptoms begs 
scientists to pursue other alternative treatment plans. One popular idea is to transplant dopaminergic 
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neurons directly into the striatum of a patient with PD. Different options include using healthy tissue 
from fetal sources, embryonic stem cells (ESCs), or induced pluripotent stem cells (Hedlund 2009). 
Science is also discovering the possibility of deriving dopaminergic neurons from other somatic cells 
such as fibroblasts (Cummins and Barker 2012). Much research and experimentation has been done to 
determine whether such an idea as transplantation of healthy nervous tissue into the damaged area of the 
brain is valid and whether it can ever be a used as a widespread treatment for PD.  
Methods: 
 This study was conducted through obtaining original experimental data on the subject matter. 
Acquiring this information was possible through the cross referencing of various articles, the matching 
of sources, and the reccomendation of articles by people knowledgable in this area of interest. 
Additionally, review articles by noteworthy professionals were also obtained and evaluated.  The 
various pieces of data from different sources was then organized by category and verified for its 
authenticity and reliability. All the works cited in this study proved to be dependable and accurate 
sources. 
Current Treatment: 
Currently, there are many treatments used to relieve symptoms of Parkinson’s disease. The most 
common and effective method is the administration of levodopa (L-Dopa), a chemical which can 
convert to dopamine once injected into the brain. For patients of PD, L-Dopa is useful as it alleviates 
rigidity and slowness of movement often associated with the disease. However, only 1-5% of levodopa 
actually enters the dopamine neurons, and the rest is broken down into dopamine elsewhere in the brain 
causing a number of adverse side effects.  The main side effect, as observed in more than 50% of PD 
patients, is a loss of muscle control or dyskinesia (Hedlund and Perlmann 2009). It has also been found 
that the effects of levodopa only last for approximately ten years. Specifically in one study, 50% of 
patients exhibited signs of decreased motor ability after being on levodopa for five years and 80% of 
patients displayed similar symptoms after ten years. Also, levodopa only targets the deficiency of 
dopamine neurons whereas to completely relieve PD patients of symptoms the restoration of other 
neurotransmitters may also be important (Hickey and Stacey 2009). Other side effects include low blood 
pressure, nausea, gastrointestinal bleeding, and disturbances in breathing.  Sometimes levodopa may be 
combined with other drugs, such as carbidopa, in order to decrease side effects. Carbidopa decreases 
some side effects of levodopa by preventing the conversion of L-dopa to dopamine before reaching the 
brain (Rao et al.2006). However, the adverse side effects can never be completely avoided and therefore 
the use of levodopa is generally avoided if possible.  
Often to temporarily defer treatment of levodopa, a dopamine agonist can be used alternatively. 
A dopamine agonist is a chemical that imitates the actions of dopamine. Unlike levodopa, a dopamine 
agonist does not convert to dopamine itself, but rather behaves like the neurotransmitter and stimulates 
the dopaminergic receptors of the brain. Yet, although the risk of developing dyskinesia is less while 
using dopamine agonists, this method is altogether less effective and can cause other issues such as 
hallucination, addiction, and drowsiness (Hudlund and Perlmann 2009).  
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Another treatment for PD is the use of monoamine oxidase-B inhibitors. Monoamine oxidase is 
an enzyme responsible for the breakdown of dopamine in the basal ganglia. By inhibiting this enzyme 
using drugs such as selegiline and rasagiline, symptoms of PD can be mildly relieved (Rao et al. 2006).  
If a patient does not significantly respond to any medication, or if the side effects are too severe, 
deep brain stimulation therapy may also be used. In brief, deep brain stimulation is a surgical procedure 
which involves implanting a device to transmit high frequency electrical currents and block abnormal 
impulses of the brain. Deep brain stimulation is effective in treating symptoms of PD involving motor 
dysfunction. However, like any other form of brain surgery, patients who undergo deep brain 
stimulation therapy run the risk of internal bleeding and infection (University of Maryland 2009).  
Transplantation 
Methodology:  
This involves transplanting healthy dopamine neurons directly into the striatum to replace the 
dysfunctional tissue and restore motor function in PD patients. However, although this suggestion does 
look promising, there are several potential complications that must be taken into consideration. First of 
all, it is crucial that the cells survive the transplantation process itself (Hedlund and Perlmann 2009). 
Some measures taken to increase survival of the cells have been to incubate the cells together with 
growth factors and substances that reduce the risk of cell death. One common substance used is glial cell 
line derived neurotrophic factor (GDNF).  Another idea is to first increase the number of dopamine 
cells by growing them in vitro prior to grafting them into the patient. This growth process not only 
proves beneficial by increasing the number of dopamine producing cells, but it also allows for increased 
cell differentiation of the graft as this way more dopamine precursor cells are enabled to reach maturity. 
In fact, in a study which used dopamine neurons derived in vitro, the chances of the graft survival were 
increased based on the cultured growth of the cells before transplantation. In this particular study, the 
growth factors used were brain-derived neurotrophic factor (BDNF) together with ascorbic acid and 
later GDNF was added amongst other substances such as FGF2, Wnt5a, and FGF20. Results of the 
experiment revealed a direct correlation between the growth of cells with growth factors in vitro the 
graft survival in vivo (Sanchez-Pernaute et al. 2008). In addition, during the actual transplantation 
process, care must be taken to inject the dopamine neurons into strategic multiple locations in the 
striatum. This is to ensure that all necessary parts of the brain are innervated and that there is maximal 
axonal coverage (Hedlund and Perlmann 2009).  
There are many studies being done to determine the optimum cellular composition and 
proportional makeup of the graft. Typically, grafted tissue contains a mix of cells including dopamine 
cells, a majority of glial cells, GABA and serotonin. Many experimental studies have proven that high 
concentrations of dopamine producing cells within the graft are most beneficial for the patient’s 
recovery. One particular experiment published in The Journal of Neuroscience yielded results which 
support this hypothesis. In animals injected with 6-hydroxydopamine (6-OHDA), an organic synthetic 
compound used by researchers to target and destroy dopaminergic neurons in the brain, the ones which 
received a graft with the highest amount of dopamine neurons had the highest rate of recovery with the 
least side effects. This was in contrast to the animals that were transplanted with tissues of higher 
concentrations of serotonin. This group exhibited the most side effects, the main one being graft induced 
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dyskinesia. It should be noted that the experiment used control groups to be sure that the success rates of 
dopamine were independent of the concentrations of serotonin and vice versa (Carlsonn et. al 2007). 
Furthermore, contained within dopaminergic neurons are two subtypes of cells, the A9 neurons, 
primarily found in the substantia nigra, and the A10 neurons of the ventral tegmental area, (located on 
the floor of the midbrain). Experimental data tends to favor the significance and functionality of the A9 
neurons as pertains to PD over the A10 neurons. Yet, there are no techniques that specialize in 
purposefully differentiating between the A9 and A10 neurons and therefore their proportional 
composition within a graft will vary, resulting in an increased variability of experimental results 
(Lindvall and Bjorklund 2012).  
 It should also be noted that formulation of the cell graft as it is injected into the patient is 
significant. Different studies have proven that the method of transplantation, (i.e. suspension of cells, 
graft of solid tissue, or pieces), can greatly impact the results of the experiment. In one specific study, 
90% of the patients who received grafts through suspension of the cells did not exhibit nearly as many 
side effects as those who received transplanted tissue through other methods (Mendez et.al 2005).  
Sources of Cells 
Fetal Tissue:  
The dopamine producing cells grafted into the patient used can be derived from several sources 
each with their own advantages and setbacks. Most logically, healthy mesencephalic tissue can be 
obtained from aborted fetal embryos. Although this tissue is ideal for its authenticity, the experimental 
results from using fetal tissue are extremely varied. One experiment was performed using aborted fetal 
embryos taken 6-9 weeks after conception. Tissue from 3-5 donors was transplanted in each patient into 
each putamen. According to the UPDRS (Unified Parkinson’s Disease Rating Scale) scores, symptoms 
of PD were reduced in these trials by 30-40% and the postoperative need of L-dopa was decreased by 
16-45% (Lindvall and Bjorkland 2012). In another trial, similar positive results were also produced. 
Embryos of seven weeks old were aborted and the tissue was cultured in preparation for the graft. In this 
experiment, however, the patients were divided into two groups. In the first group, tissue was 
transplanted unilaterally into both the putamen and caudate, (most of the time the tissue is transplanted 
into the putamen since that is the area of the brain sustaining the greatest loss of Dopamine  neurons in 
PD). In the second experimental group, tissue was transplanted bilaterally into just the putamen. 
Although in the end both groups exhibited improvement in motor function, the relief of the groups 
receiving the grafts bilaterally was slower to come. In the four to six weeks following the surgery, the 
symptoms of these patients actually worsened. The reason for this phenomenon is unclear. To test the 
results of the study, positron emission topography was used (PET scan). The PET scan indicated an 
increased uptake of fluorodopa. Fluorodopa is an organic compound that is often used as a tool to test 
dopamine function and activity. Patients with PD have a low fluorodopa uptake and in this particular 
study, all the patients displayed an increase in fluorodopa uptake (Freed et al.2011). This experiment is 
especially valid as it tested the effects of transplantation on seven humans each with different health 
backgrounds, and symptoms of PD were relieved in each individual case.  
Yet, a separate experiment displayed an increased variability of results. In this study, four 
patients received unilateral transplants into the caudate nucleus of the brain. After six months following 
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the surgery, only three of the patients exhibited signs of improvement while the symptoms of one patient 
worsened. Also, any improvement was to a small extent as no drastic recovery was recorded in any of 
the four patients tested. Interestingly enough, in this experiment there was a lack of tissue rejection after 
the transplant. It could be that using tissue from fetal sources provides the advantage that there is a 
decreased risk of immune system rejecting the graft. In this case, it is possible that the mild 
improvement can be related to the fact that all the patients were in an advanced state of PD or that not 
enough tissue was transplanted due to the lack of availability of fetal sources (Spencer et al. 1992). In 
general though, this fluctuation of results caused by using fetal cell sources can be attributed to the 
de-standardization of cells in fetal samples. Additionally, tissue from fetal sources is not available in 
large enough quantities to be used as a standard procedure as tissue from more than one donor is needed 
to treat each patient (Lindvall and Bjorklund 2012). Also, aside from the technical difficulties with using 
fetal tissue sources, there are also many ethical issues involved with obtaining the fetal embryonic tissue 
(Cummins and Barker 2012). Many believe that the life of a fetal embryo should be considered as much 
as the life of an unborn fully developed baby. 
Embryonic Stem Cells: 
 An alternative to the use of fetal tissue, the use of embryonic stem cells (ESCs) seems a more 
promising prospect. ESCs are a valuable source since they can be culturally harvested in large quantities 
in an undifferentiated state, providing unlimited access to many cell types (Kim et. al 2002). 
Nevertheless, this process of inducing ESCs into dopaminergic neurons can be complicated.  Many 
groups of neurons in the human brain are marked by Tyrosine Hydroxylase. Tyrosine Hydroxylase is a 
rate-limiting enzyme involved in the production of dopamine which in turn gives rise to other 
catecholamines. Many tyrosine hydroxylase neurons can be derived from ESCs and some even produce 
dopamine. However, it is unclear whether those dopaminergic neurons are compatible with the ones of 
the substantia nigra lost in PD, and as to whether they can serve as an effective replacement 
(Sanchez-Pernaute et al. 2008). Yet, one study did prove successful in improving symptoms of PD 
through the process of transplanting ESCs into rats subjected to PD symptoms and conditions. In this 
experiment, ESCs were obtained through the process of parthenogenesis, the development of an embryo 
without fertilization. This was to avoid many ethical problems typically associated with the use of 
embryonic stem cells. The ESCs were first culturally harvested using a variety of growth factors 
including brain-derived neurotrophic factor and ascorbic acid. Later on the cells were differentiated by 
removing certain proteins involved in organogenesis and stem cell division, such as sonic hedgehog 
hemelog, and by adding other specific growth factors and proteins, such as glial cell-derived 
neurotrophic factor and dibutyryl cAMP.  Finally, the cells were suspended and prepared for the actual 
transplantation procedure. The rats were immunosuppressed using cyclosporine A and the grafts were 
injected into the right striatum at two locations. To assess the effectiveness of the graft, throughout the 
transplantation process the rats were subjected to different behavioral tests specialized to check motor 
asymmetry and coordination. Before being grafted with the embryonic stem cells, rats exhibited severe 
motor deficits, and after the ESC transplant rats displayed an increased motor ability. To contrast, the 
experimental control group did not exhibit any significant change in behavior over time 
(Sanchez-Pernaute et. al 2008). This experiment provides hope that the use of ESCs can eventually 
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become an acceptable treatment for PD. However, this study cannot determine what the effects of such a 
type graft would have on a human. Additionally, it is possible that the experimental evidence would 
have differed with a more diverse group of rats each lesioned with 6-OHDA at a different time. (There is 
experimental evidence that the effectiveness of the treatment is related to the amount of time the patient 
had been suffering from the disease).  
Besides the benefits though, there are also a number of potential problems posed through the use 
of embryonic stem cells. There is a risk of the graft containing residual undifferentiated embryonic stem 
cells which can lead to unwanted growths and tumors. Specifically, this problem was obvious in one 
experiment where the amount of dopaminergic neurons in vivo seemed to decrease. This could possibly 
be due to the proliferation of residual undifferentiated neurons, as graft overgrowth was observed in the 
sample. Further information derived from the study proved that this overgrowth of cells did not result 
from pluripotent cells within the body, rather from  induced pluripotent stem cells cells that had failed 
to differentiate in cultures before the transplant itself. It should be noted that this particular experiment 
used the same growth factors and induction strategies as the studies that proved successful, (such as 
GDNF, SHH, FGF8 etc.) and no major differences in methodology between other experiments and this 
one were apparent. The results of this study encourage extra precautionary measures to be taken while 
dealing with the transplantation of ES cells. Safer methods of isolating and restricting composition of the 
graft to nerve cell progenitors or mature dopaminergic cells are still being developed. Additionally, 
scientists should also be concerned that the new implanted differentiated cells maintain their appropriate 
phenotype and survive once inside the CNS (Roy et al. 2006). Sometimes, to prevent or detect this 
potential danger, a chemical such as BrdU is used to detect cell division. BrdU is also helpful as it 
distinguishes the cells derived in vitro from the cells  in the transplant inside the brain 
(Sanchez-Pernaute et al. 2008).  
Induced Pluripotent Cells: 
 Another possible source for obtaining dopamine neurons is through the use of pluripotent stem 
cells, or stem cells that have the potential to differentiate into any cell type. Induced pluripotent stem 
cells (IPs) can be cultured in large quantities and can be accessed easily from patient donor tissue, 
characteristics that make IPs cells seem ideal for use. IPs cells are also useful since they avoid any 
ethical issues that can potentially arise through the use of embryonic stem cells or primary fetal tissue. 
An additional advantage is that since IPs cell lines are obtained from the patient donor all the genetic 
information is matched and no immunosuppressants are needed after transplantation (Hargus et al 2010). 
However, similar to the ES cells, induced pluripotent cells require special attention to ensure that they 
mature into their desired cell form. Because of this, researchers are developing specific markers and 
intrinsic and extrinsic factors in order to identify and induce precursor cells into their appropriate cell 
type (Aguila et al.2012). Some examples of proteins used in experimental studies to guide these 
undifferentiated stem cells include sonic hedgehog hemelog, and fibroblast growth factor 8. Sonic 
hedgehog hemelog is more commonly used by the body to regulate human organogenesis and fibroblast 
growth factor 8 also typically plays a key role in regulating biological processes and embryonic 
development (Aguila et al. 2012).  
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 One specific experimental study using IPs cell lines yielded satisfactory results. First, IP cell 
lines were obtained from a PD patient. Interestingly enough, the IP cells of a PD patient did not 
significantly differ from cells of a healthy person. Then, to test the ability of these stem cells to survive 
in vivo, differentiated IP cells were grafted into healthy rats, unlesioned by OHDA-6. All IP cell lines 
survived and integrated into the striatum with no evidence of tumor formation or graft overgrowth even 
after twelve weeks after transplantation. Finally, grafts derived from IP cell lines were transplanted into 
the striatum of a lesioned Parkisonian rat. The grafts contained a large number of dopaminergic neurons 
distributed evenly throughout. After the procedure, significant outgrowth and branching of the 
transplanted dompaminergic neurons was recorded. The grafted dopamine neurons were tested for 
markers such as Girk2 and calbindin and came out positive for most of the neurons. Additionally, no 
tumor formation or graft overgrowth was observed in the transplanted cells (Hargus et al.2010). 
Although this experiment does seem to promise a future for the use of IP cell lines in treating PD, the 
information obtained must be verified by repeated experimentation with identical or similar results. It is 
possible that if left for more time the grafts may exhibit signs of overgrowth or tumor formation. Also, 
because IP cell lines were originally derived from the patients themselves, there is a risk that the 
dopaminergic neurons may lose some function or may display symptoms of PD, (such as the appearance 
of Lewy bodies within the graft), given a significant number of years after the initial procedure.  
One experiment, in fact, came out with the idea that dopaminergic neurons derived from IP cells 
of PD patients are inferior to Da neurons derived from IP cells of a healthy person. Dopaminergic 
neurons were taken from IP cells of both a healthy person and a person with PD. The two sets of Da 
neurons were then cultured under identical conditions and were subjected to careful analytical watch. In 
the end, after a lengthy period of time, the dopaminergic neurons from the PD patient exhibited signs of 
neurodegeneration, an increase in apoptosis (cell death), and a decrease in neural branching and 
integration. This is an important discovery as it indicates that symptoms of PD are encoded in the 
genetic makeup of all the cells of the patient and the disease is not a result of environmental factors 
(Sanchez-Danes et al. 2012). Therefore, some researchers suggest that the use of IP cells be restricted to 
studying the pathology of PD through cellular modeling and to experimentation in laboratories 
(Cummins and Barker 2012).  
Reprogramming Fibroblasts: 
 Recently, science has discovered that it could be possible for one somatic cell to transform into a 
completely different type of cell with a different function. Specifically, experimentation is being 
performed using fibroblasts (Cummins and Barker 2012). Fibroblasts are a type of cell in the body that 
produces the structural matrix outside the cells, supporting them and holding the cells in place. 
Fibroblasts are in charge of the production of collagen and are found in the largest quantity in most of 
the connective tissue of the body. If a method could be developed for transforming fibroblasts into 
dopaminergic neurons it could mean a whole new avenue of treatment for PD patients. An additional 
advantage is that if this procedure were possible, the cells could avoid a pluripotent state, eliminating the 
danger of graft overgrowth and the risk of tumors. Much experimentation has been done in this area and 
many have even proven successful. It should be noted that extra care must be granted to ensure that 
within the originating fibroblast material only fibroblast cells are present. If within the sample other cells 
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such as neural glia or neural crest cells are existent, they could expand once in the culture and serve as 
contaminating material for the remainder of the transplantation process (Pﬁsterer et al.2011). In one 
specific study, specific antibodies targeting neural progenitors were employed to rid the fibroblasts of 
any unwanted material. Then the fibroblasts were induced into neural cells through certain transcription 
factors, (Ascl1, Brn2, and Myt1l). Afterwards though, further specification using viruses was required to 
further differentiate the induced neuronal cells into dopaminergic neurons. For this to occur, each cell 
had to be exposed to six viruses, including A, B, M, Fuw, Lmx1a, and FoxA2. The percentage of 
induced neuronal cells converted into Da neurons turned out to be approximately 10%. This is a 
satisfactory achievement although with further study a greater turnout rate can be anticipated. Even 
more interesting, though, is the fact that within the original induced neuronal material, no expressions of 
tyrosine hydroxylase were found, yet dopaminergic neurons were still able to be induced from these 
cells (Pfisterer et al. 2011). It is important to note that a separate experiment performed by Vierbuchen 
et al., (2012), used the same four initial transcription factors to induce a pluripotent state from the 
fibroblasts and this also proved to be a successful procedure as induced neurons were produced.  In 
both experiments these induced neuronal cells were deemed functional as they were able to conduct 
action potentials and form a performing synapse (Vierbuchen et al. 2012, Pfisterer et al.2011). Also, 
similar to IP cells, the use of fibroblast material dodges any ethical concerns typically raised in relation 
to stem cell discussions. Using induced neuronal cells for transplantation additionally provides the 
benefit that it poses no problems of rejection by the surrounding body tissue. One obstacle, however, 
with using this method of induced neuronal cells is that the number of derived Da neurons is solely 
dependent on the amount of original fibroblast cells in the starting material. So far, a limited number of 
Da neurons have been able to be successfully converted from the fibroblast cells. Further 
experimentation, though, should eventually determine  precisely the ideal amount of fibroblast cell 
starting material (Pfisterer et al.2011). 
Risks and Side Effects of Transplantation 
Graft Induced Dyskinesia: 
 Although the idea of transplanting healthy nervous tissue into the striatum of PD patients does 
sound like a tempting alternative to the current available treatments for Parkinson’s disease, there are 
still a number of remaining challenges and risk factors involved with this method that need to be 
resolved before the use of transplantation can become widespread (Hedlund and Perlmann 2009). The 
main concern associated with grafting of dopaminergic neurons is graft-induced dyskinesias (GID). It is 
suspected that a main cause for this condition is the presence of too much serotonin contained within the 
graft. The reason for this hypothesis is that in a healthy functional human brain, dopamine levels are 
regulated by the Da transporter and the D2 auto receptor feedback control mechanism. Serotonin is a 
particularly significant neurotransmitter since it has the power to convert L-dopa to dopamine, 
(Levodopa is always continuously administered to the patient during transplantation with the hopes of 
the dosage to be eventually being reduced after the patients show signs of improvement after surgery), 
store dopamine in vesicles for later use, and then release the neurotransmitter when seems necessary. 
However, when the striatum is damaged and there is a lack of regulatory feedback control, dopamine 
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can be released from the serotonin terminals in excessive quantities, possibly causing Graft Induced 
dyskinesia (GID) (Carlsson et al.2007).  
This hypothesis was proven by Carlsonn et al.(2007) in an experimental study using rats. The 
animals were first injected unilaterally with 6-OHDA, transforming them into a model of a human PD 
patient. After the lesion the rats were treated with levodopa every day to model dyskinesias in a PD 
patient. Twelve weeks later, the rats were divided into four groups. The first group was transplanted 
with cells from the anterior portion of the ventral midbrain containing high concentrations of 
dopaminergic neuroblasts and low concentrations of serotonergic neuroblasts. The second group 
received a graft containing a wider portion of  Ventral Midbrain tissue and a larger number of 
serotonergic neurons. The third group was grafted with tissue from the dorsal pontine raphe region of 
the lower pons. This type of tissue contains high concentrations of serotonergic neurons and very few, if 
any at all dopaminergic neurons. Finally, the fourth group was set aside as a control group. In addition, 
the experiment included another control group of rats who were lesioned with 6-OHDA but who 
received neither the grafts, nor administrations of levodopa. After twenty eight weeks, the rats were 
euthanized and their brains were examined. One test detected the presence of TH positivity, a marker for 
the outgrowth of dopamine neurons, in each of the samples. The results of this test are displayed in the 
picture below. The brains which received the grafts from the ventral midbrain exhibited significant 
neuronal outgrowth and integration. Interestingly enough, the graft with a narrower portion from the VM 
displayed a greater density of neuronal outgrowth than the sample that contained a wider portion of the 
ventral mesencephalon. As predicted, the graft containing tissue from the dorsal pontine raphe region 
displayed significant serotonergic neuronal outgrowth but very little TH positivity  was detected. The 
control groups displayed neither dopaminergic outgrowth nor a presence of serotonin (Carlsonn et al. 
2007). After eight weeks, the rats were subjected to behavioral testing to determine whether the 
transplant led to any functional and observable improvement. Significant progress was noticed in the 
rats who received transplants rich in dopaminergic neurons from the VM whereas little improvement 
was observed in the rats who were grafted with tissue from the lower pons. In addition, while on a 
continued dosage of L-dopa, the rats who received grafts from the VM exhibited signs of reduced 
dyskinesias, whereas the rats who were transplanted with serotonergic tissue displayed worse symptoms 
of dyskinesias than prior to the surgery (Carlsson et al.2007).  
The results of this experiment clearly indicate the risks of the graft containing serotoninergic 
neurons in large amounts. However, it is possible that if the serotonergic neurons were combined in the 
graft with high concentrations of dopaminergic neurons then the adverse effects would not prove to be 
as severe. This study may have been more productive had they included another experimental group of 
rats receiving grafts that were both dopaminergic and serotonergic rich. However, the results of this 
study can be relied upon since the results are consistent with numerous other experiments done to 
evaluate similar concerns (Carta et al.2010). If methods of transplantation should ever become a 
widespread treatment for PD, care must be taken to ensure that the graft contain only the type of cells 
that will benefit the patient and not cause graft induced dyskinesia (Hedlund and Perlmann 2009). 
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Suggested methods for differentiating between desired and undesired cell types include flourescence 
activated cell sorting and Pitx-3 enhanced green flourescent protein (Hedlund et al).  
Graft Overgrowth, Tetratoma Formation: 
 Stem cells (ESCs or IPs) differentiated in vitro with the purpose of being transplanted into a PD 
patient at a later time can present many risk factors. The primary concern regarding these cells are the 
possibility for  residual undifferentiated cells to be grafted into the brain of the patient and then 
undergo rapid proliferation (Hedlund and Perlmann 2009). A plausible solution to this potential problem 
is to use imaging and filtering techniques to efficiently differentiate  and removed the unwanted cells 
from the mature desired cells prior to transplantation (Hedlund and Perlmann 2009). One particular 
study used  biotechniques such Pitx-3 enhanced green flourescent protein and fluorescence-activated 
cell sorting  to distinguish between cells and isolate mature dopaminergic neurons from less desirable 
cell types. In this experiment, it was observed that this method of cell differentiatin is possible and 
proved benefical in rat models of PD. Grafts composed of this enhanced cell culture survived longer in 
vivo than transplants containing a larger variety of cells with different pluripotencies. In addition, rats 
who received these grafts that underwent screening before transplantation experienced greater 
symptomatic relief (Hedlund et al.2009). If this filtering method could be employed as successfully as it 
was in the experiment by Hedlund et al., then immature cells can be separated from preferred cell types 
thus decreasing the risk of tumor formation and graft overgrowth. Of course, however, further  repeated 
testing is required before such a treatment plan can become accepted. Another possible way to avoid this 
problem of tetratoma formation is to use chemicals before transplantation that inhibit the cells’ ability to 
replicate (Hedlund and Perlmann 2009). Specifically in one study, the use of mitomycin C, (a chemical 
commonly used in chemotherapy), before culturing the cells in vitro eliminated the chances of these 
cells proliferating unnecassarily  in vivo (Sanchez-Pernaute et al.2008). Even if a chemical is not used 
to isolate the desired cells, certain poisons can also rid the culture of any harmful cells before being 
transplanted into the PD patient (Hedlund and Perlmann 2009). 
Degeneration of Transplanted Tissue: 
 A major problem often encountered with transplanting healthy dopaminergic tissue into the 
striatum of a PD patient is the tendency for the graft to revert back to the previous PD state. This is often 
manifested in the observation of Lewy bodies, (a diagnostic characteristic of PD), within the graft. In 
most cases the presence of these bodies did not begin to appear until ten years after the transplantation 
took place (Hedlund and Perlmann 2009). According to Li et al. (2008), this difficulty poses the 
possibility that the disease can be transferred from the cells of the patient into the newly grafted tissue. 
One study compared the brain of a PD patient who died fourteen years  after receiving a graft, with the 
brains of two PD patients who died four years after undergoing the transplantation process. In the brain 
of the fourteen year old graft there existed diagnostic features of Parkinson’s Disease such as Lewy 
bodies and abnormal protein clusters. In the brains taken four years after the transplant, diagnostic 
features of PD did exist yet not at the same level of progression as the fourteen year old grafted brain. 
The results of this experiment suggest that the mechanism for the progression of PD is an ongoing 
process and can continue to affect even newly grafted tissue in a patient (Kordower et al.2008). 
However, it should be noted that in this particular study, only primary fetal tissue was used in the 
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patients’ grafts and it is possible that the experiment would have yielded different results if stem cell 
tissue would have been used. Additionally, it is unknown whether the results of this study are universal. 
Different results could have been possible if a larger experimental sample was used (Kordower et 
al.2008). Interestingly enough, in a separate experiment preformed by Mendez et al. (2005), three 
subjects were grafted with healthy dopaminergic tissue using very specific methods and techniques, 
(graft composition etc.), and the grafts survived without any pathological features for fourteen years.  
  Another option is that the inclusion of Lewy bodies, and other pathological features of PD such 
as neuroinflammation, in grafted tissue can be a result of cellular stress from the surgical grafting 
procedure itself (Hedlund and Perlmann 2009). It has been tested and revealed that solid grafts 
containing blood vessels are more likely to cause cellular stress and induce immunoreactivity in the 
brain than grafts that do not contain blood vessels (Hedlund and Perlmann 2009). It is noteworthy that 
the experiment by Mendez et al.2005,in which the grafts did not exhibit signs of degeneration, the 
transplanted tissue did not contain any blood vessels. However, this idea can only explain the presence 
of Lewy bodies in relatively young brains and does not give reason for the degeneration of tissue in 
older samples.  
Discussion: 
 Parkinson’s disease is a condition characterized by a loss of dopaminergic neurons in the pars 
compacta of the substancia nigra in the human midbrain. Symptoms of PD include rigidity, and a loss of 
motor ability and coordination. Currently, there are many treatments available for patients of 
Parkinson’s disease. However, due to the many side effects and imperfections associated with the 
existing treatments, science is now researching alternative options. Primarily, many studies have been 
done on the subject of transplanting healthy dopaminergic tissue directly into the striatum of a PD 
patient. Various options include the use of primary fetal tissue, embryonic stem cells, or induced 
pluripotent cells. Additionally, science has recently proposed the idea of reprogramming fibroblasts 
directly into nervous tissue. However, the results of each of these methods are highly varied and the 
methodology must be perfected before the use of this treatment can become widespread. Also, there are 
many risks and potential problems that must be resolved before the use of transplantation can be 
available as a standard treatment for PD. Such side effects include graft induced diskinesia, graft 
overgrowth, and the degeneration of the grafted tissue. Although there is still much to be improved and 
perfected in this area of treatment for PD, hopefully, with the appropriate dedication to the field and 
further testing and experimentation, patients with Parkinson’s disease can fully recover from their 
symptoms and experience risk-free relief.  
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CANCER IMMUNOTHERAPY TREATMENTS: 
CURRENT RESEARCH ON THE USAGE OF COINHIBITION BLOCKADE AND 
COMBINATORIAL APPROACHES TO TREAT CANCER 
Shifra Sadowsky 
Abstract 
 Cancer is the second leading cause of death in American, with over half a million deaths from 
cancer reported in 2009. Cancer chemotherapy treatments were developed in the nineteen hundreds and 
remain the backbone of current treatments; however, they have some limitations. New immunotherapy 
cancer treatments, where biologic agents are given to patients to influence the body’s natural immune 
response, are being researched. Among these immunotherapy treatments are co-inhibition blockade of T 
cells, and combination blockade treatments together with chemotherapy treatment. This review will 
discuss T cell activation and the role of T cell coinhibitors such as CTLA-4 and PD-1 in immune system 
function. It will go through some immune system dysfunctions seen in breast cancer patients. The 
review will focus on the usage of anti-CTLA-4 and anti-PD-1 antibodies in coinhibition blockade 
treatments, as well as combination immunotherapy approaches in clinical trials. The mechanism 
involved in the blockade of T cell coinhibition is important for understanding why this form of 
immunotherapy is successful. Anti-CTLA-4 and PD-1 antibodies have resulted in objective responses in 
a good percentage of cancer patients. New combination immunotherapy approaches, as well as 
immunotherapy treatments in addition to chemotherapy, has been shown to be more effective. Also, the 
blockade of multiple T cell receptors combined with vaccination in mice has yielded a high survival 
rate. Most of the material for this paper was located from journals, and extracted via The Touro College 
Library search engine—primarily through Pubmed. 
 
Introduction 
Cancer is the second leading cause of death in America. The Centers for Disease Control and 
Prevention reported 567,628 deaths from cancer in 2009.  One in six people in the U.S. and Europe will 
die of cancer (Paul, 1991). Cancer treatment evolution began with ancient physicians using surgery. 
Little progress was made until the early nineteen hundreds, when radiation therapy and chemotherapy 
were developed. Until the late 1990s nearly all drugs used in cancer treatment worked by killing cells 
that were in the process of mitosis. These chemotherapy drugs also killed some normal cells but had a 
greater effect on cancer cells. Better understanding of the biology of cancer cells has led to the 
development of a new type of cancer treatment called immunotherapy, where biologic agents like 
interferons, interleukins, and other cytokines are given to patients to imitate or influence the natural 
immune response. They function either by directly altering the cancer cell growth, or by acting 
indirectly to help healthy cells control the cancer (The American Cancer Society, 2012). 
In adoptive immunotherapy, or cell-transfer therapy, cells involved in immune defense are 
removed from a cancer patient and “educated” to react against the cancer, or else to enhance the 
patient’s native ability to kill cancer cells. The cells are then returned to the bloodstream. Molecules that 
are important in the immune response are administered in combination with the transfer of 
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immune-system cells, or alone. Attempts to stimulate anticancer activity directly in the body’s immune 
system cells are made with these molecules. Immunotherapy is a particularly appealing addition to all of 
the existing treatments because it can be delivered systemically to combat metastases (like 
chemotherapy). However, since the immune system is selective—it attacks only diseased cells ignoring 
the healthy ones—immunotherapies might be devised that are more cancer-specific than chemotherapies 
(Paul, 1991).  
Cancer chemotherapies remain the backbone of current treatment but they are limited by a 
narrow therapeutic index, significant toxicities and frequently acquired resistance. A lot of hematologic 
malignancies and metastatic solid tumors cannot be wiped out by the available anti-cancer therapeutic 
agents. Improved understanding of cancer pathogenesis, such as how immunosuppresion regulates 
anti-tumor immune responses, has given rise to a new treatment option—cancer immunotherapy. New 
approaches for cancer immunotherapy are being developed and tested by researchers around the world. 
One developing approach focuses on activating lymphocytes by cytokines in order to maximize their 
therapeutic potential. Another approach being investigated is the method of sensitizing patient 
lymphocytes through vaccinations (Weiss, et. al., 2003). New immunotherapy treatments alone, or used 
in combination with chemotherapy, may be able to improve the prognosis of cancer patients as well as 
the long-term outcomes of cancer survivors. In this review we will discuss T cell co-inhibition, 
co-inhibition blockade of T cells as an immunotherapy treatment, and combination immunotherapy 
approaches; we will also determine if combination immunotherapy, as well as combining 
immunotherapy with chemotherapy proves to be more effective in cancer treatments as compared to 
monotherapy treatment.  
 
Methods 
The author utilized Google and Google Scholar to find general information as well as peer 
reviewed articles on the topic.  The majority of the peer reviewed articles were found via the Touro 
College library search engine, specifically through Pubmed, Medline and Ebsco, to retrieve journal 
articles.  Background knowledge on this topic came from Touro College’s on-campus library, from 
books including, “Immunology Recognition and Response.” 
 
Discussion 
The immune system plays an active role in finding and eliminating newly developing cancer 
cells. Since immunotherapy influences the natural immune response, it is important to have a general 
understanding of the immune system and tumor immunology. The immune system has two broader 
branches: the innate immune system and the adaptive immune system.  The innate immune system is 
the first line of defense, and it responds generally to threats. The adaptive immune system is responsible 
for precise, antigen-specific, targeted immune attacks. The principle effector cells of the adaptive 
immune system are lymphocytes that have antigen-specific receptors on their cell surface. The three 
major types of lymphocytes include T cells, B cells and Natural Killer cells. T cells and their 
coreceptors, such as T helper cells (CD4+) and cytotoxic T cells (CD8+), play a key role in immunity 
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and tumor immunology. The mere presence of T cells has no effect; they need to be activated in order to 
contribute to the body’s immune response. 
The first part of T-cell activation is the T cell maturation/selection process. In the maturation 
process a T cell is committed to one of two lines: the CD4+ T helper cell line or the CD8+ cytotoxic T 
cell line. Once they have matured in the thymus, CD4 T cells and CD8 T cells are released into the 
bloodstream in search of an antigen. These newly matured T cells are naïve in the sense that they have 
never encountered the antigen that their T cell receptors were built to recognize. There are two 
determinants that decide what a naïve T cell will mature into: the type of coreceptor it expresses (CD4 or 
CD8) and the nature of its first contact with its antigen (Inman, et al., 2007). The relationship between 
the T cell and its antigen presenting cell (APC) is critical to understanding how cancers can trick the 
immune system into a state of unresponsiveness. In other words, it helps explain how cancers can 
suppress the body’s immune system, so that the body cannot eliminate the cancer. Also, the role of the 
antigen presenting cell is important in many immunotherapies. If antigens from tumors can be injected 
into naïve T cells, for example in the form of a vaccine, they have the potential to help the body become 
immune to that tumor’s antigen. Of course, the cell needs to undergo the proper activation signal in 
order to promote cancer immunity.  
For naïve CD4 T cells, activation requires the presence of a mature dendritic cell with antigen 
loaded with Major Histocompatibility Complex (MHC) II. The activation of a CD8 T cells requires a 
target cell, and antigen presenting cell (APC) with antigen loaded MHC I and an antigen-specific 
effector CD4 T cell for cytokine support. Activation of any T cell requires a team effort. The many steps 
involved show that T cell activation is not a chance occurrence. For the T cell to be activated by an 
MHC bound target antigen, several things must happen. First, cell adhesion molecules must be present 
on both the APC and the T cell. The cell adhesion molecules serve two main purposes. One is to adhere 
the T cell to the APC and help these two cells remain in contact long enough to allow as many T cell 
receptors on the T cell as possible to become activated. The adhesion molecules also help the formation 
of an immunologic synapse, which is necessary for T cell activation. After binding the right MHC 
antigen combination, the T cell receptor is phosphorylated and a suitable signal is directed into the T cell 
for processing. If enough T cell receptors bind to the MHC antigen complexes, the T cell has the 
opportunity to test itself at signal II (Inman, et al., 2007). 
After processing the first signal, the T cell must receive a second confirmatory signal in order to 
avoid apoptosis, or programmed cell death. The molecules that give this second signal are called 
costimulatory molecules. Certain molecules give the T cell the activation signal (costimulation) it is 
programmed for, while others do the opposite (coinhibition). Some costimulatory molecules can be 
either stimulatory or inhibitory such as B7-1, B7-2 and B7-H1 (Subudhi, et al., 2005). The basic 
costimulatory molecule is CD28, a receptor that is expressed on the surface of nearly all CD4 T cells, 
and most CD8 T cells. When the T cell receptor and CD28 bind to their ligands at the same time, their 
respective intracellular signals act together to stimulate the cell’s replicative mechanism and secretory 
apparatus. A coinhibitor receptor called CTLA-4 travels to the T cell plasma membrane upon activation 
by the second signal. CTLA-4 expression is rapidly upregulated following T cell activation.  A number 
of autoimmune diseases including insulin-dependent diabetes mellitus, rheumatoid arthritis and multiple 
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sclerosis, have shown genetic linkage to the CTLA-4 locus (Greenwald, et al., 2005). This means that 
the gene encoding for CTLA-4 may be involved in causing different immune diseases. CTLA-4 is 
significant in current research on T cell immunotherapy and will be discussed in detail as an example of 
coinhibition blockade.  
Ultimately, there are a lot ways a T cell can mature, which will lead to different T cell functions. 
Some of these will be helpful in fighting the cancer and some hold back the immune system from 
ridding the body of the cancer. If a tumor-antigen is presented to a T cell, and it receives the proper 
activation signal, the T cell will cause anti-cancer responses in the body. However, if the T cell does not 
receive the right stimulus it can result in the body tolerating the cancerous cells. If a T cell receives a 
signal from coinhibitory receptors like CTLA-4 this can suppress the T cell response. Interaction of a T 
cell with CTLA-4 might promote T regulatory formation. T regulatory cells are important because they 
suppress immune responses in the body which can help prevent autoimmune diseases. Unfortunately, 
they are not helpful when they prevent the body’s immune system from destroying cancerous cells.  
Several new costimulatory molecules have been discovered more recently like the PD-1 
(programmed death 1) receptor, which is found on T cells and numerous other cell types. This is another 
coinhibitor receptor currently being researched. Evidence shows that PD-1 signals inhibit T cell 
activation and proliferation (Dong, et al., 1999). PD-1 has two known ligands, PD-L1 and PD-L2. 
PD-L2 appears to have a stronger attraction for the PD-1 receptor than PD-L1 and it is expressed on 
dendritic cells and macrophages. Contrarily, PD-L1 is expressed on T cells, B cells and macrophages in 
response to inflammatory cytokines. When PD-1 interacts with PD-L1/PD-L2 it can suppress T cell 
responses. It might also promote T regulatory formation. If the PD-1/PD-L1 pathway can be blockaded, 
T cell activation activity may be enhanced. This explains why the blockade of the PD-1/ PD-L1 pathway 
is being promoted as a potential cancer treatment.  
CTLA-4 and PD-1 are similar in that they are coinhibitor receptors on T cells that block T cell 
activation and proliferation. From the other end, the antigen presenting cells (APC) which are necessary 
in T cell activation have ligands that play a role in coinhibition as well. The role of a ligand called 
B7-H3 is not completely understood; conflicting studies found evidence suggesting that B7-H3 is a 
positive costimulator while others found the exact opposite. In mice, the B7-H3 molecule is found to 
have the same effect as CTLA-4 and PD-1; it blocks T cell activation and proliferation (Prasad, et al., 
2004).  
In summary, the immune system is an important defense mechanism against cancer and is 
therefore a worthy target for cancer therapy. The adaptive branch of the immune system is responsible 
for antigen-specific immune attacks. The principle effector cell of the adaptive branch, the T cell, plays 
a major role in cancer immunotherapy. During T cell activation the T cell matures and expresses CD4 or 
CD8 coreceptors. In another step to T cell activation the T cell receives a signal from costimulatory or 
coinhibitory molecules. Some of these coinhibitory molecules, such as CTLA-4 and PD-1, inhibit T cell 
activation and proliferation. The role of these coinhibitor T cells is explored as a new immunotherapy 
approach in cancer treatment, specifically in coinhibition blockade. If coinhibitory receptors can be 
blockaded, there is a chance that immune function may be enhanced instead of suppressed.  
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As previously noted, costimulation and coinhibition through the B7 and CD28 family plays a 
role in regulating T lymphocyte activation. This can result either in cancer tolerance, or anti-cancer 
reactions by the immune system. Up-regulation of coinhibitory B7/ CD28 and PD-L1 members on 
tumor cells can create tumor evasion pathways. Chemotherapy can affect the expression of these 
molecules, for example, by increasing expression of PD-L1 on tumor cells (Janakiram, et al., 2012). 
This dampens the immune response against cancer. This is just one of many ways a tumor cell can 
suppress the immune system. While immunotherapy approaches offer the hope of activating a patient’s 
immune system (even if the cancer is already far-reaching), this hope is not reflected by the current 
reality. The slow pace of progress is likely due to incomplete understanding of immune regulation in the 
context of cancer, and the fact that the tumor microenvironment is inherently immunosuppressive. 
However as researchers expand their understanding in this regard, new ideas are advancing and being 
translated into improved anti-tumor immunotherapy. Immunotherapy targeting T cell coinhibition as 
monotherapy or combined with standard therapies, such as chemotherapy, are in early stages of clinical 
development but hold great potential for treatment of human cancer.  
Studies show that breast tumors, among other tumors, have the ability to suppress the immune 
system, specifically by suppressing the T cell response through T cell coinhibition. As previously 
discussed, activation of a T cell requires two signals: the presentation of a specific antigen on the MHC 
of an antigen presenting cell, together with a costimulatory signal delivered by the antigen presenting 
cell to the T cell. CTLA-4 is a coinhibitory member of B7/CD28 group and it is expressed in breast 
tumors. It negatively regulates the proliferation and the effector functions of T cells. In breast cancer 
patients, CTLA-4 is up-regulated in activated T cells and binds to B7-1 or B7-2. CTLA-4 reduces T cell 
activation in two ways. The first is through direct inhibitory signals, and the second is through 
opposition of CD28 binding (Krummel, Allison, 1995). CTLA-4 is strongly expressed in breast cancer 
patients, in contrast to normal breast tissue where it is weakly expressed. This abnormal expression 
helps explain the evasion of anti-tumor immune responses in breast cancer patients. Some costimulators 
are limited in where they might be expressed in the body. Costimulators B7-1 and B7-2 are limited to 
lymphoid organs. PD-L1 and B7-H3 are not limited; they can be expressed in non-lymphoid organs and 
on tumor cells in cancers. Since abnormal expression of costimulators partially explains tumor evasion 
pathways, the balance of costimulation and coinhibition can be used as an important checkpoint in T cell 
function. CTLA-4 in particular is important in the development of breast cancer. 
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Figure 1: The Co-Signal Network Model (Chen, 2004) 
 
 
This figure shows the co-inhibitory molecules of the B7-CD28 family in the control of T cell immunity 
(Chen, 2004). Costimulators and coinhibitors function in controlling the many stages of T cell 
activation. These may include priming, differentiation, maturation and memory responses. Naïve T cells 
in lymphoid organs constitutively express CD28. After ligation by the T cell ligands (CD80 or CD86) 
from an antigen presenting cell, the priming stage occurs. Then a series of costimulator and coinhibitor 
interactions occur that lead to the differentiation and maturation of primed T cells into effector T cells. 
Interactions between costimulatory molecules like CD137 and OX40 with their respective ligand 
receptors promote T cell maturation. Interactions 
between coinhibitors such as CD80/CD86 with the CTLA-4 receptor can negatively affect the 
maturation of a primed T cell into an effector T cell. It is important that strongly self-reactive T cells are 
destroyed in the lymphoid organs (like the thymus) during the maturation process. If they were not 
inhibited they might cause damage to  
the body. After maturation the effector T cells travel into peripheral tissues, where they are regulated by 
co-signals from their target cells. At this stage, the negative regulation of coinhibitors again is needed to 
prevent potential damage of tissues. One coinhibitory pathway is B7-H1-:D1 (a.k.a. programmed cell 
death 1) with receptor B7-H1-B7-H4. 
 In breast cancer, the costimulatory signal balance is skewed towards coinhibition due to 
dysregulation of the expression of some B7 and CD28 family members. Studies indicate at least three 
types of immune dysregulation in breast cancer patients. First, there is some dysregulation in breast 
cancer patients involving CTLA-4, not only in the tumor microenvironment but also possibly extending 
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to the systemic immune system (Zhang, et al., 2011). Another dysregulation recorded in breast cancer 
patients is that PD-L1 is highly expressed in breast cancer tissue samples, while PD-L1 is not expressed 
in normal breast tissue. In fact, PD-L1 expression is higher specifically in tumors that have a higher 
proliferation index (Ghebeh, et al., 2007). This suggests that the PD-L1/ PD-1 pathway is more 
important in certain, more serious and dangerous, breast cancer subtypes; this includes breast cancer 
subtypes that have a higher proliferation rate, and high lymphocytic response. A third dysregulation 
prominent in breast cancer is that B7-H3 is expressed in breast cancer tissue samples but not in normal 
breast tissue (Arigami, et al., 2010). Expression of B7-H3 is associated with an increase in tumor size 
and overall lymph node metastasis, which also indicates a more dangerous subtype of breast cancer. All 
of these dysregulations show that cancer affects the balance of costimulation and coinhibition through 
the expression of T cells. Researchers wish to reverse these dysregulations, and that is why it is 
imperative that they understand the mechanism behind the co-signal network, and T cell expression. 
Developing T cell-based immunotherapy strategies focus on coinhibition blockade of T cells as a cancer 
treatment, to rectify the skewed balance of coinhibition in cancer patients.  
 After decades of minimal results, researchers have finally managed to achieve some therapeutic 
success with the blockade of T cell coinhibitory molecules in the past few years. The development of the 
antibodies of coinhibitory molecules in the form of drugs may be the most important development in 
cancer immunotherapy history yet. Clinical studies in metastatic melanoma have shown tumor 
regression and an improvement in overall survival of patients after treatment with the anti-CTLA-4 
antibody. Both CTLA-4 and PD-1 antibodies have produced cases of long-lasting remission in patients 
treated with these antibodies. However, these drugs can also result in adverse autoimmune side effects 
including pneumonitis, colitis, hepatitis and diabetes mellitus. The most common drug-related negative 
effects include fatigue, rash, nausea, pruritis and headache. Majority of the drug-related adverse events 
in trials were low grade, and were handled with interruption or discontinuation of treatment. The side 
effects in general do not seem to be as harsh as those caused by cancer chemotherapy treatments. Many 
chemotherapy side effects occur because the treatment affects non-cancerous parts of the body in 
addition to destroying cancer cells. Since this does not happen in immunotherapy treatments, there is a 
smaller risk of painful side effects. The mechanism behind this treatment is coinhibition blockade, in 
order to reverse the dysregulation of T cell coinhibitory molecule expression. Therefore, the 
development of antibody based immunotherapy not only gives cancer patients the hope of survival, but 
also the possibility of a gentler treatment option. The overall results of coinhibition blockade therapy 
prove that stimulating the immune system in this way can effectively induce long standing anti-tumor 
immunity even in advanced cancers.  
 The creation of CTLA-4 antibody based therapy in breast cancer initially began with clinical 
trials from mouse models. In the trials, the mice were treated with a vaccine followed by anti-CTLA-4 
antibody. The result of this treatment was that the mice rejected submucosa1 cell line-induced mammary 
carcinoma. In addition, they were immune to re-challenge of the same cancerous cell line afterward. 
Following this success in mice, a human anti-CTLA-4 antibody called Tremelimumab was developed. 
Tremelimumab worked by blocking the binding of CTLA-4 to B7-1 and B7-2 on the antigen presenting 
cell. It was tested in combination with Exemestane, an inhibitor of the production of estrogen 
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(Vonderheid et al., 2012). In a phase 1 study, 26 patients with advanced hormone receptor positive 
breast cancer were treated with Tremelimumab every 28 days or every 90 days, along with Exemestane 
orally daily. Due to an increase in diarrhea, the 28 day dosing schedule was discontinued later in the 
trial. The discontinuation of treatments that cause overly harsh side effects shows the caution that 
researchers are displaying in their methods. In order to ensure the safety of the patients involved in the 
trial the maximum tolerated dose is not reached. The overall response rate was rewardingly 
positive—stable disease in 11 out of 26 patients (42 percent). The treatment was associated with an 
increase in the ratio of CD4 and CD8 T cells in comparison with T regulatory cells. This suggests 
enhanced cellular immune function due to this treatment because it led to proliferation of effector T 
cells. As previously mentioned, while T regulatory cells are important in immune regulation, they are 
not so helpful in eliminating cancer cells. Since treatment with the anti-CTLA-4 antibody increased 
effector T cell activation, and reduced Treg cells comparatively, it resulted in enhanced cellular immune 
function overall. The results of this trial were extremely encouraging, motivating the creation of Phase II 
and III trials in a similar vein, many of which are currently in progress.  
 Based on the results of anti-CTLA-4 therapy in mouse tumor models, two human anti-CTLA-4 
antibodies, Ipilimumab and Ticilimumab, were developed and have entered into multiple clinical trials.  
In addition to prostate, ovarian, breast, and colon carcinoma, these antibodies have been tested in 
metastatic melanoma and in renal cell cancer. As previously mentioned, there are a lot metastatic tumors 
that cannot be wiped out by the available anti-cancer therapies, so any progress that can be made in this 
area (i.e. metastatic melanoma) is vital. Encouraging observations can be drawn from these  phase I/II 
clinical trials. Anti-CTLA-4 monotherapy is capable of inducing objective tumor responses (meaning 
partial or even complete response) in patients with melanoma, renal cell, and non-Hodgkin’s lymphoma. 
Objective tumor responses were observed to be as high as 20 percent in heavily pretreated melanoma 
patients. This shows that anti-CTLA-4 can enhance the immune system and be used as a successful 
treatment even after many other treatments have failed to cure the patient. Another positive result was 
that CTLA-4 blockade does not appear to inhibit the function of T regulatory cells, which are necessary 
to prevent autoimmune diseases. The most common adverse reactions to these trials involved the skin 
(rash and pruritus) and the gastrointestinal tract (diarrhea and colitis). In the event of severe reactions the 
therapy was either discontinued, or the reaction was reversed with the treatment of steroids (Zang, 
Allison, 2007).  
The most successful anti-CTLA-4 drug, Ipilimumab, has already entered phase III trials in 
late-stage metastatic melanoma (Hodi, et al., 2010). This immunotherapy treatment can be used either as 
an initial treatment or after relapse. What sets Ipilimumab apart from previous cancer treatments is its 
ability to increase the chance of survival in cancer patients with no other therapeutic options. In March 
2011 the FDA granted broad approval for its usage in cancer patients suffering from metastatic 
melanoma. One of the initial goals for developing cancer immunotherapy approaches was the hope of 
being able to activate a patient’s immune system, even in the event of late-stage, advanced cancer. 
Impilimumab may have the ability to finally bring this goal to fruition.  
 Many human cancers have been reported to express the ligand PD-L1, including melanoma and 
cancers of the lung, ovary and breast. There as inverse correlation between PD-L1 expression in tumor 
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cells and poor prognosis of patients (Konishi, et al., 2004). This means that an increase in PD-L1 
expression is linked to poor prognoses of cancer patients. Patients with high expression levels of PD-L1 
displayed aggressive tumors and were at a noticeably increased risk of death from renal cell carcinoma. 
The trend appears to be that the more PD-L1 expressed by the patient the worse off they are. Studies 
also showed that intratumor expression of PD-L1 had a significant correlation with clinical outcome in 
breast cancer, ovarian cancer and pancreatic cancer. For example, 34 percent of breast cancer patients 
had intratumor expression of PD-L1. This is a decidedly significant percentage, and worthy of noting. 
Due to the correlation between PD-L1 expression and poor prognoses in cancer patients, researchers are 
looking to reverse this effect through immunotherapy strategies. One possibility of an immunotherapy 
approach may be to blockade the PD-1/PD-L1 pathway.  
Clinical trials testing the treatment of anti PD-1 antibody in cancer are in progress. In a phase 1 
study, the anti-PD-1 antibody was evaluated in 296 patients with advanced refractory solid tumors. It 
was studied at different doses of 1.0, 3.0 or 10.0 mg per kilogram of body weight (Topalian et al., 2012). 
Researchers need to experiment with different doses in order to determine the most effective one. As is 
the case in most immunotherapy trials, the maximum tolerated dose was not reached and the common 
side effects were skin rash, diarrhea and pruritus. The overall response rate was 18 percent in patients 
with non-small cell lung cancer, 28 percent in melanoma, and 27 percent in patients with renal cell 
cancer. 36 percent of patients whose tumors expressed PD-L1 demonstrated an objective response. An 
objective response means that the patients responded partially or even completely. The patients whose 
tumors did not express PD-L1 did not demonstrate a response. This is only logical because the PD-1 
receptor binds to the PD-L1 ligand. If the ligand is not expressed by the tumor, it is likely that the PD-1 
is not causing the adverse effect of coinhibition in these cancer patients. Therefore, if the tumor is not 
being assisted via PD-1 expression, then it cannot be cured through anti-PD-1 antibody treatment. Due 
to the effectiveness in this treatment in patients whose tumors expressed PD-L1 additional studies of 
different anti-PD-L1 antibodies are being evaluated. However, since the effectiveness of the anti-PD-1 
antibody is limited to patients whose tumors express PD-L1, it seems a less important development than 
the anti-CTLA-4 antibody. 
 Both CTLA-4 blockade and PD-1 blockade have specific mechanisms that are used in 
coinhibition therapy. The basis of this therapy lies in the T cell maturation process. The cross-priming 
process is critical for the initiation of T cell responses to tumors (Huaung, et al. 1994). During this 
activation process antigen presenting cells (APCs) can pick up antigens released from tumor cells, and 
present them to naïve T cells in the context of B7-1 and B7-2 costimulation (see figure 2). Upon T cell 
activation, CTLA-4 is expressed and it starts to carry out its inhibitory function. Therefore, the 
mechanism behind anti-CTLA-4 antibody treatment lies in the specific blockade of CTLA-4 signals. 
The result of the blockade is intact T cell receptor and CD28 signals, and enhanced effector T cell 
function.  
 The molecular mechanisms regulating PD-L1 expression are not as clear as CTLA-4 expression. 
Two striking trends have been recorded regarding PD-L1 expression. Apparently, inflammatory 
mediators are responsible for up-regulation of PD-L1 expression on the surface of several tumor cell 
lines. Additionally, PD-L1 expression was higher in freshly isolated tumor tissue specimens than in 
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cultured tumor cell lines (Dong, et al., 2002). The expression of PD-L1 in newly isolated tumor tissue 
suggests that cytokines in the tumor microenvironment induce the expression of PD-L1 on tumor cells. 
It follows that these cytokines are not present in cultured tumor cell lines, which would explain the 
lower level of PD-L1 expression in these samples. Understanding the regulation of PD-L1 expression in 
cancer better will help clarify the links between oncogenesis and cancer immune evasion. This will in 
turn help to refine immunotherapy approaches. Although the extent to which PD-L1 protein expression 
directly affects tumor progression remains to be determined, it is generally accepted that expression of 
PD-L1 on tumor cells impairs antitumor immunity in the body. Therefore the blockade of the PD-L1/ 
PD-1 pathway is another possibility for tumor immunotherapy.  
 
Figure 2: Blockade of T-cell Coinhibition (Barach, et al. 2012) 
 
 This figure illustrates the blockade of T cell coinhibition as an immunotherapy approach for 
cancer, specifically in prostate cancer (Barach, et al., 2012). It shows the relationship between the tumor 
cell, antigen presenting cell, T cell and T regulatory cell.  The blockade of CTLA-4 serves a dual 
purpose: first, it enhances antitumor immunity by leaving T cell receptors and CD28 signaling intact, 
and second, the blockade of CTLA-4 on T-regulatory cells reduces T-regulatory immunosuppression. 
The figure also shows that immune cells infiltrating prostate cancer have increased expression of PD-L1 
and PD-1.   
 In clinical trials of PD-1 antibodies two metastatic tumor models have already proven to be 
sensitive to PD-1 blockade (Thompson, et al, 2004) (Konishi, et al., 2004). Administration of PD-1 
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blocking antibodies markedly inhibited colon carcinoma metastasis to the lung and melanoma metastasis 
to the liver. Both antigen presenting cells and T cells express PD-L1; therefore, enhanced antitumor 
immunity via blockade of the PD-L1 pathway is likely the result of inhibition of interaction between 
PD-L1 on tumor cells and PD-1 on T cells. The anti-PD-1 antibody trials must be monitored carefully 
because PD-L1 is expressed widely, not only in tumors, but also in immune cells and other tissue cells. 
Thus, there is a possibility of a scenario where anti-PD-1 blockades PD-L1 expression in parts of the 
body where there are no cancer cells. This would not be ideal because one of the aspirations of 
immunotherapy approaches is to target cancer cells without negatively effecting normal cells (which 
chemotherapy does). Potential autoimmune diseases may be induced by the blockade of PD-L1/PD-1, 
thus necessitating meticulous attention and caution in clinical trials. 
 Combination immunotherapy approaches involving chemotherapy have been studied extensively 
in animal models, setting the stage for clinical trials. Chemotherapy may boost the immune response to 
cancer; however, the potential immunosuppressive effects of chemotherapy render issues of dosing and 
timing critical. An exciting combinatorial approach is the co-administration of multiple immunological 
treatments. For example, the combined blockade of PD1 and CTLA-4 has shown to enhance antitumor 
immune responses compared with either agent alone. Combining immunotherapies either with each 
other or with other modalities of cancer treatment, such as chemotherapy, could lead to enhanced 
effectiveness with diminished toxic effect.  
 Ipilimumab, a fully human monoclonal antibody against CTLA-4, has been clinically evaluated 
in combination with Dacarbazine, a chemotherapy agent. In a recent phase III trial, patients with 
metastatic melanoma receiving Ipilimumab in combination with Dacarbazine had significantly improved 
overall survival (11.2 months) compared with patients receiving Dacarbazine alone (9.1 months) 
(Thomas, et al., 2011). Additionally, an important phase II trial in patients with stage IIIb/1V 
non-small-cell lung cancer or extensive-disease small-cell lung cancer investigated whether it would be 
optimal to initiate Ipilimumab at the same time as chemotherapy, or after two cycles of treatment. The 
goal was to determine the timing of treatments that would yield the best prognoses for the patients. The 
results from this trial showed that a ‘phased regimen’ in which immunotherapy began after 
chemotherapy resulted in substantially improved progression-free survival compared with chemotherapy 
alone. The data clearly shows that the clinical effects of administering immunotherapy in combination 
with chemotherapy are strongly dependent on the sequencing of treatment. The study did not actively 
investigate dosing effects, so additional studies are necessary to gather more information in that regard. 
Since chemotherapy treatment was used it is likely that the typical side effects were experienced. Since 
the general adverse effects of immunotherapy are not very harsh, the addition of Ipilimumab as a 
treatment after chemotherapy appears to be a valuable option, especially considering the clear increase 
in survival rate it causes.  
 Immunotherapeutic agents, with differing mechanisms of action, could be combined as a means 
of further enhancing immune responses against tumors. In this regard, recent data suggests that 
antitumor T cells may express multiple inhibitory receptors. In order to effectively blockade the 
antitumor T cell entirely, it is likely that more than one antibody must be employed. Single blockade of 
either CTLA-4 or PD-1 have been shown to enhance the infiltration of activated T cells into tumors, but 
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the T cells accumulated high levels of unblocked negative coreceptors that eventually limited their 
expansion. Hence, singular blockade with merely one antibody can have serious limitations.  Blocking 
CTLA-4, PD1 and PD-L1 simultaneously allowed T cells to continue to survive, and resulted in 
enhanced infiltration, activation and cytokine production (Curran MA, 2010). This resulted in 
decreasing tumor-induced immune suppression, which ultimately promoted tumor rejection.  
 
Figure 3: Combination Blockade of PD-1, CTLA-4, PD-L1 with FVAX (Drake, 2012) 
 
Combination blockade of the PD1, CTLA-4 and PD-L1 coinhibitory molecules coupled with Fvax 
vaccination increased survival of mice challenged with antigen-presenting melanoma cells (Drake, 
2012). Untreated mice had survival rate of 0 percent after 27 days. Mice treated with different 
combinations such as Fvax plus anti-CTLA-4, Fvax plus anti PD-1, and Fvax plus anti-PD-L1 showed a 
survival rate of up to 25 percent after 90 days. The mice that were treated with Fvax, anti-CTLA-4, 
anti-PD1-1 and anti-PD-L1 had the highest survival rate, a rate of up to 75 percent survival after 90 
days. This study clearly shows the advantages of blockading multiple coinhibitors at once. In this case, 
combinatorial blockade treatment was experimented with vaccination as a treatment as well, and it 
resulted in an increased survival rate in those mice.  
Similar results were obtained in a mouse model of metastatic colon carcinoma, evaluating the 
combination of IL-15 with antibodies against CTLA-4 and PD-L1. IL-15 is another promising approach 
in cancer immunotherapy. In this study, although IL-15 significantly prolonged survival in mice with 
metastatic tumors, it also increased the expression of PD1 and the secretion of the immunosuppressive 
cytokine, IL-10. These unexpected side effects could potentially have a negative impact on the immune 
system. However, the mice were also given anti-CTLA-4 and anti-PD-1 antibodies, which blockade the 
expression of coinhibitors. In this situation, they could be employed to reverse the effect that the IL-15 
had in increasing coinhibitorial expression. Combining the immune stimulatory properties of IL-15 with 
the simultaneous removal of two critical immune system inhibitors significantly increased antitumor 
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activity compared with IL-15 alone or combined with either anti-PD-L1 or anti-CTLA-4 (Steel, et al., 
2010). This data supports the idea that the synergistic blockade of multiple checkpoints can enhance 
immune responses. No part of the treatment combated the secretion of additional immunosuppressive 
IL-10, so that is an aspect that might need to be addressed. However, the results of combining IL-15 and 
antibodies of CTLA-4 and PD-L1 thus far are encouraging. They prove that immunotherapy approaches 
that work to stimulate the natural immune system are effective, in that they enhance anti-tumor activity 
and increase the overall chance of survival for cancer patients.  
 
Conclusion 
 Immunotherapy, a relatively new form of cancer treatment, functions through influencing the 
immune system’s natural response. The approach offers the hope of activating a patient’s immune 
system even if the cancer is already far-reaching. However, progress has been slow in this field in the 
past due to incomplete understanding of immune regulation in the context of cancer. New understanding 
is being translated into improved anti-tumor immunotherapy. T cells in particular play an important role 
in many new developing clinical trials. Coinhibitor T cells such as CTLA-4 and PD-1 block T cell 
activation and proliferation. Their coinhibitory functions are explored in an immunotherapy approach 
called coinhibition blockade. Researchers have achieved some therapeutic success with the blockade of 
T cell coinhibitory molecules in the past few years. CTLA-4 and PD-1 antibodies have produced cases 
of durable remission in patients treated with these antibodies. Two human anti-CTLA-4 
antibodies—Ipilimumab and Ticilimumab—have been developed and entered into clinical trials. 
Ipilimumab in particular appears to be a valuable new option in cancer immunotherapy. The rationale 
behind Ipilimumab monotherapy is that anti-tumor T cells exist in the patient before the therapy, and 
these cells will exert anti-tumor activity if CTLA-4 is blockaded. PD-1 antibody therapies are also an 
option to be explored in new cancer treatments. There is an inverse correlation between PD-L1 
expression in tumor cells and poor prognosis of patients. Administration of PD-1 blocking antibodies 
has markedly inhibited colon carcinoma metastasis to the lung and melanoma metastasis to the liver. 
Even more effective than coinhibition blockade immunotherapy, are new combination immunotherapy 
approaches, as well as immunotherapy plus chemotherapy combination treatments. A study on 
Ipilimumab, an antibody against CTLA-4, combined with a chemotherapy drug called Dacarbazine 
showed significantly improved survival compared with treatment of Dacarbazine alone. Another study 
in combination immunotherapy showed that the blockade of multiple T cell receptors (CTLA-4, PD-1 
and PD-L1) combined with Fvax vaccine yielded the highest survival rate in mice. Defining the 
optimum dose and schedule of combination therapies remains a major challenge, and clinical 
investigations to optimize dose and schedule in patients are required. Combining immunotherapies, 
particularly agents that target different T cell coinhibitors, is a promising cancer treatment approach, 
with the potential for an increase in overall survival.  
 
References 
Shifra	  Sadowsky	  
	  
97 
	  
Arigami, T., Narita, N., Mizuno, R., Nguyen, L., Ye, X., Chung, A., . . . Hoon, D. S. (2010). B7-H3 
ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann 
Surg, 252(6), 1044-1051. 
Barach, Y. S., Lee, S. J., & Zang, X. (2010). T Cell Coinhibition in Prostate Cancer: New Immune 
Evasion Pathways and Emerging Therapeutics. Trends in Molecular Medicine, 17(1), 47-55. 
Chen, L. (2004). Co-inhibitory Molecules of the B7-CD28 Family in the Control of T-cell Immunity. 
Nature Reviews Immunology, 4, 336-347. 
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010). PD-1 and CTLA-4 Combination 
Blockade Expands Infiltrating T Cells and Reduces Regulatory T and Myeloid Cells Within B16 
Melanoma Tumors. Proceedings of the National Academy of Sciences of the United States of 
America, 107(9), 4275-4280. 
Dong, H., Strome, S. E., & Salomao, D. R. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: 
a potential mechanism of immune evasion. Nat Med, 8, 793-800. 
Drake, C. G. (2012). Combination Immunotherapy Approaches. Annals of Oncology, 23(8), 
viii41-viii46. 
Ghebeh, H., Tulbah, A., Mohammed, S., Elkum, N., Bin-Amer, S. M., Al-Tweigeri, T., & Dermime, S. 
(2007). Expression of B7-H1 in breast cancer patients is strongly associated with high 
proliferative Ki-67-expressing tumor cells. Int J Cancer, 121(4), 751-758. 
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005). The B7 Family Revisited. Annual Review of 
Immunology, 23(1), 515-548. 
Haidong, D., Gefeng, Z., Koji, T., & Lieping, C. (1999). A third member of the B7 family, co-stimulates 
T-cell proliferation and interleukin-10 secretion. Nature Medicine, 5, 1365-1369. 
The History of Cancer. (2012). Retrieved from The American Cancer Society website: 
http://www.cancer.org/ 
Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994). Role of 
bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science, 264, 
961-965. 
Inman, B. A., Frigola, X., Dong, H., & Kwong, E. D. (2007). Costimulation, Coinhibition and Cancer. 
Current Cancer Drug Targets, 7, 15-30. 
Janakiram, M. (2012). , T Cell Coinhibition and Immunotherapy in Breast Cancer. Discovery Medicine, 
14(77), 229-236. 
Konishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., & Nishimura, M. (2004). B7-1 
expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating 
lymphocytes and their PD-1 expression. Clin Cancer Res, 10, 5094-5100. 
Krummel, M. F., & Allison, J. P. (1995). . CD28 and CTLA-4 have opposing effects on the response of 
T cells to stimulation. J Mol Med, 182(2), 459-465. 
Leading Causes of Death. (2012). Retrieved from Centers for Disease Control and Prevention website: 
http://www.cdc.gov/ 
Paul, W. E. (Ed.). (1991). Immunology: Recognition and Response: readings from Scientific American 
magazine. New York, NY: W.H. Freeman and Company. 
CANCER	  IMMUNOTHERAPY	  TREATMENTS	  
	  
98 
Prassad, D. V., Nguyen, T., Li, Z., Yang, Y., Duong, J., Wang, Y., & Dong, C. (2004). Murine B7-H3 is 
a negative regulator of T cells. The Journal of Immunology, 173, 2500-2506. 
Subhudi, S. K., Allegre, M. L., & Fu, Y. X. (2005). The Balance of Immune Responses: Costimulation 
verses Coinhibition. J Mol Med, 83, 193-202. 
Thompson, R. H., Gillett, M. D., & Cheville, J. C. (2004). Costimulatory B7-1 in renal cell carcinoma 
patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U 
S A, 101, 17174-17179. 
Weiss, L., Morecki, S., Gurevitch, O., Zeira, M., Elkin, G., Prighozina, T., . . . Zilberstein, T. (2003). 
Bone Marrow Transplantation and Cancer Immunotherapy Cell Therapy and Transplantation 
Immunobiology Research Center Israel’s Bone Marrow Transplantation Center, Medical 
Research and Development. Research at Hadassah, 101-113. 
Yu, P., Steel, J. C., Zang, M., Morris, J. C., & Waldmann, T. A. (2010). Simultaneous Blockade of 
Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by 
Interleukin-15 in a Murine Metastatic Colon Carcinoma Model. Clinical Cancer Research. 
Zang, X., & Allison, J. P. (2007). The B7 Family and Cancer Therapy: Costimulation and Coinhibition. 
Cinical Cancer Research, 13, 5271-5279. 
Zhang, B., Beeghly-Fadiel, A., Long, J., & Zheng, W. (2011). Genetic variants associated with 
breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological 
evidence. Lancet Oncol, 12(5), 477-488. 
 
	  Daniel Silberstein graduated in June of 2013 with a B.S. in Biology  
99	  
 
THE PATHOGENESIS AND TREATMENT OF GOUT 
Daniel Silberstein 
ABSTRACT 
In the past, the etiology of gout was simplistically believed to be based in the generous 
indulgence of rich foods and alcohol. However, research has revealed that gout has complex 
environmental and genetic origins. Specifically, researchers have begun to focus attention on the 
molecular basis of gout and its related features. These features include hyperuricemia, the stages of gout, 
and the decreased solubility of uric acid. Furthermore, with epidemiologic evidence indicating that the 
prevalence of gout is consistently rising, it is imperative that medical providers understand the 
research-based guidelines for treatment. This includes what medications to administer, monitoring for 
drug-induced adverse effects, and modifying the treatment plan in elderly or unresponsive patients. 
Medical providers must also be aware of the importance of diet as a contributing factor to gout and 
which foods increase or decrease the risk of gout. This review will, therefore, attempt to present the 
current understanding of the pathophysiology of gout and guidelines for treatment and dietary 
modifications.  
Because gout is a disease related to metabolic dysfunction and produces arthritic symptoms, the 
information presented in this review was extracted from textbooks and journals chiefly relating to 
biochemistry, rheumatology, and pharmacology. The results of the research conducted revealed that 
there are three features that are genetically induced that independently contribute to the onset of gout: 
phosphoribosyl pyrophosphate (PRPP) synthetase hyperactivity, partial deficiency of 
hypoxanthine-guanine phosphoribosyltransferase (HGPT), and hyperactivity of the uric acid transporter 
in the renal tubule. In addition, diets rich in meat and seafood and devoid of dairy products substantially 
increase the risk of developing gout. Finally, research has indicated that the preferred treatment plan for 
gout includes using NSAIDs to alleviate the pain and inflammation of an acute gout attack, using 
colchicine for prophylactic therapy, and using either uricosurics or xanthine oxidase inhibitors for the 
long-term management of uric acid levels. Based on the results presented, medical providers will be 
better informed of methods to treat gout by knowing how to skillfully manage drug therapy, thereby 
reducing dangerous adverse effects and improving patient adherence to the drug regimen. In addition, by 
understanding the role of diet in the onset of gout, providers will better be able to advise patients on 
what foods to include or limit in their diet. From a research perspective, the elucidation of the 
pathophysiology of gout can lead to the development of even more effective therapeutic options. 
INTRODUCTION 
The number of patients who have developed gout has increased to approximately three to five 
million people in the United States (Smith, 2009), making gout a serious health concern. In the past, 
gout was portrayed as a demonic affliction, a punishment for immorality and excessive indulgence in 
food and alcohol; gout was, therefore, known as “the disease of kings (Smith, 2009).” Researchers, 
however, have established that the development of gout depends on the complex interplay of genetic and 
environmental influences. Gout is a syndrome chiefly defined by hyperuricemia, a term that describes 
levels of uric acid that exceed the solubility limit of the blood. Men and postmenopausal women are 
considered hyperuricemic if the serum uric acid level surpasses 7.0 mg/dl. Premenopausal women are 
considered hyperuricemic is the serum uric acid level surpasses 6.0 mg/dl. This higher threshold for 
premenopausal women is due to the increased clearance of uric acid by estrogen (Helms, et. al. 2006). 
After the concentration of uric acid surpasses its saturation point, crystallization of uric acid occurs in 
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the joints and tissues, triggering debilitating attacks involving pain and inflammation. Furthermore, gout 
is classified into two forms. Primary gout is caused by the inheritance of genetic defects that result in 
either the overproduction or the underexcretion of uric acid. In contrast, secondary gout is caused by 
other syndromes that cause secondary hyperuricemia (Wyngaarden, et. al. 1992). Regardless of the 
classification, in treating gout, medical providers seek to alleviate the inflammation and lower serum 
uric acid levels by pharmacologic intervention and nutritional adjustments. This paper will, therefore, 
explore the pathogenesis and treatment of gout by investigating the underlying biochemical dysfunction, 
by analyzing the effects of hyperuricemia, and by advancing pharmacologic and nutritional treatment 
options. 
 
METHODS 
Since gout is a disease that can be caused by a genetically induced change in metabolism, the 
author selected and extracted information from medical biochemistry texts and journals to elucidate the 
metabolic pathways related to the onset of gout and to clarify mechanisms of pathogenesis. Moreover, 
articles from journals relating to rheumatology were consulted when addressing the symptomatology of 
gout and the detrimental effects that gout causes to the integrity of the joints. Finally, pharmacology 
texts and journals were accessed to synthesize a general treatment approach for patients with gout.   
 
DISCUSSION 
Hyperuricemia is intimately related to the dysregulation of the purine metabolic cycle. As Figure 
1 illustrates, the purine metabolic cycle can be divided into three distinct metabolic pathways: purine 
biosynthesis, purine catabolism, and the purine salvage pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: A depiction of the three components of 
the purine metabolic cycle (Prescott, et. al. 
2011a). 
Figure 2: A survey of the purine biosynthetic 
pathway and its regulation by feedback inhibition 
(Nelson, Cox, 2005). 
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Although purine biosynthesis is a complex series of reactions, Figure 2 depicts the two key steps 
that determine the operation of the pathway. The first step is the catalytic conversion of 
ribose-5-phosphate and ATP into phosphoribosyl pyrophosphate (PRPP) by phosphoribosyl 
pyrophosphate synthetase (PRPP synthetase). In the second step, glutamine-PRPP amidotransferase, the 
rate limiting step of the pathway, then adds glutamine to the PRPP to produce 5-phosphoribosylamine. 
Moreover, PRPP is not only a substrate but is also the positive allosteric modulator of glutamine-PRPP 
amidotransferase. The subsequent steps involve further chemical modifications to produce the 
characteristic purine bicyclic ring structure, and these steps culminate in the production of the purines, 
adenylate monophosphate (AMP) and guanylate monophosphate (GMP) (Nelson, Cox, 2005).  
In addition, Figure 2 displays the two prominent feedback regulation mechanisms to ensure 
excess production of AMP and GMP does not occur. Firstly, the AMP and GMP end products are 
phosphorylated to ADP and GDP, which act as negative allosteric modulators, reducing the flux through 
the pathway when end products accumulate by reducing the 
catalytic activity of PRPP Synthetase. Secondly, AMP and 
GMP allosterically inhibit glutamine-PRPP amidotransferase 
(Nelson, Cox, 2005). 
Purine catabolism also plays an important role in 
regulating the concentration of purines. Cells normally 
maintain a steady concentration of the purines, adenine and 
guanine, by ensuring that the biosynthesis of purines is 
balanced by purine catabolism. As Figure 3 shows, purine 
catabolism is a series of metabolic reactions that aid in 
degrading AMP and GMP into uric acid when cellular 
requirements for these purines are met. Through a series of 
enzymatic conversions, GMP is chemically modified to 
xanthine by xanthine oxidase. AMP is also converted to 
xanthine, but through the intermediate hypoxanthine. 
Xanthine oxidase then oxidizes the xanthine from both paths 
into uric acid (Sheriff, 2004).  
The Purine Salvage Pathway ensures the recycling of 
excess guanine and hypoxanthine significantly contributing 
to AMP and GMP biosynthesis. This reaction is catalyzed by 
hypoxanthine-guanine phosphoribosyltransferase (HPRT). 
This enzyme attaches the hypoxanthine to PRPP to 
synthesize inosine monophosphate (IMP), which is further 
converted to AMP or GMP. The enzyme also attaches 
guanine to PRPP to synthesize GMP (Horton, et. al. 2002).  
The source of purine biosynthesis dysregulation is a genetically acquired defect that results in 
structural variations of PRPP synthetase that endow this enzyme with unusual catalytic or regulatory 
properties. Point mutations in the X linked gene known as PRPS1 lead to the translation of a PRPP 
synthetase that exhibits hyperactivity (Becker, et. al. 1996). The mutation can either adversely alter the 
structural integrity of the catalytic site of PRPP synthetase, resulting in an abnormally accelerated rate of 
catalysis, or target the regulatory site of PRPP synthetase, desensitizing the enzyme to the allosteric 
inhibitors GDP and ADP (Ronco, Rodeghiero, 2005). Enzymatic resistance to inhibition has been 
Figure 3: The steps of the purine catabolic 
pathway (Nelson, Cox, 2005). 
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demonstrated experimentally by comparing the catalytic activity of the mutant PRPP synthetase to the 
catalytic activity of the normal enzyme.  
As table 1 illustrates, the PRPP 
synthetase of Propositus (O.G.), who has 
inherited the mutant, is weakly responsive 
to inhibition by GDP and ADP in both the  
low and high protein media, displaying 
more than a two-fold increase in activity as 
compared to the enzyme of the control 
subjects (Zoref, et. al. 1975). In addition, 
overactive PRPP synthetase is 
hypersensitive to its allosteric activator, 
inorganic phosphate (Pi), even at low 
concentrations (ibid). PRPP synthetase 
superactivity results in the overproduction 
of PRPP, the positive allosteric modulator 
and substrate for glutamine-PRPP 
amidotransferase, which promotes purine 
biosynthesis. 
Despite the loss of PRPP 
synthetase regulation, why does the feedback mechanism fail to inhibit glutamine-PRPP 
amidotransferase if this enzyme has structural and catalytic integrity? Kinetically, it has been 
demonstrated that glutamine-PRPP amidotransferase activity is sigmoidal in the presence of its 
inhibitors (Zoref, et. al. 1975). Enzymes that possess a sigmoidal character exhibit large changes in 
catalytic activity in response to small changes in substrate concentration (Nelson, Cox, 2005). Therefore, 
an overproduction of PRPP can result in a substantial increase in catalysis even in the presence of 
enzymatic inhibitors. The consequence is excessive purine production beyond cellular needs with the 
unneeded purines sent to be degraded to uric acid, resulting in hyperuricemia.  
The source of purine salvage pathway dysregulation is a genetically induced partial deficiency of 
HPRT that results in three prominent changes in metabolism that promote hyperuricemia. Firstly, since 
the concentration of HPRT has been reduced, the need for PRPP will decline and as a result, PRPP will 
accumulate. Increased levels of PRPP will allosterically activate purine biosynthesis by stimulating 
glutamine-PRPP amidotransferase. Secondly, the inability to recycle the guanine and hypoxanthine 
released during metabolic turnover will drive significant quantities of purines into catabolic pathways 
that will produce large quantities of uric acid. Thirdly, since salvage pathways generate AMP and GMP, 
the reduced flux through the salvage pathway will result in decreased concentrations of AMP and GMP. 
The lower levels of AMP and GMP will no longer be able to allosterically reduce the activity of 
glutamine-PRPP amidotransferase, further promoting excessive purine biosynthesis (Puri, 2011). 
In contrast to purine biosynthesis and purine salvage metabolism, dysregulation of purine 
catabolism has not been implicated as a contributor to hyperuricemia. The purine catabolic pathway 
simply directs excess purines into uric acid. Although examination of the xanthine oxidase from the liver 
of patients with gout revealed an increased capacity to process purines, this observation seems to be a 
response to the elevated purine concentration rather than an independent inherited enzymatic defect 
(Wyngaarden, et. al. 1992). 
Hyperuricemia is also related to renal underexcretion of uric acid.  The regulation of the serum 
uric acid levels by the kidneys depends chiefly upon glomerular filtration and tubular reabsorption. 
Table 1: The degree of PRPP synthetase responsiveness to 
inhibition by ADP and GDP in control subjects as compared 
to the Propositus (Zoref, et. al. 1975). 
 THE PATHOGENESIS AND TREATMENT OF GOUT  
	  
	  
103	  
Secretion, however, plays a minor role in uric acid homeostasis (Schrier, 2007). Filtration is the process 
by which substances under high pressure in the glomerular capillaries are released through the capillary 
fenestrations and are captured by the glomerular capsule. Reabsorption then occurs as the filtrate flows 
from the capsule into the proximal convoluted tubule where substances are transported from the filtrate 
into the blood. (Tortora, Derrickson, 2006).  The urate transporter 1(URAT-1) has been recently 
identified as the organic anion protein transporter that is responsible for orchestrating the reabsorption of 
uric acid. The URAT-1 is located in the apical membrane of the cells that line the proximal convoluted 
tubule and is coded by a gene known as SLC22A12 (Hediger, et. al. 2005). The role that URAT-1plays 
was confirmed by analyzing patients that possessed mutations in SLC22A12gene that rendered the 
expressed URAT-1 nonfunctional. The kidneys of these patients were unable to reabsorb urate from the 
filtrate, resulting in hypouricemia and hyperuricosuria. This patient analysis illustrates that URAT-1 is 
the principal mediator of urate reabsorption, and in its absence, the filtered urate is excreted in the urine 
(Klippel, 2008). Furthermore, URAT-1 has been recognized by researchers as playing a significant role 
in the development of hyperuricemia. Research conducted on the German Caucasian population strongly 
suggests that underexcretion of uric acid is associated with genetic variations of the N terminus of the 
URAT-1gene (Graessler, et. al. 2006).The genetic polymorphisms induce URAT-1 hyperactivity, 
promoting excessive uric acid reabsorption with a subsequent elevation of serum uric acid (Prescott, et. 
al. 2011a).  
In contrast to primary gout, the classification of secondary gout is warranted when an 
independent syndrome results in secondary hyperuricemia. Tumor lysis syndrome (TLS) is an example 
of this phenomenon. Patients that are diagnosed with acute leukemia, a malignancy characterized by a 
heightened sensitivity to chemotherapy and a high rate of cellular division, have greater risk for 
developing TLS. Two to three days after the administration of chemotherapy treatment, large numbers 
of leukemic cells may burst, releasing enormous quantities of DNA and RNA into circulation. The free 
nucleotides derived from the degradation of the DNA and RNA are then directed into the purine 
catabolic pathway, significantly elevating the serum uric acid level. The patient, therefore, will 
experience the clinical features of gout (Del Toro, et. al. 2005). 
All the signs and symptoms of gout can be traced back to the decreased solubility and subsequent 
crystallization of uric acid (Bhagavan, 2002). Therefore, although hyperuricemia is a predisposing factor 
for uric acid crystallization, factors that affect uric acid solubility play significant roles in determining 
the onset, location and severity of uric acid deposits. The elements that influence uric acid solubility 
include: the local biochemical environment, temperature, and pH. 
The local biochemical environment strongly determines the solubility of uric acid. A reduced 
concentration of albumin, which binds to uric acid,  and the occurrence of trauma may stimulate crystal 
formation (McCance, Huether, 1998). Furthermore, an elevated local ion concentration, the presence of 
a large proportion of compounds that promote crystal growth, and a relatively small concentration of 
compounds that hinder crystallization elevate the risk of developing gout. The variable presence of these 
factors in the human population helps to explain why many patients with hyperuricemia are 
asymptomatic. A similar explanation can be offered to explain the symptomatology of gout in patients 
with a serum uric acid level less than 7.0 mg/dl (Oloff, 1994). 
The solubility of uric acid is a function of temperature, with the saturating concentration of uric 
acid rising with an increasing temperature. For example, at 37°C with a pH of 7 the solubility of uric 
acid is 6.8 mg/dl. Under identical conditions, but at a lower temperature of 30°C, only 4.5 mg/dl of uric 
acid is soluble. The dependency of solubility on temperature explains the tendency of gout to manifest 
itself chiefly in the extremities like the knee or ankle which have temperatures of 32°C and 29°C 
respectively (Wyngaarden, et. al. 1992).  
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Figure 4: A linear portrayal of how neutrophils trigger an inflammatory response that 
results in painful acute gout attacks (McCance, Huether, 1998). 
The solubility of uric acid is a function of pH. Uric acid is a weak organic acid with a 
physiologically relevant pKa1 of 5.5. The pKa1 value describes the tendency for uric acid to release a 
proton.  A medium that has a pH above the pKa1 of uric acid will promote ionization of uric acid and 
cause an increase in the urate anion concentration. Since urate is a charged species, it has an increased 
solubility in water. In a medium with a pH below 5.5, a large percentage of uric acid remains protonated 
and exists as a neutral species, thereby displaying poor solubility in water. For example, after adding 
uric acid to a medium with a pH of 7.0, the urate ion was the predominate species and displayed a 
solubility of 200 mg/dl. In contrast, after adding uric acid to a medium with a pH of 5.0, uric acid was 
the predominate species with a measured solubility of only 15 mg/dl. This has significant implications in 
patients who have hyperuricemia. Hyperuricemic patients excrete higher concentrations of uric acid and 
if the patients’ urine is acidic, the uric acid may crystallize forming renal calculi (Dipiro, et. al. 1997). 
In the absence of medical intervention, a hyperuricemic patient can gradually develop 
increasingly severe symptoms that culminate in joint deterioration and potential immobility. The course 
of gout can be segmented into four distinct stages. The first stage is the asymptomatic stage. The patient 
presents with elevated serum uric acid but does not experience any symptoms of gout. Approximately 
twenty-percent of the patients in the asymptomatic stage will progress to the next stage known as the 
acute gouty arthritis stage where the manifestation of gout takes the form of painful and debilitating 
arthritis. The extremities are chiefly affected during this stage with, for example, 90% of patients 
eventually experiencing an arthritic attack involving the metatarsophalangeal joint (Oloff, 1994). 
Depending on the severity of the attack, the duration of the symptoms can range from several hours to 
several weeks. The characteristic symptoms of swelling, redness, and pain are a result of the leukocyte 
mediated inflammatory reaction in response to uric acid crystallization in the joints. The cellular 
sequence that initiates the inflammatory response is described in Figure 4.  Figure 4 depicts a 
neutrophil engulfing uric acid crystals by enclosing the crystals in a membrane vesicle. The vesicle then 
fuses with a lysosome, forming a phagolysosome. The crystals, however, puncture the phagolysosome 
and cause the release of hydrolytic enzymes into the cytoplasm. The release of enzymes that promote 
cellular degradation causes a loss of membrane integrity, which results in the discharge of the 
cytoplasmic contents of the neutrophil into the synovial fluid of the joint. The discharge attracts mast 
cells, macrophages, and lymphocytes that gather at the site releasing pro-inflammatory chemicals, such 
as leukotriene B4 and interleukin1. Moreover, the antibody Immunoglobulin G binds to the uric acid 
crystals inducing increased neutrophil phagocytic activity (McCance, Huether, 1998).  
With the termination of the symptoms, the patient enters the intercritical stage. This stage is 
defined as the time interval between acute gouty arthritic attacks. Although the patient experiences  
 
 
symptomatic relief of the arthritic symptoms, an analysis of the synovial fluid would reveal uric acid 
crystals. Moreover, the concentration of uric acid continues to rise during this stage, potentially 
promoting a regression to the second stage. For example, it has been found that approximately 62% of 
patients revert to the second stage and suffer another arthritic attack; with each recurrence, the severity 
and the duration of the attacks escalate. Approximately five to    twenty- five percent of patients with 
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gout will advance to the fourth stage known as the chronic tophaceous gout stage. During this stage, uric 
acid exerts deleterious effects on the structural integrity of the cartilage and bone, resulting in joint 
degeneration and hampered patient mobility. In addition, uric acid also accumulates subcutaneously, 
forming localized areas of uric acid deposition known as tophi (Oloff, 1994).  
Because untreated gout can progress and cause irreversible joint damage and painful arthritis, it 
is essential that a treatment plan be formulated. However, since research has shown that many patients 
with asymptomatic hyperuricemia never develop the more severe stages of gout (Koda-Kimble, et. al. 
2005), medical providers initiate treatment when the patient experiences recurrent gouty arthritic attacks 
or renal complications. Table 2 lists the optimum dosage, dose schedule, and potential adverse side 
effects for a number of pharmaceutical agents that are used in the course of treating a patient who is 
diagnosed with gout. Medical providers utilize pharmacological intervention to address three principal 
aims. Firstly, if the patient is currently experiencing an acute gout attack, it is imperative that the 
inflammation and pain is controlled. Secondly, it is vital that future attacks are limited or prevented. 
Thirdly, the patient’s serum uric acid must be reduced and maintained at a level less than 6.0mg/dl 
(Helms, et. al. 2006).   
 
Nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine are used to alleviate and control 
the intense inflammation and incapacitating pain that is characteristic of acute gout flares. Upon the 
Table 2: A survey of the pharmaceutical agents that are used to treat gout, with the 
optimum dosage, dose schedule, and potential adverse effects provided (Prescott, et. al. 
2011b). 
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initiation of an acute gout flare, colchicine is administered in doses of 0.6 mg every one to two hours for 
a maximum of ten doses in a twelve-hour time period or until the patient experiences relief. 
Furthermore, the therapeutic effects of colchicine are only achieved if it is administered less than 48 
hours after the start of symptoms. The adverse effects of colchicine, which include vomiting and 
diarrhea, limit its usage. Medical providers are, therefore, prescribing NSAIDs more frequently because 
of limited side effects and equivalent effectiveness as compared to colchicine (Fiebach, et. al. 2007).  
The most popular NSAID prescribed is indomethacin. For optimal effectiveness, Indomethacin should 
be initially administered within one to two days of the start of the gout flare at 75 mg. After the 
administration of the initial dose, the dosage is adjusted to 50 mg every six hours for the following two 
days, and is then modified to 50 mg every eight hours for the fourth day of treatment (Dipiro, et. al. 
1997). 
Though immediate treatment with anti-inflammatory drugs offers considerable relief to patients 
who are afflicted with acute gout flares, there are certain characteristics that promote susceptibility to 
future attacks. There are three features that aid in the identification of a patient that requires prophylaxis 
against a potentially impending attack: a serum uric acid level that surpasses 10.0 mg/dl, a history of 
renal calculi, and persistent gout flares. Prophylactic therapy is terminated when the serum uric acid 
levels decline to below 7.0 mg/dl and when the patient has not experienced recurrent flares for a period 
of a year (Dipiro, 1997). Though NSAIDs are the optimum choice for combatting acute gout attacks, 
chronic use of NSAIDs during prophylactic therapy is associated with more severe adverse effects as 
compared to colchicine. Therefore, medical providers prefer a low dosage of 0.6 mg of colchicine 
administered twice a day for the long term prevention of recurrent gout attacks (Fiebach, et. al. 2007). 
Long term management of serum uric acid levels is indispensable for precluding future acute 
gout attacks and detrimental effects to the skeletal system. Serum uric acid levels that are less than 6.0 
mg/dl result in substantial improvements in patients with recurrent gout flares (Helms, et. al. 2006). 
There are two classes of drugs that are commonly used to reduce serum uric acid levels: Uricosuric 
drugs, which enhance renal excretion of uric acid, and xanthine oxidase inhibitors, which decrease the 
production of uric acid.  
Probenecid and sulfinpyrazone are the two uricosuric agents that are frequently prescribed to 
enhance uric acid excretion. These drugs, therefore, should be preferentially prescribed to patients that 
have demonstrated uric acid underexcretion in a twenty-four hour urine collection test; if the urine 
contains less than 800 mg of uric acid when the patient is on a regular western diet, it strongly suggests 
that the patient is an underexcreter (Prescott, et. al. 2011a). Although sulfinpyrazone is more effective as 
a uricosuric agent as compared to probenecid, sulfinpyrazone possesses additional antiplatelet biological 
activity. Uricosuric drugs promote renal excretion of uric acid by interfering with the proximal tubular 
reabsorption of uric acid (West, 2002). These drugs are weak organic acids that competitively inhibit 
URAT-1, the protein transporter responsible for mediating the selective passage of uric acid from the 
filtrate into the blood. Inhibition of this transporter prevents excessive tubular reabsorption of urate from 
the filtrate, resulting in a reduction of serum uric acid with a simultaneous elevation of uric acid in the 
urine (Klippel, 2008; West, 2002). These changes have been observed in patients given doses of 1-2 mg 
of Probenecid; the urinary uric acid excretion level in these patients increased between four to six fold 
(Helms, et. al. 2006).  
The dosage of probenecid and sulfinpyrazone is low upon initiation of drug therapy to prevent an 
abrupt elevation in the quantity of uric acid excreted. For example, the dosage of probenecid is 250 mg 
twice a day for the first week and is subsequently increased to 500 mg twice a day (Koda-Kimble, et. al. 
2005). Similarly, the dosage of sulfinpyrazone is started at 50 mg twice a day for four days, with the 
dose subsequently increased to 100 mg twice a day. Thereafter, the dose is increased by 100 mg every 
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week until the maximum dose of 800 mg is reached. This precautionary measure is necessary to lessen 
the possibility of developing uric acid nephrolithiasis or kidney stones in patients that have a low urinary 
pH; a low pH promotes protonation of urate, raising the concentration of poorly soluble uric acid in the 
urine (Dipiro, 1997).  
There are other methods of further reducing the risk of nephrolithiasis. Patients are advised to 
increase their fluid intake by drinking 2.0 L per day to ensure that their urine becomes more dilute, 
reducing the concentration of uric acid. In addition, sodium bicarbonate dosed at one gram three times a 
day can be used to alkalinize their urine, effecting the ionization of uric acid to the more soluble urate 
anion. Furthermore, since a diminished renal clearance results in a decrease in the volume of the filtrate 
and a consequent increase in uric acid concentration, patients with a creatinine clearance lower than 50 
ml/min should avoid using uricosurics (Helms, et. al. 2006). Therefore, patients with a history of uric 
acid nephrolithiasis, or patients who have renal insufficiency characterized by a glomerular filtration rate 
that is less than 60ml/dl, or patients above 60 years old who have experienced the inevitable renal 
impairment that accompanies aging should not be administered uricosuric drugs (Panda, 2002). The 
adverse side effects of uricosurics include gastrointestinal upset, rash, headaches, and allergic reactions 
(West, 2002). 
The xanthine oxidase inhibitors, allopurinol and the newly designed febuxostat, on the other 
hand, are commonly prescribed to reduce uric acid biosynthesis. These drugs, therefore, should be 
preferentially prescribed to patients who have demonstrated uric acid overproduction by excreting more 
than 800mg of uric acid in a twenty-four hour urine collection test (Koda-Kimble, et. al. 2005). 
Therefore, xanthine oxidase inhibitors are warranted in a situation where uric acid overproduction is a 
result of enzymatic deficiency or hyperactivity (Panda, 2002). However, xanthine oxidase inhibitors 
would also be effective in underexcreters, reducing the load of uric acid the kidney has to process 
(Koda-Kimble, et. al. 2005). To reduce the possibility of triggering an acute attack by dramatically 
altering the serum uric acid concentration, allopurinol is dosed gradually; a daily dose of 100 mg is 
administered and the dose is steadily raised during a three-week period until the dose reaches 300 mg 
daily (Seth, Seth, 2009). In addition, the magnitude and frequency of the dose must reflect the creatinine 
clearance, an indicator of renal function. A patient with a reduced creatinine clearance will be 
administered a decreased dose of allopurinol (Seyffart, 1991). In contrast, the dosage of febuxostat 
remains unaltered regardless of renal efficiency, with doses of either 80 mg daily or 120 mg daily 
available depending on the severity of the gout symptoms (Seth, Seth, 2009).  
The effectiveness of Allopurinol as compared to Febuxostat was tested in the Febuxostat 
Allopurinol Controlled trial (FACT). This randomized, double blind trial attempted to evaluate what 
percentage of patients taking either allopurinol or febuxostat would achieve a uric acid level below 
6.0mg/dl, called the endpoint. When patients were administered 80 mg and 120 mg of febuxostat, 53 
percent and 62 percent of patients achieved the endpoint, respectively. In contrast, only 21 percent of the 
patients achieved the endpoint when administered allopurinol. This result suggests that febuxostat is 
more effective than Allopurinol. Moreover, both drugs produced approximately the same number of 
adverse effects (Becker, et. al. 2005). The adverse effects of allopurinol include the development of 
rashes and allopurinol hypersensitivity syndrome, a potentially fatal syndrome that is characterized by 
fever, cutaneous rash, and multi-organ injury (Lee, et. al. 2008). The side effects of febuxostat include 
liver and gastric complications as well as headaches (Bridgeforth, cherf, 2011). 
Allopurinol inhibits the inordinate production of uric acid by interfering with both purine 
biosynthesis and catabolism. Since allopurinol is structurally similar to the purine hypoxanthine, 
hypoxanthine-guanine phosphoribosyl transferase (HGPT) catalyzes the attachment of PRPP to 
allopurinol to produce allopurinol ribonucleotide. The impact of this reaction is twofold. Firstly, the 
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production of allopurinol ribonucleotide consumes PRPP, the allosteric stimulator and substrate of the 
rate limiting step of purine biosynthesis. Secondly, the allopurinol ribonucleotide operates as a negative 
allosteric effector to glutamine-PRPP amidotransferase, further strengthening the inhibition of purine 
synthesis (Bhagavan, 2002). In addition, allopurinol functions as a xanthine oxidase inhibitor, inhibiting 
the final two steps that are responsible for synthesizing uric acid. Allopurinol is converted into 
alloxanthine in the active site of xanthine oxidase, and it acts as a competitive inhibitor, resulting in an 
increase in the more soluble endogenous substrates xanthine and hypoxanthine (Finkel, et. al. 2009). The 
consequence of allopurinol’s effects is to decrease excessive purine biosynthesis and reduce the 
production of uric acid. Febuxostat administration achieves its hypouricemic effect by exclusively 
targeting xanthine oxidase for inhibition and, in contrast to allopurinol, does not interfere in purine 
biosynthesis. The selectivity of febuxostat can be attributed to its non-purine structure, preventing 
catalysis by HGPT (Seth, Seth, 2009).  
Table 3: A listing of different food categories patients with gout should consume in 
limited quantities because of their elevated purine content (Prescott, et. al. 2011b). 
 
Although drug therapy is effective in the management of gout, the patient needs to dramatically 
modify dietary habits to ensure a low and stable uric acid level. Table 3 lists six categories of foods that 
have been shown to have elevated purine content. An increase in ingested purines will increase the 
production of uric acid. Therefore, it is essential for the patient to recognize foods that are high in purine 
content and those foods that promote a decrease in serum uric acid. A study carried out by the Third 
National Health and Nutrition Examination Survey, which was conducted on 14, 363 subjects, sought to 
evaluate how different food categories influence the serum uric acid level. The study found a link 
between the daily consumption of milk and reduced serum uric acid levels. The importance of 
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expanding one’s diet to include the daily consumption of dairy products was further strengthened by the 
discovery of an association between a diet devoid of dairy products and an elevated serum uric acid 
level (Choi, et. al. 2005).  Furthermore, Choi et al organized a study to assess the relationship between 
a person’s dietary practices and the onset of gout. It was found that compared to the participants who 
consumed 0.5 daily servings of meat, participants who consumed 2.5 daily serving had a 41 percent 
increased risk of developing gout. Seafood consumption was also shown to significantly increase the 
risk of developing gout. As compared to the participants who consumed 0.04 daily servings of seafood, 
participants who consumed 0.8 daily servings had a 51 percent elevated risk of developing gout (Choi, 
et. al. 2004). The results of the above-mentioned studies emphasize how diet can be a significant 
contributing factor to the onset of gout. Therefore, patients need to modify their dietary practices in 
order to ensure maximum reduction and stabilization of serum uric acid levels. 
 
CONCLUSION 
Though it can be a potentially debilitating and painful metabolic disease, gout is not as disabling 
as it was in the past. With a deeper understanding of the purine metabolic cycle and the identification of 
the URAT-1 transporter in the renal tubules, researchers have made headways into clarifying the 
pathogenesis of gout. These advances will likely lead to even more effective therapeutic solutions. 
However, the current treatment regimen generally includes the use of NSAIDs to control the acute gout 
attacks, the use of colchicine for prophylactic therapy, and the use of either uricosurics or xanthine 
oxidase inhibitors for the long-term management of uric acid levels. The patient must also make lifestyle 
changes by limiting the intake of purine-rich foods. If the patient is committed to a new dietary regimen 
and is compliant with drug therapy, gout will be a chronic but manageable disease. 
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